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Liangping  Li  
ROLE  OF  POSTSYNAPTIC  DENSITY  PROTEIN  95  (PSD95)  AND  NEURONAL  
NITRIC  OXIDE  SYNTHASE  (NNOS)  INTERACTION  IN  THE  REGULATION  OF  
CONDITIONED  FEAR  
  
Stimulation  of  N-­methyl-­D-­aspartic  acid  receptors  (NMDARs)  and  the  
resulting  activation  of  neuronal  nitric  oxide  synthase  (nNOS)  are  critical  for  fear  
memory  formation.  A  variety  of  previously  studied  NMDAR  antagonists  and  NOS  
inhibitors  can  disrupt  fear  memory,  but  they  also  affect  many  other  CNS  
functions.  Following  NMDAR  stimulation,  efficient  activation  of  nNOS  requires  
linking  nNOS  to  a  scaffolding  protein,  the  postsynaptic  density  protein  95  
(PSD95).  We  hypothesized  that  PSD95-­nNOS  interaction  in  critical  limbic  regions  
(such  as  amygdala  and  hippocampus)  during  fear  conditioning  is  important  in  
regulating  fear  memory  formation,  and  disruption  of  this  protein-­protein  binding  
may  cause  impairments  in  conditioned  fear  memory.    
  
Utilizing  co-­immunoprecipitation,  electrophysiology  and  behavioral  
paradigms,  we  first  showed  that  fear  conditioning  results  in  significant  increases  
in  PSD95-­nNOS  binding  within  the  basolateral  amygdala  (BLA)  and  the  ventral  
hippocampus  (vHP)  in  a  time-­dependent  manner,  but  not  in  the  medial  prefrontal  
cortex  (mPFC).  Secondly,  by  using  ZL006,  a  small  molecule  disruptor  of  PSD95-­
nNOS  interaction,  it  was  found  that  systemic  and  intra-­BLA  disruption  of  PSD95-­
nNOS  interaction  by  ZL006  impaired  the  consolidation  of  cue-­induced  fear.  In  
   vii  
contrast,  disruption  of  PSD95-­nNOS  interaction  within  the  vHP  did  not  affect  the  
consolidation  of  cue-­induced  fear,  but  significantly  impaired  the  consolidation  of  
context-­induced  fear.  At  the  cellular  level,  disruption  of  PSD95-­nNOS  interaction  
with  ZL006  was  found  to  impair  long-­term  potentiation  (LTP)  in  the  BLA  neurons.  
Finally,  unlike  NMDAR  antagonist  MK-­801,  ZL006  is  devoid  of  adverse  effects  on  
many  other  CNS  functions,  such  as  motor  function,  social  activity,  cognitive  
functions  in  tasks  of  object  recognition  memory  and  spatial  memory.    
  
These  findings  collectively  demonstrated  that  PSD95-­nNOS  interaction  
within  the  conditioned  fear  network  appears  to  be  a  key  molecular  step  in  
regulating  synaptic  plasticity  and  the  consolidation  of  conditioned  fear.  Disruption  
of  PSD95-­nNOS  interaction  holds  promise  as  a  novel  treatment  strategy  for  fear-­
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CHAPTER  1    




   Fear  is  an  adaptive  emotional  response  to  environmental  threats.  It  
motivates  and  organizes  autonomic  and  endocrine  changes  supporting  defensive  
behaviors  necessary  for  survival.  Fear  responses  can  be  triggered  by  a  variety  of  
stimuli  that  may  cause  treats  to  personal  safety,  including  predators,  pain  and  
heights.  Defensive  behaviors  induced  by  these  types  of  stimuli  do  not  depend  on  
a  learning  process  where  a  valence  of  danger  is  assigned  to  the  threat.  This  type  
of  fear  has  been  referred  to  as  ‘innate  fear’  or  ‘unlearned  fear’  (Blanchard  &  
Blanchard  1989).  When  experiencing  innate  fear,  an  association  between  the  
innate  fear-­inducing  stimulus  and  a  neutral  stimulus,  such  as  the  context  related  
to  the  threat,  will  be  established.  This  associative  form  of  memory,  where  a  
neutral  stimulus  acquires  the  ability  to  elicit  fear  responses,  has  been  referred  to  
as  ‘conditioned  fear’  or  ‘learned  fear’.  Conditioned  fear  has  been  the  focus  of  




In  the  laboratory,  conditioned  fear  or  learned  fear  is  modeled  by  Pavlovian  
fear  conditioning  paradigm,  in  which  a  neutral  stimulus  (conditioned  stimulus,  
   2  
CS),  is  paired  with  an  aversive  stimulus  (unconditioned  stimulus,  US).  After  
several  CS-­US  pairings,  the  subject  learns  that  the  presentation  of  CS  is  
predictive  of  the  US.  Once  learned,  the  CS  acquires  the  ability  to  induce  fear  
responses  termed  conditioned  response  (CR),  regardless  of  the  presentation  of  
US  (Johansen  et  al  2011).    
  
   In  rodents,  a  typical  fear  conditioning  procedure  involves  an  auditory  CS  
(such  as  a  tone)  that  co-­terminated  with  an  aversive  US  (usually  a  foot  shock).  
Upon  repeated  CS-­US  pairings,  the  subject  would  develop  fear  behavior  to  the  
CS  alone.  Besides,  the  context  in  which  the  subject  received  fear  conditioning  
will  also  induce  fear  responses  due  to  context-­US  association.  Expression  of  fear  
can  be  measured  using  the  species-­specific  CRs,  such  as  behavioral  freezing  
(Blanchard  &  Blanchard  1969).  Pavlovian  fear  conditioning  is  a  well-­established  
laboratory  model  of  fear  learning  to  cues  and  contextual  stimuli.  It  is  often  used  to  
study  the  neural  circuits  and  the  molecular  mechanisms  of  fear  learning  and  
memory  (Johansen  et  al  2011).  In  the  laboratory,  conditioned  fear  can  be  
attenuated  through  a  procedure  in  which  a  tone  previously  paired  with  a  foot  
shock  is  delivered  repeatedly  in  the  absence  of  foot  shock.  This  procedure  
results  in  a  gradual  decrease  in  fear  responses  that  is  attributed  to  a  process  
called  fear  extinction  (Myers  &  Davis  2007).  
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   Animal  studies  using  fear  conditioning  models  have  revealed  that  there  is  
a  distributed  network  of  brain  regions  that  are  involved  in  the  acquisition,  
consolidation  and  extinction  of  conditioned  fear.  Among  those  involved  brain  
regions,  the  amygdala,  the  hippocampus  and  the  medial  prefrontal  cortex  
(mPFC)  have  received  the  most  intensive  attention,  and  these  three  different  
brain  structures  regulate,  in  concert,  the  different  aspects  of  a  conditioned  fear  
response.  Figure  1  shows  a  schematic  representation  of  the  major  neural  
circuitry  in  cued  and  contextual  fear  memory.  Briefly,  tone  (CS)  and  shock  (US)  
inputs  from  the  thalamus  (LeDoux  et  al  1990)  and  contextual  inputs  (CS)  from  
the  hippocampus  (Pitkänen  et  al  2000)  are  transmitted  to  the  amygdala,  which  
serves  as  the  primary  site  at  which  information  related  to  the  CS  and  the  US  
converge.  The  amygdala  sends  projections  to  a  variety  of  structures  in  the  brain  
stem,  which  regulate  fear  responses,  such  as  freezing  (LeDoux  et  al  1988).  
mPFC  innervates  amygdala  and  plays  a  critical  role  in  the  extinction  of  
conditioned  fear  (Cho  et  al  2013).  The  roles  of  amygdala,  hippocampus  and  
mPFC  in  fear  memory  are  described  in  greater  details  in  the  following  three  
subsections.    
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Figure  1.  Neural  circuits  modulating  fear  memory  
  
Amygdala  is  the  critical  structure  regulating  fear  acquisition  and  consolidation.  
Auditory  cue  (CS)  input  from  auditory  thalamus/auditory  cortex  and  foot  shock  
(US)  inputs  from  somatosensory  thalamus  converge  in  the  basolateral  amygdala  
(BLA).  The  BLA  projects  to  the  central  nucleus  of  the  amygdala  (CeA),  which  is  
the  major  output  structure  of  amygdala.  The  CeA  projects  to  brain  stem  and  
control  fear  response,  such  as  freezing.  Hippocampus  (HP)  plays  a  crucial  role  in  
regulating  contextual  fear  conditioning  where  the  context  is  associated  with  
shock.  Configural  representation  of  several  contextual  elements  (e.g.  lighting,  
olfactory  cues,  spatial  cues  and  floor  texture)  is  formed  in  the  HP  and  then  
transmitted  to  the  BLA  where  the  associative  connections  between  the  
hippocampal  representation  of  context  and  the  aversive  stimulus  (such  as  a  foot  
shock)  is  established.  HP  also  modulates  fear  responses  through  an  indirect  
projection  to  the  BLA  via  the  medial  prefrontal  cortex  (specifically,  the  prelimbic  
cortex  (PL)  and  the  infralimbic  cortex  (IL)).  PL  innervates  the  BLA  and  plays  a  
role  in  mediating  fear  expression,  whereas  IL  exerts  feed-­forward  inhibition  of  
neurons  in  the  BLA  and  CeA,  thereby  suppressing  the  expression  of  fear  in  
response  to  the  conditioned  stimulus  that  was  previously  extinguished.  Figure  1  
was  modified  from  Maren  and  Quirk  (2004).  
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1.3.1  Role  of  the  amygdala  
   The  amygdala  is  an  almond-­shaped  structure  located  in  the  anterior  
portion  of  the  temporal  lobe.  It  consists  of  several  functionally  and  anatomically  
distinct  nuclei,  including  the  lateral  nucleus  (LA),  the  basal  nucleus  (BA)  (together  
referred  to  as  the  basolateral  amygdala,  BLA)  and  the  central  nucleus  (CeA)  
(LeDoux  2003).  The  BLA  is  the  sensory  gateway  of  the  amygdala;;  it  receives  
inputs  from  the  auditory  thalamus  and  auditory  cortex,  somatosensory  thalamus  
and  hippocampus,  allowing  different  information  of  fear  memory  to  converge  
(LeDoux  2003).  The  CeA  serves  as  the  primary  output  area  of  the  amygdala;;  it  
projects  to  various  structures  in  the  brain  stem  and  mediates  conditioned  fear  
responses  (CR)  (LeDoux  et  al  1988).  A  series  of  inactivation  and  lesion  studies  
using  fear  conditioning  paradigm  has  demonstrated  that  the  amygdala  is  one  of  
the  critical  brain  structures  for  fear  acquisition  and  consolidation.  Selective  
inactivation  of  BLA  using  gamma-­aminobutyric  acid  type  A  receptors  (GABAARs)  
agonist  muscimol  before  fear  conditioning  significantly  attenuate  the  acquisition  
of  conditioned  fear  response  (Maren  et  al  2001,  Muller  et  al  1997,  Wilensky  et  al  
1999).  Animals  with  excitotoxic  lesions  of  BLA  displayed  a  slow  acquisition  of  
conditioned  fear  and  a  substantial  forgetting  when  remote  memory  was  tested  
(Poulos  et  al  2009).  Animals  that  received  intra-­BLA  infusion  of  muscimol  prior  to  
test  also  showed  low  level  of  freezing  to  the  CS  (Muller  et  al  1997).  As  a  result,  
BLA  is  thought  to  be  the  primary  storage  site  of  the  association  between  CS  and  
US  and  also  plays  an  essential  role  in  the  fear  memory  expression.    
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Similar  to  the  BLA,  the  CeA  has  also  been  shown  to  be  essential  for  fear  
acquisition  and  expression.  Lesions  in  CeA  block  or  attenuate  the  expression  of  
conditioned  fear  responses  to  both  auditory  and  contextual  cues  (Campeau  &  
Davis  1995,  Goosens  &  Maren  2001,  Zimmerman  et  al  2007).  A  study  using  a  
combination  of  in  vivo  electrophysiological,  pharmacological  and  optogenetic  
techniques  further  demonstrated  that  the  lateral  subdivision  of  the  CeA  is  
required  for  the  acquisition  of  fear,  whereas  the  medial  subdivision  of  the  CeA  is  
required  for  driving  conditioned  fear  responses  (Ciocchi  et  al  2010).    
  
1.3.2  Role  of  the  hippocampus  
   Following  auditory  cue  associated  fear  conditioning  that  is  induced  after  
several  tone/shock  pairings,  animals  act  fearful  the  moment  they  are  put  into  the  
conditioning  box,  i.e.,  even  before  the  delivery  of  conditioned  stimulus  (tones).  
This  phenomenon  of  contextual  fear  conditioning  (CFC)  indicates  that  animals  
learn  to  associate  the  general  context  of  the  conditioning  box  with  the  noxious  
foot  shock.  By  using  cued  fear  conditioning  and  contextual  fear  conditioning  
where  the  context  (the  conditioning  box)  is  paired  with  shock,  many  studies  have  
demonstrated  a  critical  role  of  the  hippocampus  in  processing  the  contextual  
information  of  fear  memories.    
  
   Studies  with  electrolytic  lesions  to  the  dorsal  hippocampus  (dHP)  have  
shown  an  impaired  acquisition  of  conditioned  fear  responses  to  the  context  
(Phillips  &  LeDoux  1992,  Phillips  &  LeDoux  1994).  Similarly,  inactivation  of  the  
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ventral  hippocampus  (vHP)  with  muscimol  also  reduced  contextual  fear  memory  
(Rudy  &  Matus-­Amat  2005).  In  addition,  post-­training  lesions  of  either  dHP  or  
vHP  can  significantly  disrupt  contextual  fear  conditioning  (Frankland  et  al  1998,  
Maren  &  Holt  2004).  The  functional  role  of  the  hippocampus  in  contextual  fear  
conditioning  is  to  assemble  several  independent  contextual  elements  (e.g.  
lighting,  olfactory  cues,  spatial  cues,  floor  texture)  into  a  unified,  configured  
representation  in  order  to  use  them  as  a  CS  (Young  et  al  1994).  This  view  was  
further  supported  by  a  recent  study  using  a  targeted  optogenetic  approach  in  
mice  (Ramirez  et  al  2013).  The  authors  have  found  that  the  hippocampal  
neurons  that  have  been  previously  activated  in  a  context  can  serve  as  functional  
CS  in  a  different  context  when  optically  reactivated  during  the  delivery  of  US.  As  
a  result,  animals  showed  increases  freezing  responses  in  the  original  context,  in  
which  a  US  (foot  shock)  was  never  delivered  (Ramirez  et  al  2013).  More  
interestingly,  the  role  of  the  hippocampus  in  contextual  fear  conditioning  seemed  
to  be  time-­limited  as  contextual  fear  deficits  were  only  found  when  hippocampal  
lesions  were  made  a  couple  of  days  (1  to  14  days)  after  conditioning.  Animals  for  
which  the  interval  between  conditioning  and  hippocampal  lesions  was  longer  
(weeks)  retained  significant  contextual  fear  memory  (Anagnostaras  et  al  1999,  
Kim  &  Fanselow  1992,  Maren  et  al  1997).  These  findings  suggested  that  the  
integrated  representation  of  the  context  was  initially  developed  in  the  
hippocampus  but  was  subsequently  stored  elsewhere.    
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   The  hippocampus  transmits  the  contextual  information  to  the  amygdala  via  
the  ventral  angular  bundle  (VAB)  which  arises  from  the  CA1  area,  the  ventral  
subiculum  and  the  lateral  entorhinal  cortex  (Canteras  &  Swanson  1992,  Ottersen  
1982).  In  the  BLA,  the  associative  connections  between  the  hippocampal  
representation  of  context  and  the  aversive  stimulus  (such  as  a  foot  shock)  are  
established  (Fanselow  &  Poulos  2005,  LeDoux  2003).  Therefore,  the  HP-­BLA  
circuit  is  critical  in  the  regulation  of  contextual  fear  conditioning.  Animal  studies  
have  shown  that  lesions  in  the  hippocampal  regions  that  project  to  the  BLA  
(ventral  subiculum  and  lateral  entorhinal  cortex)  resulted  in  an  impaired  
contextual  fear  conditioning  (Maren  &  Fanselow  1995);;  Similarly,  lesions  in  the  
BLA  also  produced  deficits  in  contextual  fear  conditioning  (Maren  &  Fanselow  
1995).  
  
1.3.3  Role  of  the  medial  prefrontal  cortex    
   The  medial  prefrontal  cortex  (mPFC)  is  usually  defined  as  a  collection  of  
brain  regions  lying  along  the  medial  wall  of  the  frontal  lobe,  including  anterior  
cingulate,  infralimbic  (IL),  prelimbic  (PL)  and  medial  orbito-­frontal  cortex  
(Heidbreder  et  al  2003).  mPFC  has  been  implicated  in  the  extinction  of  fear  
memory  in  a  variety  of  studies  (Herry  &  Garcia  2002,  Herry  &  Mons  2004,  
Morgan  &  LeDoux  1995,  Morgan  et  al  1993,  Santini  et  al  2004).  Later  research  
with  manipulations  restricted  to  subregions  of  mPFC  has  pinpointed  the  IL  as  the  
critical  area  involved  in  fear  extinction.  For  example,  electrophysiological  studies  
found  that  IL  neurons  displayed  increased  activity  to  the  CS  after  extinction  
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training  (Milad  &  Quirk  2002).  Furthermore,  the  increase  in  the  IL  responses  to  
the  CS  was  inversely  correlated  with  freezing  responses  (Milad  &  Quirk  2002).  In  
support  of  the  view  that  IL  is  involved  in  fear  extinction,  studies  using  
pharmacological  or  electrical  stimulation  techniques  showed  that  intra-­IL  infusion  
of  GABAA  receptor  agonist  muscimol  significantly  impaired  fear  extinction  
(Laurent  et  al  2009),  whereas  microstimulation  of  IL  enhanced  fear  extinction  
(Maroun  et  al  2012,  Milad  et  al  2004,  Vidal-­Gonzalez  et  al  2006).  Consistent  with  
these  findings,  a  more  recent  study  using  optogenetics  demonstrated  that  
activation  of  IL  neurons  during  extinction  training  via  channelrhodopsin  2  (ChR2)  
stimulation  reduced  fear  responses  and  enhanced  extinction  memory  the  
following  day,  whereas  inactivation  of  IL  neurons  via  halorhodopsin  stimulation  
impaired  the  memory  of  fear  extinction  (Do-­Monte  et  al  2015).  In  contrast  to  the  
fear-­suppressing  role  of  IL,  PL  region  of  mPFC  has  been  shown  to  be  involved  in  
the  expression  of  fear.  For  example,  microstimulation  of  PL  significantly  
enhanced  the  freezing  responses  to  CS  (Vidal-­Gonzalez  et  al  2006),  whereas  
inactivation  of  PL  using  either  sodium  channel  blocker  tetrodotoxin  (Corcoran  &  
Quirk  2007)  or  GABAA  receptor  agonist  muscimol  (Sierra-­Mercado  et  al  2011)  
resulted  in  impaired  fear  responses.    
  
   Both  IL  and  PL  have  bidirectional  connections  with  the  amygdala.  IL  
projects  to  the  LA,  lateral  division  of  central  nucleus  (CeL)  as  well  as  intercalated  
cell  mass  (ITC),  a  region  between  the  BLA  and  CeA  (McDonald  et  al  1996,  
McDonald  1998).  In  contrast,  PL  primarily  targets  BA  (McDonald  et  al  1996,  
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McDonald  1998).  In  return,  both  IL  and  PL  receive  projections  from  the  BLA  
(Hoover  &  Vertes  2007,  Jin  &  Maren  2015).  It  has  been  thought  that  PL  and  IL  
exert  effects  on  fear  memory  via  their  interactions  with  the  amygdala  (Arruda-­
Carvalho  &  Clem  2015,  Marek  et  al  2013).  Both  PL  and  IL  also  receive  
substantial  inputs  from  the  vHP  with  sparse  inputs  from  the  dHP  (Cenquizca  &  
Swanson  2007,  Hoover  &  Vertes  2007).  HP-­IL  pathway  has  been  thought  to  play  
a  key  role  in  mediating  context-­dependent  modulation  of  fear  extinction  (for  
reviews  see  (Maren  et  al  2013,  Rozeske  et  al  2015)).  
       
  
   With  the  substantial  evidence  for  the  critical  role  of  the  amygdala  in  fear  
learning  and  expression,  intensive  research  has  been  conducted  to  elucidate  the  
cellular  and  molecular  mechanisms  in  the  amygdala  (specifically  in  the  BLA)  
underlying  fear  conditioning.  Considerable  evidence  indicates  that  long-­term  
potentiation  (LTP)  of  synaptic  transmission  in  the  BLA  neurons  underlies  fear  
conditioning.    
  
LTP  was  first  discovered  in  the  hippocampus  (Bliss  &  Collingridge  1993a,  
Bliss  &  Lømo  1973).  Subsequently,  it  was  found  in  a  large  number  of  brain  
structures,  including  various  cortical  areas  (Artola  &  Singer  1987,  Hirsch  &  
Crepel  1992,  Iriki  et  al  1989),  the  amygdala  (Chapman  et  al  1990,  Clugnet  &  
LeDoux  1990)  and  the  midbrain  structures  (Liu  et  al  2005,  Overton  et  al  1999,  Pu  
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et  al  2006),  paved  the  way  for  a  widely  accepted  concept  of  synaptic  plasticity.  
Traditionally,  LTP  is  induced  by  high  frequency  stimulation  (HFS)  of  presynaptic  
afferents  or  by  pairing  presynaptic  activity  with  a  sufficient  level  of  postsynaptic  
depolarization.  In  both  cases,  the  NMDA  (N-­methyl-­d-­aspartate)  receptors  with  
bound  glutamate  are  allowed  to  be  relieved  from  Mg2+  blockade,  facilitating  a  
large  Ca2+  influx  into  postsynaptic  compartments,  resulting  in  a  cascade  of  
molecular  changes,  and  thereby  strengthening  the  synaptic  efficacy  for  
prolonged  periods,  referred  to  as  LTP  (Caporale  &  Dan  2008).    
  
   In  this  section,  I  will  first  briefly  introduce  the  evidence  supporting  the  
notion  that  increased  synaptic  efficacy  in  the  BLA  is  the  basis  of  fear  conditioning  
and  then  review  the  molecular  processes  underlying  fear  conditioning.  Upon  fear  
conditioning,  fear  memory  is  newly  formed  (or  acquired)  and  undergoes  a  further  
strengthening  process,  referred  to  as  ‘consolidation’,  where  it  becomes  stabilized  
and  resilient  to  rapid  decay  or  disruption  (McGaugh  2000).  Considerable  work  
has  been  done  to  understand  the  molecular  mechanisms  by  which  the  
transient/labile  synaptic  changes  become  stabilized  during  the  consolidation  
process.  At  the  end  of  this  section,  the  molecular  processes  in  the  amygdala  
underlying  consolidation  are  briefly  discussed  (for  a  thorough  review,  see  
(Johansen  et  al  2011)).  
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1.4.1  Cellular  mechanism  underlying  fear  conditioning:  synaptic  plasticity  
in  the  amygdala  
There  are  some  neurons  in  the  BLA  that  display  responses  to  both  
auditory  and  somatosensory  stimuli  (Romanski  et  al  1993),  leading  to  a  notion  
that  the  BLA  may  be  responsible  for  linking  information  about  the  CS  and  the  US  
(Maren  &  Quirk  2004).  Indeed,  it  has  been  shown  that  fear  conditioning  induces  
changes  in  the  electrophysiological  responses  of  the  BLA  neurons.  The  
responses  of  BLA  neurons  to  the  CS+  (tones  that  were  paired  with  shock),  but  
not  to  the  CS-­  (tones  that  did  not  paired  with  shock)  were  enhanced  following  
training  (Collins  &  Paré  2000,  Ghosh  &  Chattarji  2015,  McKernan  &  Shinnick-­
Gallagher  1997,  Quirk  et  al  1995,  Rogan  et  al  1997).    
  
Parallel  work  has  revealed  that  LTP  exists  at  the  thalamic  afferent  to  the  
BLA.  For  example,  in  a  study  utilized  HFS  protocol  demonstrated  that  by  
stimulation  of  the  medial  geniculate  body  (MGB,  a  part  of  the  auditory  thalamus),  
LTP  could  be  induced  in  the  BLA  (Clugnet  &  LeDoux  1990).  In  a  more  recent  
study,  Kwon  and  Choi  showed  that  contingent  pairings  of  MGB  stimulation  (CS)  
and  a  foot  shock  (US)  can  also  induce  LTP-­like  increases  in  the  evoked  field  
potentials  in  the  BLA  (Kwon  &  Choi  2009).  More  importantly,  by  concurrently  
measuring  CS-­evoked  field  potential  in  the  amygdala  and  CS-­evoked  freezing  
behavior,  LeDoux  and  colleagues  showed  that  fear  conditioning  alters  CS-­
evoked  responses  in  the  same  way  as  LTP  induction,  and  the  changes  in  CS-­
evoked  responses  reflect  the  processes  underlying  behavioral  fear  responses  
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(Rogan  et  al  1997).  LTP  has  also  been  shown  to  occur  at  the  cortical  input  to  the  
BLA  (Doyère  et  al  2003,  Schroeder  &  Shinnick-­‐‑Gallagher  2004,  Schroeder  &  
Shinnick-­‐‑Gallagher  2005).  However,  LTP  at  cortical  inputs  are  quite  different  
from  those  at  thalamic  input  in  terms  of  magnitude  and  duration.  Studies  have  
shown  that  the  magnitude  of  cortico-­amygdala  LTP  was  robust  within  24  hours  
and  gradually  faded  within  3  days.  In  contrast,  LTP  at  thalamic  input,  although  
initially  smaller  than  cortical  LTP,  can  remain  stable  for  a  longer  time  (6  days)  
(Doyère  et  al  2003).  These  findings  indicated  that  thalamic  and  cortical  inputs  
may  play  different  roles  in  the  acquisition  and  consolidation  of  fear  memory  
(Doyère  et  al  2003).  
     
One  of  the  essential  features  of  LTP  is  input-­specificity,  which  means  LTP  
is  only  induced  at  activated  synapses  rather  than  all  synapses  on  the  same  
neuron  (Bliss  &  Collingridge  1993b,  Nishiyama  et  al  2000).  Although  
considerable  work  has  been  done  to  explore  the  relationship  between  amygdalar  
LTP  and  fear  conditioning,  it  is  still  unclear  whether  input-­specific  LTP  in  the  
amygdala  is  associated  with  memory  in  fear  conditioning.  By  using  a  combination  
of  behavioral  labeling  approach,  electrophysiology  and  behavioral  paradigm,  a  
recent  study  performed  by  Kim  and  Cho  showed  that  discriminative  fear  
conditioning  induces  LTP  in  the  CS+  pathway  but  not  in  the  CS-­  pathway  to  the  
LA  (Kim  &  Cho  2017).  Furthermore,  by  employing  dual  behavioral  labeling  
approach,  they  were  able  to  show  that  upon  photostimulation  of  CS+-­responding  
auditory  cortex/thalamus  axons  (labeled  with  ChR2-­eYFP),  the  AMPA/NMDA  
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EPSC  ratio  was  only  increased  in  tdTomato-­positive  LA  neurons  labeled  by  fear  
conditioning,  but  not  in  non-­labeled  neurons  (Kim  &  Cho  2017).  Collectively,  
these  findings  showed  that  fear  conditioning  is  associated  with  synapse-­specific  
or  input-­specific  LTP  in  the  amygdala.    
  
   The  electrophysiological  studies  described  above  collectively  showed  that  
BLA  neurons  display  synaptic  plasticity  during  auditory  fear  conditioning.  While  
these  studies  provide  correlational  rather  than  causal  evidence  for  fear  
conditioning,  additional  studies  showed  that  disruption  of  synaptic  plasticity  in  the  
BLA  during  fear  conditioning  prevented  memory  formation  of  fear  conditioning.  
For  example,  application  of  NMDA  receptor  antagonists  APV  to  the  amygdala  
slices  impaired  HFS-­induced  LTP  at  the  thalamic  inputs  to  the  BLA  (Bauer  et  al  
2002);;  and  intra-­BLA  infusion  of  APV  blocked  the  acquisition  of  conditioned  fear  
(Campeau  et  al  1992,  Gewirtz  &  Davis  1997,  Kim  et  al  1991).  NMDA  receptor  is  
a  heteromeric  complex  comprised  of  two  different  subunits:  NR1  subunit,  which  
is  required  for  the  ion  pore,  and  NR2  subunit,  which  consists  of  proteins  NR2A-­
2D  and  has  been  suggested  to  modulate  the  biophysics  of  channels  (Monyer  et  
al  1992).  NMDA  receptors  with  NR2B  subunit  display  longer  excitatory  post-­
synaptic  potentials  (EPSPs)  (Monyer  et  al  1994),  indicating  NR2B-­containing  
NMDA  receptors  might  be  particularly  well  suited  for  the  coincidence  detection,  
and  thus  promoting  synaptic  plasticity  and  fear  conditioning.  Indeed,  intra-­
amygdala  infusion  of  ifenprodil,  a  selective  NR2B  receptor  antagonist  also  blocks  
LTP  at  thalamic  inputs  to  BLA  in  vitro  (Bauer  et  al  2002)  and  the  acquisition  of  
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conditioned  fear  in  vivo  (Rodrigues  et  al  2001).  Recently,  by  employing  advanced  
techniques,  Nabavi  and  his  colleagues  showed  that  optogenetically  induced  
depotentiation  in  the  auditory  input  to  the  LA  prevents  the  conditioned  fear  
responses  to  the  shock  (Nabavi  et  al  2014).  This  is  further  supported  by  a  more  
recent  study  performed  by  Kim  and  Cho,  showing  that  dampening  LTP  at  CS+  
pathway  to  the  LA  significantly  reduced  CS-­elicited  freezing  behavior  (Kim  &  Cho  
2017).    
  
1.4.2  Molecular  mechanisms  for  fear  acquisition  and  consolidation  
   The  overall  rise  in  the  intracellular  Ca2+  concentration  upon  NMDA  
receptors  activation  during  fear  conditioning  triggers  various  downstream  
signaling  pathways,  including  CaMKII  signaling,  protein  kinases  and  nNOS-­NO-­
PKG  signaling,  etc.  These  signaling  pathways  are  mutually  interconnected  and  
are  eventually  transduced  to  the  nuclei  to  regulate  protein  synthesis,  which  is  
essential  for  the  stabilization  of  synaptic  structures  and  the  consolidation  of  fear  
memory.  A  schematic  graph  summarizing  the  molecular  processes  in  the  
amygdala  mediating  fear  acquisition  and  consolidation  is  shown  in  Figure  2  and  
are  further  discussed  in  the  following  sections.  
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Figure  2.  A  working  model  of  molecular  cascades  in  the  amygdala  
mediating  acquisition  and  consolidation  of  fear  memory  
  
A  postsynaptic  increase  in  intracellular  Ca2+  concentration,  mediated  through  
Ca2+  influx  via  NMDARs,  voltage-­gated  calcium  channels  (VGCCs)  and  through  
the  release  from  intracellular  calcium  stores  upon  activation  of  metabotropic  
glutamate  receptors  (mGluRs),  triggers  various  downstream  signaling  cascades.  
Three  major  signaling  pathways  that  are  mutually  interconnected  are  
Ca2+/calmodulin-­dependent  protein  kinases  II  (CaMKII),  the  protein  kinase  (PK)  
family,  and  nNOS  pathways.  Signaling  mediated  by  activated  CaMKII  and  
PKA/PKC  include  phosphorylation  of  NMDARs  as  well  as  Ser845  site  of  GluR1,  
which  could  promote  AMPARs  insertion  to  the  synapses.  In  addition,  activation  of  
the  dopamine  receptor  (DR)  and  β-­adrenergic  receptor  (β-­AR)  could  also  
modulate  the  insertion  of  AMPARs  through  the  activation  of  PKA.  These  
molecular  cascades  are  thought  to  be  involved  in  the  acquisition  of  fear  memory.  
Protein  kinases  signals  converge  on  the  extracellular  regulated  kinases  (ERK)  
signaling  transduction  pathway.  ERK  translocates  into  the  nucleus  and  
phosphorylates  transcription  factors,  such  as  cAMP  response  element  binding  
protein  (CREB),  which  in  turn  triggers  mRNA  transcription  and  protein  synthesis  
that  is  critical  for  the  stabilization  of  synaptic  structures  and  the  consolidation  of  
fear  memory.  BDNF  (brain-­derived  neurotrophic  factor)-­TrkB  signaling  pathway  
could  also  regulate  protein  synthesis  via  activation  of  ERK.  The  role  of  
PSD95/nNOS-­NO-­PKG  signaling  in  the  memory  consolidation  is  of  particular  
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research  interest  as  it  regulates  ERK-­triggered  transcriptional  changes  not  only  in  
the  post-­synaptic  neurons  but  also  in  the  pre-­synaptic  neurons  via  diffusion  of  
NO  into  the  pre-­synapses;;  in  addition  to  the  transcriptional  effects,  NO  also  
cause  effects  on  protein  functions  at  both  pre-­  and  post-­synaptic  neurons  via  a  
post-­translational  modification  process  called  S-­nitrosylation  (this  part  will  be  
further  discussed  in  the  following  section).  CaM,  Calmodulin;;  IP3,  inositol  1,4,5-­
triphosphate;;  AC,  adenyl  cyclase;;  PI3-­K,  phosphatidylinositol-­3  kinase;;  EGR-­1,  
early  growth  response  gene  1;;  Arc,  activity-­regulated  cytoskeletal-­associated  
protein  
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1.4.2.1  Molecular  processes  in  the  amygdala  that  underlie  fear  acquisition  
CaMKII:  Upon  activation  by  increased  intracellular  Ca2+  signaling  through  
NMDARs,  CaMKII  undergoes  autophosphorylation  on  a  specific  threonine  
residue  (Thr286)  which  allows  the  kinase  to  remain  activated  even  after  the  
intracellular  Ca2+  concentration  fall  to  the  baseline  level  (Miller  &  Kennedy  1986,  
Yang  &  Schulman  1999).  Autophosphorylation  of  CaMKII  is  essential  for  memory  
formation  in  various  types  of  learning  models  (Silva  2003).  By  using  Pavlovian  
fear  conditioning,  studies  found  an  increased  level  of  autophosphorylated  (active)  
form  of  CaMKII  in  BLA  spines  15  min  following  fear  conditioning  (Rodrigues  et  al  
2004).  Furthermore,  intra-­amygdala  infusion  of  a  CaMKII  inhibitor,  KN-­62  prior  to  
conditioning  can  dose-­dependently  impair  fear  acquisition  (Rodrigues  et  al  2004).  
Autophosphorylation  of  CaMKII  can  then  engage  a  variety  of  downstream  
molecular  events  in  the  BLA,  which  participate  in  the  formation  of  fear  memories  
(Lisman  et  al  2002).  
  
   AMPA  receptors:  The  role  of  α-­amino-­3-­hydroxy-­5-­methyl-­4-­
isoxazolepropionic  acid  (AMPA)  receptors  in  the  fear  conditioning  was  revealed  
by  a  series  of  behavioral  studies  in  a  combination  of  molecular,  genetic  and  
electrophysiological  techniques.  It  has  been  shown  that  fear  conditioning  induces  
increased  synaptic  membrane  insertion  of  GluR1  subunit-­containing  AMPA  
receptors  in  the  BLA,  which  is  required  for  fear  memory  formation  (Humeau  et  al  
2007,  Rumpel  et  al  2005,  Yeh  et  al  2005).  In  animals  with  genetically  knock  out  
of  GluR1,  acquisition  of  auditory  fear  conditioning  and  LTP  at  thalamo-­BLA  
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spines  was  significantly  impaired  (Humeau  et  al  2007).  This  finding  was  
consistent  with  an  earlier  study  in  rats  showing  that  AMPA  receptors  trafficking  
into  the  synapses  of  LA  (part  of  the  BLA)  is  essential  for  fear  conditioning  in  a  
wild-­type  background  (Rumpel  et  al  2005).  In  this  study,  the  ability  to  learn  fear  
was  tested  in  animals  that  received  bilateral  intra-­LA  injections  of  virus  encoding  
the  C-­terminal  of  GluR1  fused  with  GFP.  This  recombinant  protein  acts  as  a  
dominant-­negative  construct  to  prevent  endogenous  GluR1-­AMPA  receptors  
from  trafficking  to  the  synapses.  Remarkably,  animals,  in  which  this  recombinant  
protein  was  expressed  in  as  few  as  10%-­20%  of  LA  neurons,  showed  a  
significant  impairment  in  fear  conditioning  (Rumpel  et  al  2005).    
  
   Monoamine  neurotransmitters:  Previous  studies  support  the  idea  that  
the  monoamine  neurotransmitters  such  as  norepinephrine  (NE)  and  dopamine  
(DA)  released  in  the  emotional  state  contributes  to  the  synaptic  plasticity  and  fear  
conditioning.  Aversive  stimulus  (foot  shock)  activates  neurons  in  the  locus  
coeruleus  (LC)  and  ventral  tegmental  area  (VTA),  which  result  in  increased  NE  
and  DA  content,  respectively,  to  the  amygdala  (Brischoux  et  al  2009,  Chen  &  
Sara  2007,  Galvez  et  al  1996,  Yokoyama  et  al  2005).  These  findings  implicated  
that  NE  and  DA  acting  through  their  respective  receptors  in  the  amygdala  may  
modulate  the  acquisition  of  fear  conditioning.  Indeed,  infusion  of  NE  β-­adrenergic  
receptors  (β-­AR  receptors)  antagonist,  propranolol  into  the  amygdala  prior  to  
training  impaired  acquisition  of  fear  conditioning  (Bush  et  al  2010).    
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   mGluRs:  Behavioral  and  pharmacological  studies  indicate  that  
metabotropic  glutamate  receptors  (mGluRs)  are  important  for  the  acquisition  of  
fear  memory.  Intra-­amygdala  infusion  of  2-­methyl-­6-­(phenyl-­ethynyl)-­pyridine  
(MPEP),  a  specific  mGluR5  antagonist,  dose-­dependently  impairs  the  
acquisition,  but  not  consolidation  of  fear  memory  (Rodrigues  et  al  2002).  In  
contrast,  intra-­amygdala  infusion  of  (R.S.)-­3,5-­dihydroxyphenylglycine  (DPHG),  a  
group  1  mGluR  agonist  enhances  fear  responses  typically  produced  by  weak  foot  
shock  (Rudy  &  Matus-­Amat  2009).  Furthermore,  LTP  at  thalamo-­BLA  synapses  
is  impaired  by  bath  application  of  MPEP  in  brain  slices  (Rodrigues  et  al  2002).  
  
   Summary  of  acquisition:  Evidence  from  previous  studies  suggests  that  
NMDA  receptors,  especially  those  containing  NR2B  subunits,  as  well  as  AMPA  
receptors  and  CaMKII  are  involved  in  the  acquisition  of  conditioned  fear.  In  
addition,  neuromodulators,  such  as  NE,  DA  and  mGluRs  may  also  regulate  the  
initial  formation  of  fear  memory.  
  
1.4.2.2  Molecular  processes  in  the  amygdala  that  underlie  fear  consolidation  
Consolidation  is  the  process  by  which  short-­lasting  memory  is  stabilized  
into  persistent  memory.  Unlike  covalent  modification  of  existing  synaptic  proteins,  
such  as  phosphorylation  of  glutamate  receptors  that  are  involved  in  the  
acquisition  of  conditioned  fear  responses,  consolidation  process  often  engages  
activation  of  second  messengers,  including  CREB,  ERK  and  NO.  Second  
messenger  signaling  are  eventually  transduced  into  the  nuclei  and  regulate  gene  
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transcription  and  protein  synthesis,  which  may  lead  to  structural  changes  at  the  
synapses  (e.g.,  morphological  changes  in  dendritic  spines)  (Lamprecht  &  LeDoux  
2004).  
  
   Gene  transcription  and  protein  synthesis:  Considerable  evidence  
indicates  that  both  gene  transcription  and  protein  synthesis  in  the  amygdala  are  
required  for  the  consolidation  of  fear  memory.  For  example,  intra-­BLA  infusion  of  
actinomycin-­D  (a  mRNA  synthesis  inhibitor)  before  training  disrupted  fear  
retention.  However,  fear  responses  to  the  CS-­US  pairings  in  the  initial  training  
session  remained  intact  (Bailey  et  al  1999).  This  finding  was  supported  by  a  later  
study  using  two  different  mRNA  synthesis  blockers,  α-­Amanitin  and  DRB.  Intra-­
amygdala  infusion  of  these  blockers  dose-­dependently  impairs  memory  retention  
of  conditioned  fear  tested  24  hours  after  acquisition,  but  leaves  the  short-­term  
memory  (tested  4  hours  after  acquisition)  intact  (Duvarci  et  al  2008).  Similarly,  
intra-­BLA  infusion  of  anisomycin,  a  protein  synthesis  inhibitor,  dose-­dependently  
attenuates  fear  memory  retention  24  hours  after  training,  but  the  short-­term  
memory  tested  4  hours  after  training  remain  intact  (Schafe  &  LeDoux  2000).    
  
   Protein  kinases:  Protein  kinases,  such  as  PKA  (protein  kinase  A),  PKC  
(protein  kinase  C)  and  MAPK  (mitogen-­activated  protein  kinase),  have  been  
shown  to  be  involved  in  the  consolidation  of  fear  memory.  They  may  exert  their  
effects  on  consolidation  via  phosphorylating  CREB  (cAMP  response  element  
(CRE)  binding  protein).  Activation  of  CREB  triggers  transcriptions  of  numerous  
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plasticity-­related  genes  through  binding  with  CRE  during  the  consolidation  
process  (Alberini  2009).  Behavioral  studies  with  pharmacological  and  genetic  
techniques  have  shown  that  both  PKA  and  PKC  are  required  in  the  BLA  for  the  
consolidation  of  fear  memory  (Goosens  et  al  2000,  Schafe  &  LeDoux  2000,  
Weeber  et  al  2000).  PKA  and  PKC  signals  are  known  to  converge  on  the  MAPK  
signaling  pathways  (Adams  &  Sweatt  2002).  MAPK,  originally  called  ERK  
(extracellular  regulated  kinase),  has  been  widely  implicated  in  the  long-­term  
synaptic  plasticity  and  memory  consolidation  (Kandel  2001,  Thomas  &  Huganir  
2004).  Studies  have  shown  that  MAPK  is  transiently  activated/phosphorylated  in  
the  BLA  following  fear  conditioning  and  intra-­amygdala  blockade  of  MAPK  with  
its  inhibitor  U0126  impairs  the  consolidation  of  fear  memory  (Schafe  et  al  2000).  
In  support  of  the  important  role  of  MAPK  in  fear  memory  consolidation,  intra-­
amygdala  inhibition  of  PI3-­K  (phosphatidylinositol-­3  kinase),  an  upstream  of  
MAPK,  also  blocked  consolidation  of  fear  memory  (Lin  et  al  2001).  
  
   BDNF  signaling:  Brain-­derived  neurotrophic  factor  (BDNF)  signaling  via  
tyrosine  kinase  receptor  B  (TrkB)  has  also  been  shown  to  be  involved  in  the  
consolidation  of  fear  memory  (Bekinschtein  et  al  2008,  Cowansage  et  al  2010).  
Several  studies  found  an  enhanced  BDNF  signaling  in  the  BLA  after  fear  
conditioning,  as  evidenced  by  increased  BDNF  mRNA  and  protein  levels  as  well  
as  activation  of  TrkB  receptors  (Ou  &  Gean  2006,  Ou  &  Gean  2007,  Ou  et  al  
2010,  Rattiner  et  al  2004a,  Rattiner  et  al  2004b).  Furthermore,  intra-­amygdala  
inhibition  of  BDNF-­TrkB  signaling  via  infusion  of  a  TrkB  ligand  scavenger  (TrkB-­
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IgG)  or  Trk  receptor  inhibitor  (K252a)  attenuates  memory  consolidation  of  
conditioned  fear  (Ou  et  al  2010).  In  addition,  stimulation  of  TrkB  receptors  
induces  activation  of  PI3-­K  and  MAPK,  indicating  that  BDNF  signaling  may  exert  
its  effects  on  fear  consolidation  through  activation  of  PI3-­K  and  MAPK  (Ou  &  
Gean  2006).  
  
   nNOS-­NO-­PKG  signaling:  In  response  to  NMDA  receptors-­mediated  
Ca2+  signaling,  activation  of  the  enzyme  neuronal  nitric  oxide  synthase  (nNOS)  
results  in  a  production  of  the  signaling  molecule  nitric  oxide  (NO).  NO  is  a  gas  
neurotransmitter  that  is  known  to  modulate  synaptic  plasticity  and  fear  memory  
via  both  pre-­  and  post-­synaptic  mechanisms  in  the  amygdala.  Studies  have  
shown  that  during  fear  conditioning,  NO  signaling  in  the  BLA  coordinately  
regulates  MAPK-­driven  transcriptional  changes  in  both  auditory  thalamus  and  
BLA  neurons  that  serve  to  regulate  pre-­  and  post-­synaptic  changes  at  thalamo-­
BLA  synapses,  respectively.  In  addition  to  the  transcriptional  effects,  NO  also  
exerts  effects  on  the  functions  of  several  plasticity-­related  proteins  via  a  
posttranslational  modification  called  S-­nitrosylation.  Disruption  of  nNOS-­NO-­PKG  
signaling  via  pharmacological  and  genetic  means  impairs  the  consolidation  of  
fear  memory.  This  topic  will  be  more  intensively  discussed  in  the  following  text  in  
section  1.5.  
  
   Structural  changes  at  the  synapses:  A  previous  study  reported  that  fear  
conditioning  produces  an  increase  in  synapse  size  in  the  amygdala  (Ostroff  et  al  
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2010),  and  this  increase  may  be  in  part  due  to  rearrangement  of  cytoskeletal  
filaments  (Lamprecht  &  LeDoux  2004).  Studies  have  shown  that  fear  conditioning  
induces  movement  of  profilin,  an  actin-­polymerization  regulatory  protein,  into  the  
spines  in  the  amygdala  and  profilin-­positive  spines  display  enlarged  sizes  
(Lamprecht  et  al  2006).  Fear  conditioning  does  not  only  affect  the  size  of  spines,  
but  also  has  been  shown  to  affect  the  spine  density  in  the  amygdala.  Previous  
work  using  immunostaining  or  Golgi-­Cox  staining  showed  that  the  spine  density  
in  the  amygdala  was  significantly  increased  after  fear  conditioning  (Heinrichs  et  
al  2013,  Radley  et  al  2006).  Alternations  in  the  spine  number  and  morphology  
have  been  thought  to  contribute  to  the  endurance  of  synaptic  changes  and  the  
long-­term  consolidation  of  memory  (Bonhoeffer  &  Caroni  2016,  Lamprecht  &  
LeDoux  2004).  
  
   Summary  of  consolidation:  Ca2+  influx  through  NMDA  receptors  during  
CS-­US  pairings  recruits  a  variety  of  protein  kinases,  including  PKA,  PKC  and  
MAPK,  which  in  turn,  activate  downstream  substrates  in  the  nucleus,  including  
CREB.  These  nuclear  substrates,  in  turn,  trigger  mRNA  transcription  and  new  
protein  synthesis  that  may  lead  to  structural  modifications  of  synapses  and  
thereby  contribute  to  the  consolidation  of  fear  memory.  Also,  neurotrophin  
signaling,  especially  BDNF-­TrkB  pathway,  facilitates  memory  stabilization  via  
activation  of  MAPK  and  PI3-­K.  The  role  of  nNOS-­NO-­PKG  signaling  in  the  
memory  consolidation  is  of  particular  research  interest  as  it  regulates  
transcriptional  changes  as  well  as  post-­translational  changes  not  only  in  the  post-­
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synaptic  neurons  but  also  in  the  pre-­synaptic  neurons  via  a  NO-­driven  retrograde  
signaling  mechanism.    
  
  
   Nitric  Oxide  (NO)  is  a  highly  soluble  gas  generated  by  the  conversion  of  
the  amino  acid  L-­arginine  to  L-­citrulline  by  the  members  of  the  nitric  oxide  
synthase  (NOS)  family  of  enzymes.  There  are  three  isoforms  of  NOS:  neuronal  
NOS  (nNOS),  endothelial  NOS  (eNOS)  and  inducible  NOS  (iNOS)  (Förstermann  
&  Sessa  2011).  nNOS  is  constitutively  expressed  in  brain  areas  such  as  the  
cortex,  the  amygdala,  the  hippocampus  and  etc.  It  has  been  widely  implicated  in  
the  regulation  of  synaptic  signaling  and  plasticity.  eNOS  is  expressed  primarily  in  
the  endothelial  cells  and  regulates  vascular  function.  Activities  of  nNOS  and  
eNOS  are  primarily  regulated  by  an  increase  in  the  intracellular  Ca2+,  which  
activate  nNOS  and  eNOS  through  calmodulin  binding  (Bredt  &  Snyder  1990).  
iNOS  is  expressed  in  many  cell  types  throughout  the  body  in  responses  to  pro-­
inflammatory  cytokines  or  endotoxins,  thus  playing  a  role  in  the  regulation  of  
immune  responses  (Förstermann  &  Sessa  2011).  Unlike  the  Ca2+-­  dependence  
feature  of  nNOS  and  eNOS  activity,  the  activity  of  iNOS  is  not  regulated  by  Ca2+  
signaling  (Galea  et  al  1992)  .  
  
In  this  section,  I  will  first  discuss  the  possible  mechanisms  through  which  
nNOS-­NO  signaling  may  affect  synaptic  plasticity,  and  then  summarize  the  
findings  from  the  behavioral  studies  using  fear  conditioning  paradigm  that  
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support  the  important  role  of  nNOS-­NO  signaling  in  conditioned  fear  memory.  A  
schematic  graph  summarizing  the  key  molecular  processes  involved  in  synaptic  
plasticity  that  are  affected  by  nNOS-­NO  signaling  is  shown  in  Figure  3  and  are  
further  discussed  in  the  following  sections.     
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Figure  3.  The  effects  of  nNOS-­NO  signaling  on  both  pre-­  and  post-­  synaptic  
molecular  processes  involved  in  synaptic  plasticity  
  
Upon  the  activation  of  nNOS  by  Ca2+/calmodulin,  NO  is  synthesized  (①)  and  
acts  on  a  wide  array  of  targets  mainly  through  the  following  two  mechanisms:  1)  
NO-­cGMP-­PKG  signaling  mechanism.  In  the  post-­synapse,  activation  of  
soluble  guanyl  cyclase  (sGC)  by  NO  produces  cyclic  GMP  (cGMP),  which  in  turn  
activates  a  variety  of  downstream  signaling,  including  cGMP-­dependent  protein  
kinase  (PKG)  (②).  Activated  PKG  has  been  found  to  form  a  complex  with  GluR1  
and  directly  phosphorylate  GluR1  (③),  which  promotes  synaptic  insertion  of  
AMPA  receptors.  Activated  PKG  also  phosphorylates  vasodilator-­stimulated  
phosphoprotein  (VASP),  which  may,  in  turn,  contribute  to  the  clustering  of  GluR1  
(④).  By  triggering  the  phosphorylation  of  the  transcription  factor  CREB,  PKG  
affects  the  transcription  of  a  variety  of  genes  that  are  required  for  the  
maintenance  of  LTP  (⑤).  Upon  its  synthesis,  NO  freely  diffuse  from  the  post-­
synapse  to  the  pre-­synapse  (⑥),  where  it  activates  sGC-­cGMP-­PKG  signaling  
pathway.  Activated  PKG  in  the  pre-­synapse  may  increase  the  clustering  of  
vesicle  related  proteins,  such  as  synaptophysin  and  synapsin  (⑦).  In  addition,  
presynaptic  N-­type  Ca2+  channel  activities  have  been  found  to  be  affected  by  
PKG  activity  (⑧).  2)  Post-­translational  modification  mechanism  by  S-­
nitrosylation.  In  the  presynapse,  S-­nitrosylation  of  syntaxin  1,  an  essential  
component  of  vesicle  release/fusion  machinery,  releases  syntaxin  1  from  
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interaction  with  Munc  18-­1,  thereby  facilitating  the  interaction  of  syntaxin  1  with  
vesicular  fusion  machinery  and  the  resulted  vesicle  release.  Synaptobrevin  and  
SNAP25,  the  other  two  essential  components  of  vesicle  release  machinery  have  
also  been  shown  to  be  S-­nitrosylated  (⑨).  In  the  post-­synapse,  receptors  like  
NR2A  subunit  of  NMDARs  and  scaffolding  proteins,  such  as  PSD95,  NSF  (N-­
ethylmaleimide  sensitive  factor),  gephyrin  and  stargazin  can  be  nitrosylated  by  
NO,  which  in  turn  produce  various  synaptic  outcomes  (⑩).    
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1.5.1  NMDA-­nNOS-­NO  signaling  in  the  modulation  of  synaptic  plasticity  
   The  first  evidence  supporting  a  role  for  NO  as  a  neurotransmitter  was  
reported  by  Garthwaite  et  al.,  who  observed  that  by  acting  on  NMDARs  in  the  
cerebellum,  glutamate  induces  the  release  of  a  diffusible  molecule  with  similar  
properties  to  endothelial-­derived  relaxation  factor  (EDRF)  (Garthwaite  et  al  
1988).  Before  this  study  was  published,  research  has  shown  that  the  biological  
activity  and  chemical  properties  of  NO  were  indistinguishable  from  those  of  
EDRF,  suggesting  that  NO  and  EDRF  are  identical  (Ignarro  et  al  1987,  Palmer  et  
al  1987).  Subsequently,  a  larger  number  of  studies  have  shown  that  NO  acts  as  
a  neurotransmitter  and  modulates  synaptic  activities  at  many  synapses  
throughout  CNS.  
  
   Upon  the  activation  of  nNOS  by  Ca2+/calmodulin,  NO  is  synthesized  and  
freely  diffuses  from  cell  to  cell.  After  synthesis,  NO  acts  on  a  wide  array  of  
targets,  among  which  soluble  guanyl  cyclase  (sGC)  is  the  most  prominent  one.  
Activation  of  sGC  by  NO  produces  cyclic  GMP  (cGMP),  which  in  turn  activates  a  
variety  of  downstream  signaling,  including  cGMP-­dependent  protein  kinase  
(PKG).  It  has  been  established  that  NO-­cGMP-­PKG  signaling  pathway  plays  a  
role  in  the  synaptic  plasticity  in  various  brain  regions.  In  addition  to  the  cGMP-­
mediated  signaling,  NO  also  exerts  synaptic  effects  via  a  posttranslational  
modification  mechanism.  By  covalently  binding  to  the  cysteines  of  proteins  (S-­
nitrosylation),  NO  affects  the  activities  of  key  proteins  involved  in  synaptic  
transmission  and  vesicle  release.    
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1.5.1.1  Role  of  NO-­cGMP-­PKG  signaling  in  synaptic  plasticity  
   As  discussed  above  in  section  1.4.2,  activation  of  NMDA  receptors  
induces  clustering  of  AMPA  receptors,  especially  GluR1  subunit  to  the  post-­
synaptic  membrane,  which  plays  a  critical  role  in  the  formation  of  LTP.  Studies  
have  found  that  inhibitors  of  nNOS  or  PKG  can  block  both  the  synaptic  
potentiation  and  the  increase  in  GluR1  cluster  induced  by  glutamate  in  
hippocampal  neurons  (Wang  et  al  2005).  Moreover,  the  blockade  of  GluR1  
clustering  can  be  rescued  by  8-­pCPT-­cGMP,  a  potent  cGMP  analog  which  
activates  PKG  (Wang  et  al  2005).  Vasodilator-­stimulated  phosphoprotein  (VASP)  
is  a  synaptic  protein  that  has  been  implicated  in  the  stabilization  of  actin  following  
glutamate  stimulation.  Further  experiments  found  that  during  potentiation,  
activated  PKG  phosphorylated  VASP,  which  may,  in  turn,  contribute  to  the  
clustering  of  GluR1  by  regulating  the  dynamics  of  actin  (Wang  et  al  2005).  In  
addition,  in  a  separate  study,  Serulle  et  al.  found  that  activated  PKG  induced  by  
NO  donor  application  forms  a  complex  with  GluR1  and  in  this  complex,  PKG  
phosphorylates  GluR1  at  S845,  which  promotes  the  priming  of  AMPA  receptors  
for  synaptic  insertion  (Serulle  et  al  2007).  Overall,  these  findings  clearly  
suggested  involvement  of  NO-­cGMP-­PKG  signaling  pathway  in  the  modulation  of  
synaptic  plasticity,  and  the  effects  of  this  pathway  on  plasticity  may  act  through  
the  mechanisms  regulating  AMPARs  trafficking.    
  
   Previous  studies  have  also  indicated  a  different  mechanism  by  which  NO-­
cGMP-­PKG  signaling  pathway  regulates  synaptic  potentiation,  especially  the  
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maintenance  of  potentiation.  This  mechanism  involves  the  phosphorylation  of  the  
transcription  factor  CREB  (cAMP  response  element  binding  protein)  and  the  
expression  of  a  variety  of  genes.  Studies  have  shown  that  during  the  late  phase  
of  LTP  (L-­LTP),  which  persisted  beyond  one  hour,  phosphorylation  of  CREB  was  
enhanced  in  the  hippocampus  (Lu  et  al  1999).  Furthermore,  both  increased  
phospho-­CREB  and  L-­LTP  can  be  blocked  by  either  direct  PKG  inhibition  or  
inhibition  of  the  PKG  downstream  target,  the  ryanodine  receptors  (Lu  &  Hawkins  
2002).  Upon  the  phosphorylation  of  CREB,  the  transcriptional  program  is  initiated  
and  is  thought  to  produce  new  RNA  and  protein  synthesis  that  are  required  for  
the  maintenance  of  LTP  (Benito  &  Barco  2010).  
  
   Earlier  studies  have  found  that  hippocampal  LTP  can  also  be  impaired  by  
hemoglobin  and  oxymyoglobin  which  bind  NO  and  cannot  be  taken  up  by  cells  
(O'dell  et  al  1991,  Schuman  &  Madison  1991).  On  the  contrary,  LTP  can  be  
facilitated  by  NO  donor  when  it  was  injected  into  the  presynaptic  neurons  
(Arancio  et  al  1995,  Arancio  et  al  1996).  Increased  cGMP  was  also  found  in  the  
presynaptic  neurons  after  NO  donor  treatment  (Southam  &  Garthwaite  1993).  
These  findings  suggested  that  NO  might  act  as  a  retrograde  messenger  that  
induces  cGMP  formation  in  the  pre-­synaptic  terminals,  thus  modulating  cellular  
processes  which  are  required  for  LTP.  In  support  of  this  view,  a  subsequent  
study  found  an  increase  in  clusters  of  presynaptic  protein  synaptophysin  during  
potentiation  and  this  increase  was  accompanied  by  NO-­mediated  increase  in  
cGMP  (Wang  et  al  2005).  Furthermore,  increased  synaptophysin  cluster  can  be  
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reduced  by  PKG  inhibitor,  Rp-­8-­Br-­cGMPS  (Wang  et  al  2005).    Evidence  from  
other  synapses  also  supports  a  presynaptic  site  of  action  of  NO-­cGMP-­PKG  
signaling.  At  cerebellar  mossy  fiber-­granule  cell  synapses,  NO  induces  
presynaptic  current  changes  during  LTP  induction  (Maffei  et  al  2003).  In  rostral  
ventrolateral  medulla  neurons,  the  NO  donor  spermine  NONOate  was  found  to  
significantly  promote  glutamate  release  through  enhanced  presynaptic  N-­type  
Ca2+  channel  activities  that  mediated  by  cGMP-­PKG  signaling  (Huang  et  al  
2003).  
  
1.5.1.2  Role  of  S-­nitrosylation  in  synaptic  plasticity    
   In  addition  to  the  NO-­cGMP-­PKG  signaling  pathway  discussed  above,  NO  
has  also  been  implicated  in  other  pathways,  including  posttranslational  
modification.  NO  can  lead  to  nitrosylation  of  the  thiol  side  chain  of  cysteine  
termed  S-­nitrosylation  (–SNO,  the  addition  of  a  NO  molecule  to  a  thiol  group).  S-­
nitrosylation  can  cause  effects  on  protein  activities,  protein  structures  and  
protein-­protein  interactions.  Increasing  evidence  shows  that  critical  proteins  
which  mediate  synaptic  transmission  and  plasticity  can  undergo  S-­nitrosylation  at  
both  pre-­synaptic  and  post-­synaptic  sites.  
  
   At  the  pre-­synaptic  site:  There  is  a  large  protein  complex  regulating  
vesicular  release  of  neurotransmitters  termed  as  SNARE  proteins  (an  acronym  
derived  from  soluble  N-­ethylmaleimide  sensitive  factor  attachment  protein  
receptor).  Vesicular  SNAREs  (vSNAREs,  located  on  synaptic  vesicles),  such  as  
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synaptobrevin  and  target  SNAREs  (tSNAREs,  located  on  the  presynaptic  
membrane),  such  as  SNAP-­25  and  syntaxin  are  essential  components  of  vesicle  
release/fusion  machinery.  A  previous  study  has  found  that  NO  donor  caused  
widespread  S-­nitrosylation  of  proteins  in  purified  synaptic  vesicle  fractions,  
including  above-­mentioned  SNAREs  (Prior  &  Clague  2000).  Later  studies  
identified  specific  sites  in  some  of  SNARE  proteins  to  be  S-­nitrosylated.  For  
example,  a  study  demonstrated  that  Cys145  of  syntaxin  1  can  be  S-­nitrosylated  by  
NO  donor  treatment  in  rat  brain  homogenates  and  S-­nitrosylation  at  this  site  acts  
as  a  molecular  switch,  turning  off  the  closed  state  of  syntaxin  1  by  releasing  it  
from  interaction  with  Munc  18-­1,  thereby  facilitating  the  interaction  of  syntaxin  1  
with  vesicular  fusion  machinery  and  the  resulted  vesicle  release  (Palmer  et  al  
2008).  Expression  of  nitrosomimetic  syntaxin  1  (a  mutated  syntaxin  1  with  a  
mutation  that  approximate  an  S-­nitrosylated  cysteine  residue)  in  living  cells  
disrupts  Munc  18-­1  interaction  with  syntaxin  and  alters  exocytosis  release  kinetic  
and  quantal  size  (Palmer  et  al  2008).    
  
   At  the  post-­synaptic  sites:  S-­nitrosylation  modifies  the  functions  and  
structures  of  a  variety  of  receptors  and  scaffolding  proteins.  Studies  have  
reported  a  critical  cysteine  residue  (Cys  399)  in  NR2A  subunit  of  NMDA  
receptors  undergoes  S-­nitrosylation  by  both  exogenous  and  endogenous  NO.  
When  this  single  cysteine  was  substituted  by  alanine  (an  amino  acid  that  cannot  
be  S-­nitrosylated),  inhibition  of  NMDA-­evoked  currents  by  endogenous  NO  was  
significantly  abolished  (Choi  et  al  2000).  NMDA  receptors  are  located  within  the  
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post-­synaptic  density  regions  which  contains  a  principal  scaffolding  protein  post-­
synaptic  density-­95  (PSD95)  that  influence  synaptic  plasticity.  Compelling  
evidence  has  shown  that  NO  physiologically  nitrosylated  PSD95  at  Cys3  and  
Cys5,  and  thus  inhibiting  synaptic  PSD95  clustering  (Ho  et  al  2011).  Another  
post-­synaptic  receptor  that  undergoes  S-­nitrosylation  is  AMPA  receptor.  Previous  
work  has  shown  that  the  GluR1  subunit  of  AMPA  receptor  is  physiologically  S-­
nitrosylated  under  basal  conditions  and  upon  the  stimulation  of  NMDA  receptors,  
S-­nitrosylation  of  GluR1  became  increased  (Selvakumar  et  al  2013).  Moreover,  
S-­nitrosylation  of  GluR1  has  been  found  to  play  an  important  role  in  regulating  
NMDARs-­dependent  phosphorylation  of  GluR1  (Selvakumar  et  al  2013).  A  family  
of  small  transmembrane  AMPA  receptor  regulatory  proteins  is  auxiliary  subunits  
of  AMPARs  that  control  both  AMPARs  trafficking  and  channel  gating.  Stargazin  
and  NSF  (N-­ethylmaleimide  sensitive  factor)  are  two  of  these  auxiliary  subunits  
that  have  been  best  characterized  (Nicoll  et  al  2006).  It  has  been  reported  that  
stargazin  also  undergoes  S-­nitrosylation  under  physiological  condition.  
Nitrosylated  stargazin  has  a  higher  binding  affinity  with  GluR1,  causing  increased  
surface  expression  of  AMPAR  (Selvakumar  et  al  2009).  Similarly,  it  has  been  
shown  that  NO  production  upon  NMDARs  stimulation  elicits  S-­nitrosylation  of  
NSF  whose  binding  with  GluR2  is  thereby  enhanced,  thus  facilitating  the  surface  
insertion  of  AMPARs  (Huang  et  al  2005).  Gephyrin  is  one  of  the  key  scaffolding  
protein  at  inhibitory  synapses  that  is  essential  for  post-­synaptic  clustering  of  
GABAARs.  A  series  of  studies  found  that  gephyrin  interacts  with  nNOS  and  that  
gephyrin  is  S-­nitrosylated  in  vivo.  Pharmacological  inhibition  of  nNOS  caused  a  
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loss  of  S-­nitrosylation  of  gephyrin  and  a  larger  cluster  of  gephyrin  at  synaptic  
sites,  ultimately  increasing  the  surface  expression  of  GABAARs  and  enhancing  
inhibitory  transmission  (Dejanovic  &  Schwarz  2014).  
  
1.5.2  Evidence  for  the  role  of  nNOS-­NO  signaling  in  conditioned  fear  from  
animal  studies  
   The  critical  role  of  NO  signaling  in  the  formation  of  conditioned  fear  has  
been  revealed  by  a  series  of  studies  utilizing  pharmacological  and  genetic  
techniques  in  a  combination  of  animal  models  of  fear  conditioning.  A  study  
performed  by  Schafe  et  al.  showed  that  intra-­amygdala  infusion  of  NOS  inhibitor  
7-­Nitroindazole  (7-­Ni)  impairs  the  consolidation  of  fear  memory  using  a  rat  model  
of  auditory  fear  conditioning  (Schafe  et  al  2005).  This  fear-­reducing  effect  of  NOS  
inhibition  was  later  shown  to  act  through  NO-­cGMP-­PKG  pathway  (Ota  et  al  
2008).  Intra-­amygdala  infusion  of  either  PKG  inhibitor  Rp-­8-­Br-­PET-­cGMPS  or  
PKG  agonist  8-­Br-­cGMP  dose-­dependently  attenuates  or  improves  fear  memory  
consolidation,  respectively  (Ota  et  al  2008).  Consistent  with  this  finding,  PKG-­
deficient  animals  also  exhibit  impaired  cued  fear  memory  retention  (Paul  et  al  
2008).  Interestingly,  the  consolidation  of  cued  fear  memory  can  also  be  disrupted  
by  intra-­amygdala  infusion  of  NO  scavenger  c-­PTIO  (Schafe  et  al  2005).  In  
addition,  bath  application  of  either  7-­Ni  or  c-­PTIO  effectively  blocked  LTP  at  
thalamic  inputs  to  the  BLA  (Schafe  et  al  2005).  Considering  that  c-­PTIO  is  
membrane-­impermeable,  these  findings  strongly  suggested  that  both  nNOS  
activation  and  NO  diffusion  into  extracellular  spaces  are  required  for  synaptic  
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plasticity  and  fear  memory  formation.  Animal  studies  with  genetic  manipulations  
also  supported  the  important  role  of  nNOS-­NO  signaling  in  conditioned  fear  
memory.  Mice  with  nNOS  gene  knock  out  exhibit  impairments  in  both  cued  fear  
learning  and  contextual  fear  learning  (Kelley  et  al  2009).    
  
   Auditory  fear  conditioning  has  been  shown  to  be  associated  with  
significant  increases  in  the  expressions  of  several  synaptic  proteins  in  the  
amygdala,  such  as  GluR1  at  the  postsynaptic  membrane,    synapsin  and  
synaptophysin  at  the  presynaptic  membrane  (Ota  et  al  2010).  Studies  have  
shown  that  these  pre-­  and  post-­synaptic  changes  are  regulated  by  NO-­cGMP-­
PKG  signaling  pathway.  Intra-­amygdala  infusion  of  either  7-­Ni  or  Rp-­8-­Br-­PET-­
cGMPS  significantly  reduces  fear  conditioning  induced  expression  of  GluR1,  
synapsin  and  synaptophysin  in  the  LA,  whereas  animals  received  intra-­amygdala  
infusion  of  8-­Br-­cGMP  displayed  increased  expression  of  these  proteins  in  the  LA  
(Ota  et  al  2010).  However,  animals  infused  with  NO  scavenger  c-­PITO  only  
showed  reduced  expression  of  synapsin  and  synaptophysin  in  the  LA,  but  no  
impairment  in  the  expression  of  GluR1  (Ota  et  al  2010).  These  results  suggested  
that  NO-­cGMP-­PKG  signaling  pathway  regulates  both  pre-­  and  post-­synaptic  
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   nNOS  is  preferentially  activated  by  the  Ca2+  influx  through  the  NMDA  
receptors  but  not  through  non-­NMDA  receptors  that  also  generate  Ca2+  influx  
(Kiedrowski  et  al  1992,  Sattler  et  al  1999),  suggesting  a  specific  link  between  
NMDA  receptors  mediated  Ca2+  signaling  and  nNOS.  Studies  have  identified  a  
ternary  complex  containing  NMDA  receptors,  PSD95  and  nNOS  (Christopherson  
et  al  1999).  PSD95  in  this  complex  serves  as  a  linker  that  brings  nNOS  in  the  
proximity  of  the  NMDA  receptors,  where  nNOS  can  be  efficiently  activated  by  
Ca2+  infux  through  NMDA  receptors  (Christopherson  et  al  1999).  In  the  following  
sections,  I  will  describe  the  structures  of  nNOS  enzyme,  especially  the  PDZ  
domain  of  nNOS  that  interact  with  PSD95,  followed  by  an  introduction  of  small  
molecules  that  disrupt  PSD95-­nNOS  interaction.  
  
1.6.1  Structure  and  isoforms  of  nNOS  enzyme  
   The  structure  of  nNOS  monomer  consists  of  two  domains:  oxygenase  
domain  (N-­terminal)  and  reductase  domain  (C-­terminal),  which  are  separated  by  
a  calmodulin  (CaM)  binding  motif.  The  oxygenase  domain  is  responsible  for  the  
binding  of  the  substrate  L-­arginine.  It  also  contains  binding  sites  for  
tetrahydrobiopterin  (BH4)  and  haem.  The  reductase  domain  binds  the  reduced  
adenine  dinucleotide  phosphate  (NAPDH)  and  contains  binding  sites  for  flavin  
mononucleotide  (FMN)  and  Flavin  adenine  dinucleotide  (FAD)  (Figure  4A).  
nNOS  monomer  is  capable  of  transferring  electrons  (e-­)  provided  by  NADPH  to  
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FDA  and  FMN  and  has  a  limited  capacity  to  catalyze  NO  production.  Therefore,  
nNOS  displays  limited  activity  as  monomer.  Upon  binding  of  cofactor  BH4,  haem  
and  L-­arginine,  nNOS  became  a  functional  dimer,  coupling  haem  and  O2  
reduction  to  the  synthesis  of  NO  (Figure  4B).  Binding  of  CaM  facilitates  the  flow  
of  NADPH-­derived  electrons  in  the  reductase  domain  to  the  location  of  haem  in  
the  oxygenase  domain,  thus  enhancing  nNOS  activity  (Abu-­Soud  &  Stuehr  1993,  
Noguchi  et  al  2001,  Roman  &  Masters  2006,  Sagami  et  al  2001,  Szaciłowski  et  al  
2005).  
  
   Due  to  alternations  in  mRNA  splicing,  there  are  five  isoforms  of  nNOS:  
nNOSα,  nNOSβ,  nNOSγ,  nNOSμ  and  nNOS-­2  (Luo  &  Zhu  2011).  Only  nNOSα  
and  nNOSμ  have  an  N-­terminal  PDZ  domain  (post-­synaptic  density/Discs-­
large/ZO-­1)  that  participates  in  the  dimerization  of  nNOS  and  interacts  with  other  
proteins  via  PDZ-­PDZ  interactions,  including  PSD95  (Luo  &  Zhu  2011).  nNOSα  is  
the  full-­length  form  of  nNOS  with  a  predicted  molecular  weight  of  160  KDa.  It  is  
the  predominant  isoform  in  the  brain  that  contributes  significantly  to  NO  
production  (Alderton  et  al  2001).  nNOSμ  is  a  muscle-­specific  isoform  of  nNOS  
with  a  unique  34-­amino  acid  insertion  between  the  FMN  and  Calmodulin  domains  
(Silvagno  et  al  1996).  In  vitro  experiments  with  purified  nNOSμ  demonstrated  that  
nNOSμ  has  a  similar  catalytic  activity  to  that  of  nNOSα,  and  the  dependence  of  
its  activity  on  Ca2+/CaM  is  also  very  similar  to  that  of  nNOSα  (Silvagno  et  al  
1996).  Due  to  the  lacking  of  PDZ  domain,  nNOSβ  and  nNOSγ  are  thought  to  be  
localized  to  the  cytosolic  fraction  and  might  not  be  responsive  to  NMDARs  
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stimulation  (Brenman  et  al  1996).  Catalytic  assays  in  COS  cells  with  
overexpression  of  nNOSβ  or  nNOSγ  indicated  that  nNOSγ  displayed  limited  
activity  which  was  ~3%  that  of  nNOSα,  whereas  nNOSβ  had  activity  comparable  
to  nNOSα  (~80%  of  nNOSα)  (Brenman  et  al  1996).  Previous  studies  using  in  situ  
hybridization  and  immunostaining  showed  that  nNOSβ  also  accounts  for  NO  
production  in  the  brain,  especially  in  the  cortex  and  striatum  (Eliasson  et  al  
1997).    nNOS-­2  has  been  detected  in  mouse  brain  (Ogura  et  al  1993)  and  
human  neuroblastoma  cell  lines  (Fujisawa  et  al  1994).  It  has  a  deletion  of  105  
amino  acids  in  the  L-­arginine  binding  domain,  leading  to  speculation  that  nNOS-­2  
may  be  catalytically  inactive  and  negatively  regulate  the  activity  of  nNOS  
(Brenman  et  al  1997).  The  functional  role  of  nNOS-­2  in  the  brain  remains  
unclear.       
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Figure  4.  Schematic  representation  of  nNOS  protein  structure  
  
(A)  The  structure  of  nNOS  consists  of  two  domains:  The  N-­terminal  oxygenase  
domain  and  the  C-­terminal  reductase  domain,  which  are  linked  by  a  calmodulin  
(CaM)  binding  motif.  The  reductase  domain  contains  binding  sites  for  
nicotinamide  adenine  dinucleotide  phosphate  (NAPDH),  flavin  adenine  
dinucleotide  (FAD)  and  flavin  mononucleotide  (FMN).  The  oxygenase  domain  
binds  the  substrate  L-­arginine  and  contains  binding  sites  for  tetrahydrobiopterin  
(BH4)  and  haem.  Electrons  transfers  from  the  reductase  domain  to  the  
oxygenase  domain.  Adapted  from  Zhou  &  Zhu,  2005  (B)  Scheme  of  nNOS  dimer.  
Arrows  indicate  electron  transfer  pathways.  Dimerization  of  two  oxygenase  
domains  allows  NADPH-­derived  electrons  to  transfer  from  FAD  and  FMN  to  
hame  irons;;  Electron  transfer  between  reductase  and  oxygenase  domains  on  the  
same  subunit  does  not  occur.  Adapted  from  Szaciłowski  et  al  2005.  
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1.6.2  Mechanisms  for  PSD95/nNOS  PDZ  dimer  formation  
   The  nNOS  PDZ  domain  terminates  with  a  ~30  residue  amino  acids,  which  
forms  the  β  finger  peptide.  Previous  studies  have  shown  that  the  β  finger  peptide  
is  required  for  PSD95/nNOS  PDZ  dimer  formation  (Christopherson  et  al  1999,  
Tochio  et  al  2000).  Furthermore,  point  mutational  analysis  indicated  that  the  salt  
bridge  between  Arg121  in  the  β  finger  peptide  and  Asp62  in  the  canonical  PDZ  
domain  of  nNOS  is  critical  for  the  binding  of  β  finger  peptide  with  PSD95  PDZ2.  
Disruption  of  this  salt  bridge  by  Arg121Gln  mutation  melts  the  β  finger  structure,  
therefore  preventing  nNOS  PDZ  from  binding  to  PSD  PDZ2  (Tochio  et  al  2000)  
(Figure  5).     
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Figure  5.  The  ternary  complex  containing  NMDA  receptors,  PSD-­95  and  
nNOS  
  
The  NR2B  subunit  of  NMDA  receptors  interacts  with  both  the  first  and  second  
PDZ  domain  of  PSD-­95  via  its  C-­terminus  (tSXV  motif)  (Kornau  et  al  1995).  
nNOS  interact  with  the  second  PDZ  domain  of  PSD-­95  via  the  β  finger  peptide,  
which  is  a  30-­amino  acid  extension  beyond  the  canonical  nNOS  PDZ  domain.  
PSD-­95  serves  as  a  scaffolding  protein  that  links  nNOS  to  the  proximity  of  the  
NMDA  receptors,  where  nNOS  can  be  efficiently  activated  by  the  stimulation  of  
NMDA  receptors  to  produce  NO.  Adapted  from  Christopherson  et  al  1999.  
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1.6.3  Small  molecules  disrupting  PSD95/nNOS  interaction  
   Disruption  of  PSD95/nNOS  interaction  has  been  achieved  with  a  group  of  
unique  small  molecules.  2-­((1H-­benzo  {d}  {1,2,3}  triazol-­5-­ylamino)  methyl)-­4,6-­
dichlorophenol  (IC87201)  was  first  identified  in  a  high  throughput  screen  using  a  
PSD95/nNOS  binding  assay  with  an  IC50  of  31  µM  (Florio  et  al  2009).  IC87201  
inhibited  NMDARs  dependent  cGMP  production  (an  indirect  measurement  of  NO  
production)  in  neuronal  cultures  and  it  attenuates  nerve-­injury  induced  
mechanical  allodynia  (Florio  et  al  2009)  as  well  as  formalin-­evoked  nociceptive  
behavior  in  rats  (Carey  et  al  2017).  An  analog  related  to  IC87201,  4-­(3,5-­
Dichloro-­2-­hydroxy-­benzylamino)-­2-­hydroxybenzoic  acid  (ZL006)  was  
synthesized  based  on  the  molecular  determinants  required  for  PSD95  and  nNOS  
interaction  (Zhou  et  al  2010).  ZL006  was  designed  to  interact  with  several  
residues  in  the  nNOS  PDZ,  including  Arg121,  resulting  in  a  disrupted  salt  bridge  
which  is  critical  for  the  binding  of  nNOS  PDZ  to  PSD95  PDZ2.  ZL006  has  been  
verified  to  selectively  inhibit  PSD95/nNOS  interaction  without  affecting  PSD95  
interactions  with  other  proteins  (Lee  et  al  2015,  Zhou  et  al  2010).  In  rodents,  
ZL006  crosses  the  blood  brain  barrier  and  demonstrates  neuroprotection  (Zhou  
et  al  2010).  
  
  
   My  central  hypothesis  is  that  activation  of  the  NMDA  receptor  associated  
PSD95-­nNOS  complex  in  critical  limbic  regions  such  as  the  amygdala  and  
hippocampus  during  fear  conditioning  is  a  key  molecular  step  in  regulating  the  
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development  of  conditioned  fear,  and  disruption  of  this  protein-­protein  binding  
may  cause  impairments  in  conditioned  fear  memory.  
  
1.7.1  Fear  conditioning  associated  PSD95-­nNOS  interaction  in  critical  brain  
regions,  and  the  effects  of  small  molecule  mediated  disruption  of  PSD95-­
nNOS  interaction  
   Chapter  2  describes  how  I  determined  the  distribution  and  dynamics  of  
PSD95-­nNOS  interaction  within  the  conditioned  fear  network,  including  the  BLA,  
the  vHP  and  the  mPFC  following  fear  conditioning.  I  showed  that  fear  
conditioning  results  in  significant  increases  in  PSD95-­nNOS  binding  within  the  
BLA  and  the  vHP  in  a  time-­dependent  manner,  but  not  in  the  mPFC.  In  addition,  
systemic  treatment  with  a  small  molecule,  ZL006  that  disrupts  PSD95-­nNOS  
binding  shortly  after  fear  conditioning  prevented  the  increases  in  PSD95-­nNOS  
complex  in  both  BLA  and  vHP.  These  results  suggest  that  amygdalar  and  
hippocampal  PSD95-­nNOS  interaction  are  temporally  regulated  molecular  
processes  subsequent  to  fear  conditioning,  indicating  a  role  for  this  protein-­
protein  interaction  in  the  consolidation  of  fear  memory.  
  
1.7.2  The  effects  of  disruption  of  PSD95-­nNOS  interaction  on  conditioned  
fear  responses  and  other  non-­fear  related  behaviors  
In  chapter  3,  I  first  determined  the  effects  of  systemic  and  regional  
disruption  of  PSD95-­nNOS  binding  on  the  consolidation  of  conditioned  fear  
responses.  By  utilizing  a  rat  model  of  auditory  fear  conditioning,  I  showed  that  
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systemic  injection  of  ZL006,  a  small  molecule  that  disrupts  PSD95-­nNOS  
binding,  impairs  cue-­induced  fear  memory.  Disrupting  PSD95-­nNOS  binding  
directly  within  the  BLA  also  attenuates  cue-­induced  fear  memory.  In  contrast,  
disrupting  PSD95-­nNOS  binding  within  the  vHP  has  no  effects  on  cue-­induced  
fear  memory,  but  leads  to  an  impaired  context-­induced  fear  memory.  These  
results  indicate  that  PSD95-­nNOS  complex  in  different  brain  regions  mediate  
different  aspects  (cue-­  or  context-­related)  of  conditioned  fear  responses.  Next,  it  
was  shown  that  disruption  of  PSD95-­nNOS  interaction  by  ZL006  has  no  effects  
on  locomotion,  social  activity,  object  recognition  memory  and  spatial  memory.  
These  findings  indicate  that  the  disrupting  PSD95-­nNOS  interactions  with  ZL006  
may  be  specific  to  fear-­related  behaviors.  Disruption  of  PSD95-­nNOS  interaction  
may  represent  a  novel  therapeutic  approach  for  reducing  conditioned  fear  
responses  without  eliciting  motor  deficits  and  adverse  cognitive  effects.  
  
1.7.3  The  synaptic  mechanism  in  the  amygdala  associated  with  conditioned  
fear  and  the  effects  of  disruption  of  PSD95-­nNOS  interaction    
   In  chapter  4,  the  cellular  and  network  mechanism  underlying  the  effects  of  
ZL006  on  conditioned  fear  memory  was  investigated.  By  utilizing  
electrophysiological  recording  in  amygdalar  slices,  it  was  shown  that  disruption  of  
PSD95-­nNOS  interaction  by  ZL006  application  blocks  the  long-­term  potentiation  
(LTP),  a  cellular  model  of  memory  in  the  BLA  neurons.       
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CHAPTER  2    
Fear  Conditioning  Associated  PSD95-­nNOS  Interaction  in  Critical  Brain  




   PSD95  is  a  scaffolding  protein  that  interacts  with  both  nNOS  and  NMDA  
receptors  at  excitatory  synapses  and  assembles  them  into  a  ternary  signaling  
complex  (Christopherson  et  al  1999,  Sattler  et  al  1999).  Efficient  activation  of  
nNOS  requires  its  interaction  with  PSD95,  which  brings  it  to  the  proximity  of  
NMDA  receptors  and  thus  the  NMDAR-­mediated  calcium  influx  (Zhou  &  Zhu  
2009).  Therefore,  the  interaction  between  PSD95  and  nNOS  serves  as  a  key  
factor  in  the  regulation  of  nNOS  activity  upon  NMDARs  stimulation.  It  is  known  
that  nNOS  signaling  is  one  of  the  critical  molecular  cascades  triggered  by  the  
activation  of  NMDA  receptors  that  underlie  memory  formation  of  conditioned  fear  
(Ota  et  al  2010,  Ota  et  al  2008).  Inhibition  of  nNOS,  similar  to  NMDARs  
antagonism,  has  been  shown  to  disrupt  fear  memory  in  multiple  animal  models  of  
fear  conditioning  (Kelley  et  al  2009,  Pavesi  et  al  2013,  Schafe  et  al  2005).  
Despite  of  the  involvement  of  nNOS  signaling  in  fear  conditioning,  little  is  known  
about  the  distribution  and  dynamics  of  PSD95-­nNOS  complex  within  the  
conditioned  fear  network  during  the  processes  of  fear  memory  formation.  In  this  
chapter,  by  using  co-­immunoprecipitation  technique,  I  tested  if  fear  conditioning  
can  time-­dependently  induce  significant  increases  in  PSD95-­nNOS  binding  within  
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the  CNS  circuit  implicated  in  conditioned  fear  that  includes  the  amygdala,  the  
hippocampus  and  the  mPFC;;  and,  if  pretreatment  of  ZL006,  a  small  molecule  
that  disrupts  PSD95-­nNOS  interaction  can  prevent  the  increases  in  PSD95-­
nNOS  complex  within  the  conditioned  fear  network.  
  
  
Fear  conditioning  induced  robust  increases  in  PSD95-­nNOS  interaction  
within  the  BLA  and  the  vHP,  but  not  in  the  mPFC  
In  the  first  experiment,  by  using  co-­immunoprecipitation,  I  determined  the  
PSD95-­nNOS  complex  levels  within  the  conditioned  fear  network  at  several  time  
points  following  conditioned  fear  training.  Animals  who  underwent  fear  
conditioning  training  were  sacrificed  and  the  levels  of  PSD95/nNOS  binding  in  
the  BLA,  the  vHP  and  the  mPFC  were  quantified  with  co-­immunoprecipitation  
(Co-­IP)  with  nNOS  antibody  followed  by  immunoblotting  with  nNOS  and  PSD95  
antibodies.  Previous  studies  showed  that  molecular  changes  usually  occur  within  
several  hours  (<  6  h)  following  fear  conditioning  (Igaz  et  al  2002,  Schafe  &  
LeDoux  2000),  therefore  Co-­IP  experiments  were  conducted  at  multiple  time  
points  following  fear  conditioning  ranging  from  0.5  to  6  h  to  determine  the  time  
course  for  PSD95-­nNOS  interaction  (Figure  6).  As  a  control,  a  separate  group  of  
rats  which  received  the  same  procedure  but  without  shock  were  sacrificed  0.5  h  
following  no  shock  training  (‘Tone  only’)  (Figure  6).  Significantly  increased  
interaction  between  PSD95  and  nNOS  were  observed  at  1  h  and  2  h  after  fear  
conditioning  in  both  BLA  and  vHP,  when  compared  with  ‘Tone  only’  controls  
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(Figure  7A  and  B).  The  increased  interaction  between  PSD95  and  nNOS  
recovered  to  baseline  level  by  6h  for  both  regions  (Figure  7A  and  B).  However,  
no  significant  changes  of  the  interaction  were  observed  at  any  time  points  
following  fear  conditioning  in  the  mPFC  (Figure  7C).  To  exclude  the  possibility  
that  the  observed  differences  found  in  PSD95-­nNOS  interaction  among  the  
groups  were  due  to  different  abilities  of  fear  learning,  behavioral  performances  
during  fear  conditioning  were  analyzed  for  each  animal.  It  was  found  that  all  of  
the  fear  conditioned  groups  showed  comparable  freezing  responses  during  fear  
training  (Figure  8A  and  B).     
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Figure  6.  Schematic  protocol  of  the  Co-­IP  experiment  in  different  brain  
regions  following  fear  conditioning  
  
Fear  conditioned  rats  received  a  training  of  3  tone/shock  pairings  and  were  
sacrificed  either  0.5,  1,  2  or  6  hours  after  conditioning.  The  ‘Tone  only’  group  
received  the  same  training  but  without  shock  pairing  and  were  sacrificed  0.5  h  
after  the  non-­shock  training.  Tissue  punches  from  the  BLA,  the  vHP  and  the  
mPFC  were  prepared  for  Co-­IP  experiment.     
   50  
  
  
Figure  7.  Fear  conditioning  induces  dynamic  changes  in  PSD95/nNOS  
binding  within  the  BLA  and  the  vHP,  but  not  in  the  mPFC  
  
Protein  lysates  from  the  BLA  (A),  the  vHP  (B)  and  the  mPFC  (C)  were  
immunoprecipitated  with  nNOS  antibody  and  the  PSD95-­nNOS  complex  was  
then  probed  with  PSD95  antibody  and  nNOS  antibody  (tops,  representative  
blots).  Levels  of  PSD95/nNOS  ratio  were  expressed  as  a  percentage  of  those  in  
‘Tone  only’  controls  (bottoms,  for  the  BLA,  n  =  3  or  4,  F4,  14  =  3.526,  P  <  0.05;;  for  
the  vHP,  n  =  4,  F4,  15  =  3.262,  P  <  0.05;;  for  the  mPFC,  n  =  4,  F4,  15  =  1.792,  P  >  
0.05).  *  P  <  0.05,  **  P  <  0.01  relative  to  ‘Tone  only’  group;;  #  in  (A)  P  <  0.05  
relative  to  1  h  group;;  #  in  (B)  P  <  0.05  relative  to  0.5  h  group       
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Figure  8.  Acquisition  of  conditioned  fear  in  animals  used  for  Co-­IP  
experiments  
  
Animals  in  fear  conditioned  groups  acquired  fear  normally  and  equivalently  (for  
graph  A:  n  =  3-­4,  Trial:  F2,  22  =  237.6,  P  <  0.0001;;  Treatment:  F3,  11  =0.2241,  P  >  
0.05;;  Treatment  x  Trial:  F6,  22  =  0.9237,  P  >  0.05;;  for  graph  B:  n  =  4,  Trial:  F2,  24  =  
82.95,  P  <  0.0001;;  Treatment:  F3,  12  =0.04454,  P  >  0.05;;  Treatment  x  Trial:  F6,  24  =  
0.091,  P  >  0.05).  Animals  in  ‘Tone  only’  group  showed  no  freezing  responses  to  
the  tone.  After  fear  conditioning,  animals  were  sacrificed  at  different  time  points  
as  indicated  in  the  graphs.  BLA  punches  were  obtained  from  animals  in  (A)  and  
vHP  and  mPFC  punches  were  obtained  from  animals  in  (B);;  these  punches  were  
further  processed  for  Co-­IP  experiments  that  was  described  in  Figure  6.  
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The  expression  levels  of  PSD95  and  nNOS  were  not  altered  over  time  
following  fear  conditioning  in  the  vHP  and  the  mPFC  
Increased  or  decreased  interaction  between  PSD95  and  nNOS  that  were  
observed  in  the  above  Co-­IP  experiments  may  result  from  up-­regulation  or  down-­
regulation  of  protein  expressions.  To  this  end,  the  expression  levels  of  PSD95  
and  nNOS  at  various  time  points  were  probed.  Results  from  western  blot  
experiments  showed  that  neither  the  expression  level  of  PSD95  or  that  of  nNOS  
was  changed  over  time  following  fear  conditioning  within  the  vHP  (Figure  9A  and  
B).  This  data  indicated  that  the  dynamic  changes  (increased  or  decreased)  in  the  
PSD95-­nNOS  complex  within  the  vHP  following  fear  conditioning  were  not  due  to  
altered  expression  levels  of  PSD95  or  nNOS,  but  simply  resulted  from  enhanced  
or  weakened  interaction  between  these  two  proteins.  The  preliminary  study  in  our  
laboratory  also  showed  similar  results  in  the  BLA  that  the  expression  levels  of  
PSD95  and  nNOS  were  not  changed  over  time  following  fear  conditioning  (data  
not  shown).  In  the  mPFC,  consistent  with  the  Co-­IP  experiment,  the  expressions  
of  PSD95  and  nNOS  remained  at  similar  levels  over  time  following  fear  
conditioning  (Figure  9C  and  D).    
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Figure  9.  The  expression  levels  of  PSD95  and  nNOS  were  not  altered  over  
time  following  fear  conditioning  in  the  vHP  and  the  mPFC  
  
(A,  C)  Representative  western  blots  of  nNOS  and  PSD95  in  vHP  (A)  and  mPFC  
(C).  β-­actin  was  used  for  normalization  purpose.  (B,  D)  Quantification  graphs  of  
nNOS  (Top)  and  PSD95  (Bottom)  levels  in  the  vHP  (B)  and  mPFC  (D).  The  
results  are  presented  as  a  percentage  change  relative  to  the  ’Tone  only’  group,  
which  was  assigned  a  value  of  100  (n  =  4,  P  >  0.05  for  all  graphs).  
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Fear  conditioning-­induced  increased  PSD95-­nNOS  binding  within  the  BLA  
and  the  vHP  can  be  prevented  by  a  pretreatment  of  ZL006  
Next,  I  tested  if  the  fear  conditioning-­induced  increases  in  PSD95-­nNOS  
complex  could  be  blocked  by  pre-­treatment  with  ZL006,  a  small  molecule  that  
disrupts  PSD95-­nNOS  binding.  Animals  that  were  subjected  to  conditioned  fear  
training  (tone-­shock  pairings)  were  administrated  with  an  i.p.  injection  of  either  
vehicle  or  10  mg/kg  ZL006  immediately  following  conditioning  (Figure  10).  The  
dose  of  10  mg/kg  was  chosen  based  on  previous  data  (Carey  et  al  2017,  Lee  et  
al  2015)  and  the  current  data  (discussed  in  Chapter  3)  indicating  ZL006  at  this  
dose  was  effective  in  disrupting  behaviors  related  with  pain  and  fear  in  rats.  The  
levels  of  PSD95/nNOS  complex  within  the  BLA  and  the  vHP  were  quantified  with  
Co-­IP  1  h  after  conditioned  fear  training,  the  time  point  when  the  PSD95/nNOS  
interaction  peaked  following  fear  conditioning  as  previously  described  (Figure  
10).  Once  again,  the  levels  of  PSD95-­nNOS  complex  within  the  BLA  and  vHP  
were  significantly  increased  at  1  h  following  fear  conditioning  and  these  robust  
increases  were  blocked  in  the  animals  treated  with  ZL006  (Figure  11A  and  B).    
Animals  that  were  used  in  these  Co-­IP  experiments  showed  comparable  
conditioned  freezing  response  during  fear  conditioning  training  (Figure  12A  and  
B).  
  
In  addition,  I  tested  if  pre-­treatment  of  ZL006  had  effects  on  the  
expression  of  PSD95  and/or  nNOS.  Results  from  western  blot  experiments  
demonstrated  that  pre-­treatment  of  ZL006  did  not  alter  the  expression  levels  of  
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PSD95  and  nNOS  in  the  vHP  (Figure  13).  Preliminary  data  also  showed  similar  
expression  levels  of  PSD95  and  nNOS  in  the  BLA  from  animals  with  or  without  
ZL006  treatment  (data  not  shown).  In  summary,  these  results  indicated  that  fear  
conditioning-­induced  enhanced  interaction  between  PSD95  and  nNOS  can  be  
blocked  by  a  pre-­treatment  of  ZL006.  
  
Locations  of  the  punches  from  different  brain  regions  that  used  for  Co-­IP  
experiments  and  western  blotting  
A  schematic  graph  in  Figure  14  depicts  the  locations  of  the  punches  from  
different  brain  regions  that  used  for  Co-­IP  experiments  and  western  blotting  
experiments.  
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Figure  10.  Schematic  protocol  of  the  Co-­IP  experiment  in  animals  treated  
with  ZL006  
  
Immediately  (less  than  5  minutes)  following  fear  conditioning,  rats  were  treated  
with  i.p.  injections  of  either  vehicle  or  10  mg/kg  ZL006.  Animals  in  the  ’Tone  only’  
group  received  a  non-­shock  training  during  fear  conditioning  and  were  treated  
with  vehicle.  All  animals  were  sacrificed  1  h  following  fear  conditioning.  Tissue  
punches  from  the  BLA  and  the  vHP  were  collected  for  Co-­IP  experiment.  
  
     
   57  
  
  
Figure  11.  Fear  conditioning-­induced  increases  in  the  PSD95-­nNOS  
complex  within  the  BLA  and  the  vHP  can  be  prevented  by  pre-­treatment  of  
ZL006  
  
Protein  lysates  from  the  BLA  (A)  and  the  vHP  (B)  were  immunoprecipitated  with  
nNOS  antibody  and  then  immunoblotted  with  PSD95  antibody  (tops,  
representative  blots).  Levels  of  PSD95/nNOS  ratio  were  expressed  as  a  
percentage  of  those  in  ‘Tone  only’  controls  (bottoms,  n  =  5,  F2,  12  =  5.895,  P  <  
0.05  for  BLA;;  n  =  4,  F2,  9  =  7.149,  P  <  0.05  for  vHP).    *  P  <  0.05,  **  P  <  0.01  
relative  to  ‘Tone  only’  group;;  #  P  <  0.05  relative  to  vehicle  group.  
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Figure  12.  Acquisition  of  conditioned  fear  in  animals  used  for  Co-­IP  
experiments  
  
Fear  conditioned  animals  in  the  vehicle  and  ZL006  group  acquired  fear  normally  
and  no  difference  was  found  in  the  freezing  level  across  trials  between  groups  
(for  graph  A:  n  =  5;;  Trial:  F2,  16  =  55.77,  P  <  0.0001;;  Treatment:  F1,  8  =0.3638,  P  >  
0.05;;  Treatment  x  Trial:  F2,  16  =  0.0598,  P  >  0.05;;  for  graph  B:  n  =  4;;  Trial:  F2,  12  =  
34.24,  P  <  0.0001;;  Treatment:  F1,  6  =0.5950,  P  >  0.05;;  Treatment  x  Trial:  F2,  12  =  
0.2274,  P  >  0.05).  Animals  in  ‘Tone  only’  group  showed  no  freezing  responses  to  
the  tone.  After  fear  conditioning,  BLA  punches  and  vHP  punches  were  obtained  
from  animals  in  (A)  and  animals  in  (B)  respectively,  and  were  further  processed  
for  Co-­IP  experiments  that  was  described  in  Figure  9.  
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Figure  13.  Pre-­treatment  of  ZL006  did  not  alter  the  expression  levels  of  
PSD95  and  nNOS  in  the  vHP  
  
(A)  Representative  western  blots  of  nNOS  and  PSD95  in  the  vHP.  β-­actin  was  
used  for  normalization  purpose.  (B)  Quantification  graphs  of  nNOS  (left)  and  
PSD95  (Right)  levels.  The  results  are  presented  as  a  percentage  change  relative  
to  the  ’Tone  only’  group,  which  was  assigned  a  value  of  100  (n  =  4,  P  >  0.05  for  
both  graphs).  
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Figure  14.  Schematic  image  depicting  the  locations  of  the  punches  from  
different  regions  that  used  for  Co-­IP  experiments  and  western  blotting  
  
The  blue,  yellow  and  red  circles  delimit  the  tissue  punches  from  the  BLA,  the  
vHP  and  the  mPFC  respectively.  LA:  lateral  nucleus  of  the  amygdala;;  BA:  basal  
nucleus  of  the  amygdala.  Drawings  are  adapted  from  an  atlas  (Paxinos  and  
Watson  2005).  Numbers  indicate  the  distance  from  bregma  (in  mm).  
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   The  role  of  PSD95-­nNOS  interaction  has  been  investigated  in  various  
NMDARs-­dependent  neurological  and  neuropsychiatric  disorders,  such  as  stroke  
(Zhou  et  al  2010),  chronic  pain  (Florio  et  al  2009,  Lee  et  al  2015),  Parkinson’s  
disease  (Hu  et  al  2014)  and  depression  (Doucet  et  al  2013,  Sherwin  et  al  2017).  
It  has  been  shown  that  ischemia  can  cause  a  significant  increase  in  the  PSD95-­
nNOS  complex  within  the  cortex  24  hours  following  reperfusion  and  block  of  the  
interaction  reduces  ischemic  injury  following  stroke  in  mice  (Zhou  et  al  2010).  
The  PSD95-­nNOS  complex  has  also  been  found  in  the  spinal  cord  of  rats  who  
developed  chronic  pain  by  receiving  treatments  of  paclitaxel  (Carey  et  al  2017).  
Small  molecules  that  disrupt  PSD95-­nNOS  interaction,  such  as  ZL006  has  been  
shown  to  demonstrate  pain-­reducing  effects  in  distinct  models  of  NMDARs-­
mediated  hyperalgesia  and  allodynia  (Florio  et  al  2009,  Lee  et  al  2015).  In  this  
chapter,  I  extended  the  investigation  of  PSD95-­nNOS  interaction  to  auditory  fear  
conditioning.    
  
   Pavlovian  fear  conditioning  is  acquired  when  a  previously  neutral  event  is  
paired  with  an  aversive  event.  Numerous  studies  have  shown  that  fear  
conditioning  processes  are  dependent  on  the  activation  of  NMDARs  and  its  
various  downstream  molecular  changes  that  result  in  neuroplasticity  within  the  
fear  network.  One  such  downstream  effect  following  NMDARs  stimulation  
involves  activation  of  nNOS,  which  is  coupled  to  the  scaffolding  protein  PSD95.  
In  this  chapter,  by  utilizing  Co-­IP  assay,  I  first  determined  the  levels  of  PSD95-­
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nNOS  binding  as  a  function  of  time  following  cue-­induced  fear  conditioning  within  
the  amygdala,  the  hippocampus  and  the  mPFC,  three  critical  regions  involved  in  
fear  regulation.  The  results  showed  that  amygdalar  PSD95-­nNOS  interaction  
appeared  to  begin  to  increase  by  30  minutes  following  fear  conditioning,  peaked  
at  1  h,  and  remained  increased  until  6  hours  after  fear  conditioning.    Systemic  
treatment  of  ZL006  by  i.p.  injection  immediately  after  fear  conditioning  blocked  
the  increases  in  PSD95-­nNOS  interaction  measured  at  1  h  following  conditioning.  
These  results  collectively  suggested  that  the  increased  PSD95-­nNOS  interaction  
within  the  BLA  is  involved  in  the  subsequent  consolidation  process  following  fear  
conditioning  and  that  ZL006  is  an  effective  tool  for  the  disruption  of  PSD95-­nNOS  
interaction.    
  
   The  brain  tissues  used  for  the  Co-­IP  experiments  were  from  animals  
which  underwent  cue-­induced  (auditory)  fear  conditioning,  where  an  association  
between  the  phasic  CS  (a  tone)  and  the  US  (foot  shock)  is  established  by  
delivering  multiple  pairings  of  tone  and  shock.  In  the  meanwhile,  the  association  
also  formed  between  the  context  (overall  environment  of  the  conditioning  box)  
and  the  US,  although  the  context-­US  association  is  usually  weaker  than  the  CS-­
US  association  (Phillips  &  LeDoux  1994).  It  is  widely  believed  that  the  
hippocampus  plays  a  vital  role  in  the  contextual  processing  and  conditioning  
(Maren  et  al  2013).  The  results  from  Co-­IP  experiments  showed  that  auditory  
fear  conditioning  also  induced  an  enhancement  of  PSD95-­nNOS  interaction  
within  the  vHP  in  a  time-­dependent  manner  that  was  seen  within  the  amygdala.  
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The  maximal  level  of  PSD95-­nNOS  interaction  in  the  vHP  was  observed  at  1  h  
after  fear  conditioning,  and  this  binding  was  prevented  by  treating  the  animals  
with  ZL006  immediately  after  training.  These  results  indicated  an  involvement  of  
hippocampal  PSD95-­nNOS  complex  in  the  formation  of  the  context-­US  
association  and  disrupting  this  complex  may  interfere  with  contextual  fear  
conditioning  and/or  contextual  fear  expression.  
  
   In  contrast  to  the  enhanced  PSD95-­nNOS  interaction  found  in  the  
amygdala  and  the  hippocampus,  the  interaction  of  these  two  proteins  in  the  
mPFC  remained  at  baseline  levels  even  up  to  6  hours  following  fear  conditioning,  
suggesting  that  PSD95-­nNOS  interaction  in  the  mPFC  may  play  a  minimal  role  in  
the  processes  immediately  following  fear  conditioning.  This  is  not  surprising  as  
considerable  literature  has  demonstrated  a  critical  role  for  mPFC  in  the  regulation  
of  fear  expression  and  extinction  rather  than  in  the  regulation  of  consolidation  
(see  section  1.3.3).  A  previous  study  showed  that  the  activation  of  nNOS  
signaling  in  the  mPFC  plays  an  important  role  in  the  expression  of  contextual  fear  
conditioning  (Moraes  Resstel  et  al  2007).  Bilateral  administration  of  nNOS  
inhibitor  into  the  ventral  medial  prefrontal  cortex  (vmPFC)  shortly  before  the  
testing  of  contextual  fear  significantly  reduced  the  freezing  responses  to  the  
conditioned  context  (Moraes  Resstel  et  al  2007).  This  finding  indicates  that  
nNOS  may  undergo  activation  during  the  expression  of  contextual  fear.  
Considering  the  critical  role  of  PSD95-­nNOS  interaction  in  the  regulation  of  
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nNOS  activation,  it  is  speculated  that  the  interaction  between  PSD95  and  nNOS  
could  be  enhanced  during  contextual  fear  expression.  
  
   Overall,  these  results  provided  evidence  that  the  interaction  between  
PSD95  and  nNOS  within  both  amygdala  and  hippocampus  are  part  of  the  
molecular  processes  subsequent  to  auditory  fear  conditioning.  These  temporally  
regulated  binding  of  PSD95-­nNOS  in  the  BLA  and  vHP  following  fear  
conditioning  further  suggests  the  possibility  that    amygdalar  PSD95-­nNOS  
interaction  may  play  a  role  in  the  formation  of  the  cue-­US  association,  whereas  
PSD95-­nNOS  interaction  in  the  hippocampus  may  contribute  to  the  fear  
responses  to  the  context.  Although  the  increases  of  PSD95-­nNOS  interaction  
within  the  mPFC  were  not  observed  following  auditory  fear  conditioning,  it  does  
not  exclude  the  possibility  that  enhanced  PSD95-­nNOS  interaction  in  the  mPFC  
may  be  seen  in  the  expression  and/or  extinction  of  fear  conditioning.  The  results  
also  showed  that  the  increases  in  the  amygdalar  and  hipppcampal  PSD95-­nNOS  
interaction  can  be  prevented  by  pretreatment  of  ZL006,  providing  us  a  useful  tool  
to  test  the  effects  of  disrupting  this  protein-­protein  interaction  on  the  conditioned  
fear  responses.  The  effects  of  ZL006  at  the  behavioral  level  will  be  discussed  in  
the  following  chapter.  
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CHAPTER  3    
The  Effects  of  Disruption  of  PSD95-­nNOS  Interaction  on  Conditioned  Fear  
Responses  and  Other  Non-­Fear  Related  Behaviors  
  
  
   The  results  from  Chapter  2  demonstrate  that  PSD95-­nNOS  interaction  in  
the  BLA  and  vHP  is  temporally  regulated  molecular  processes  subsequent  to  
fear  conditioning  (e.g.  consolidation).  Here,  I  hypothesized  that  disruption  of  this  
PSD95-­nNOS  interactions  could  reduce  fear,  similar  to  NMDAR  antagonists.  Due  
to  the  different  roles  the  amygdala  and  hippocampus  play  in  the  fear  
conditioning,  it  is  further  hypothesized  that  disruption  of  PSD95-­nNOS  interaction  
within  the  amygdala  and  the  hippocampus  would  more  likely  disrupt  cued-­
induced  fear  and  context-­induced  fear,  respectively.  To  this  end,  a  series  of  
behavioral  studies  utilizing  auditory  fear  conditioning  with  tests  of  cued  fear  and  
contextual  fear  were  performed.    
  
   Although  a  number  of  studies  have  demonstrated  fear-­reducing  effects  of  
NMDAR  antagonists  when  administered  to  animals  undergoing  fear  conditioning  
(Campeau  et  al  1992,  Fendt  2001,  Lee  et  al  2001,  Miserendino  et  al  1990,  
Rodrigues  et  al  2001,  Zhang  et  al  2008),  NMDAR  antagonists  also  affect  many  
other  important  physiological  processes  (Krystal  et  al  1994,  Olney  &  Wang  
1991).    Therefore,  NMDA  antagonists  have  limitations  in  their  potential  as  
therapeutic  avenues  for  treating  fear-­related  disease,  such  as  post-­traumatic  
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stress  disorder  (PTSD).  Disrupting  PSD95-­nNOS  interaction  would  allow  for  a  
specific  inhibition  of  a  sub-­pathway  downstream  of  NMDAR  activation,  i.e.,  
NMDARs-­nNOS-­NO  signaling,  therefore  circumventing  undesirable  effects  on  
many  other  CNS  functions  mediated  by  NMDA  receptors.  To  test  this  idea,  a  
battery  of  behavioral  assays  was  utilized  to  establish  and  compare  the  behavioral  
effects  profile  for  NMDAR  antagonist  MK-­801  against  the  PSD95-­nNOS  
interaction  disruptor  ZL006.  
  
  
Systemic  disruption  of  PSD95-­nNOS  interaction  and  inhibition  of  NMDARs  
impaired  cue-­induced  conditioned  fear  memory  
To  investigate  if  disruption  of  PSD95-­nNOS  interaction  could  impair  
conditioned  fear  memory,  rats  were  treated  with  i.p.  injections  of  different  doses  
of  a  small  molecule  disruptor  of  PSD95-­nNOS  interaction,  ZL006  (1  mg/kg,  3  
mg/kg  or  10  mg/kg)  immediately  following  fear  conditioning.  Their  cue-­induced  
fear  memories  were  tested  24  hours  after  fear  conditioning  by  presenting  10  
tones  alone  without  foot  shock  (Figure  15A).  In  these  tests,  a  group  of  animals  
that  received  the  same  training  procedure  but  without  shock  pairing  (‘Tone  only’)  
were  utilized  as  controls  to  make  sure  the  fear  response  was  induced  by  the  
tone/shock  pairing,  not  by  the  tone  itself.  During  the  fear  conditioning  training,  
animals  who  acquired  fear  froze  during  the  presentation  of  auditory  cues  (tones),  
whereas  ‘Tone  only’  controls  do  not  freeze  to  the  tone.  When  given  systemically  
immediately  after  fear  training,  animals  in  the  vehicle  control  group  showed  
robust  conditioned  fear  responses  (freezing)  during  the  fear  expression  tests,  
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whereas  rats  treated  with  10  mg/kg  ZL006  displayed  significantly  reduced  
freezing  responses  to  the  tones  (multiple  comparisons  post  hoc  Fisher’s  LSD  
test,  P  <  0.05)  (Figure  15A  and  B).  Lower  doses  of  ZL006  (1  mg/kg  and  3  mg/kg)  
failed  to  impair  freezing  responses  in  these  tests.  As  the  first  3  to  5  tones  in  the  
fear  expression  test  are  usually  used  to  measure  the  consolidation  of  memory,  
the  averaged  freezing  time  across  the  first  4  tones  was  also  analyzed  among  all  
of  the  groups.  Rats  treated  with  10  mg/kg  ZL006  displayed  significantly  lower  
averaged  freezing  time  in  the  first  4  tones  than  vehicle  treated  groups;;  Rats  
treated  with  1  mg/kg  or  3  mg/kg  ZL006  displayed  comparable  averaged  freezing  
time  in  the  first  4  tones  than  vehicle  controls  (Figure  15C).  ZL007  is  a  close  
structural  analog  of  ZL006  but  is  inactive  in  disrupting  PSD95-­nNOS  interaction.  
It  was  utilized  as  a  negative  control  in  these  tests.  Animals  who  treated  with  10  
mg/kg  ZL007  showed  comparable  freezing  responses  as  vehicle  controls  (Figure  
15B  and  C).  Similar  to  ZL006  (10  mg/kg),  post-­training  systemic  administration  of  
NMDAR  antagonist  MK-­801  (0.1  mg/kg)  also  significantly  impaired  cue-­induced  
freezing  responses  in  the  fear  expression  test  (Figure  16A,  B  and  C).  
Collectively,  these  findings  showed  that  similar  to  NMDAR  antagonist  MK-­801,  
disruption  of  PSD95/nNOS  interaction  can  impair  the  consolidation  of  cue-­
induced  conditioned  fear  memory.       
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Figure  15.  Systemic  disruption  of  PSD95-­nNOS  interaction  by  ZL006  
impaired  the  consolidation  of  cue-­induced  conditioned  fear  
  
(A)  Schematic  of  the  behavioral  protocol.  Immediately  following  fear  conditioning,  
rats  were  treated  with  i.p.  injections  of  indicated  treatments.  Cue-­induced  
conditioned  fear  memory  was  tested  24  hours  later.  (B)  The  five  groups  of  
animals  that  were  trained  with  tone/shock  pairings  displayed  normal  fear  
acquisition  (Trial:  F2,  56  =  299.4,  P  <  0.0001;;  Treatment:  F4,  28  =  0.3566,  P  >  0.05;;  
Treatment  x  Trial:  F8,  56  =  1.009,  P  >  0.05).  In  the  test  of  fear  expression,  animals  
treated  with  ZL006  at  10  mg/kg  (n  =  8)  showed  significantly  reduced  freezing  
responses  when  compared  with  vehicle  controls  (n  =  7)  (post  hoc  Fisher’s  LSD  
test:  t  =  3.77,  DF  =  28,  P  <  0.001).  ###  P  <  0.001  ZL006  10  mg/kg  Vs.  vehicle;;  
Groups  with  lower  doses  of  ZL006  (1  mg/kg  and  3  mg/kg,  n  =  6)  and  ZL007  
group  (n=  6)  showed  comparable  freezing  responses  during  fear  expression  test  
compared  to  the  vehicle  group  (P  >  0.05).  Rats  in  the  ‘Tone  only’  group  (n  =  7)  
did  not  freeze  to  the  tones  during  neither  fear  training  nor  fear  expression  test.  
(C)  Averaged  freezing  time  across  the  first  4  tones  of  the  expression  test  in  
different  groups.  (F4,  28  =  5.764,  P  <  0.01).  ***  P  <  0.001  relative  to  vehicle  group;;  
&&  P  <  0.01  relative  to  ZL007  group;;  #  P  <  0.05,  ##  P  <  0.01  relative  to  ZL006  10  
mg/kg  group.  
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Figure  16.  Systemic  inhibition  of  NMDARs  by  MK-­801  impaired  
consolidation  of  cue-­induced  conditioned  fear  
  
(A)  Schematic  of  the  behavioral  protocol.  Rats  were  given  i.p.  injections  of  either  
vehicle  (N=7)  or  0.1  mg/kg  MK-­801  (N=7)  immediately  after  fear  conditioning.  
Cue-­induced  conditioned  fear  memory  was  tested  24  hours  later.  (B)  Both  groups  
of  animals  acquired  fear  normally  (Trial:  F2,  24  =  59.62,  P  <  0.0001;;  Treatment:  F1,  
12  =  0.03817,  P  >  0.05;;  Treatment  x  Trial:  F2,  24  =  0.6815,  P  >  0.05).  However,  MK-­
801  treated  animals  displayed  significantly  reduced  freezing  responses  in  cue-­
induced  fear  expression  test  (Treatment:  F1,  12  =  8.550,  P  <  0.05;;  Trial:  F9,  108  =  
9.593,  P  <  0.0001;;  Treatment  x  Trial:  F9,  108  =  0.9450,  P  >  0.05).  (C)  Averaged  
freezing  time  across  the  first  4  tones  of  the  expression  test  in  vehicle  and  MK-­
801  treated  groups  (t  =  4.163,  DF  =  12,  P  <  0.05).  *P  <  0.05,  **  P  <  0.01  relative  
to  vehicle  group.  
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Inhibiting  PSD95-­nNOS  interaction  directly  in  the  amygdala  also  reduces  
cue-­induced  conditioned  fear  memory  
Next,  it  was  tested  if  local  injections  of  PSD95-­nNOS  interaction  disruptor  
ZL006  directly  into  the  BLA  could  impair  cue-­induced  memory  formation  of  
conditioned  fear.  Seven  days  before  fear  conditioning,  rats  were  implanted  with  
guide  cannulas  into  the  BLA.  Intra-­BLA  infusions  of  vehicle  or  ZL006  at  10  µM  
were  applied  immediately  following  fear  conditioning  and  the  conditioned  fear  
memory  for  each  rat  was  tested  24  hours  after  conditioning  (Figure  17A).    During  
fear  conditioning,  all  groups  of  animals  showed  comparable  freezing  responses  
to  the  tone  (Figure  17B).  However,  in  the  fear  expression  test,  animals  that  
received  intra-­BLA  infusions  of  ZL006  displayed  significantly  decreased  freezing  
responses  compared  with  vehicle  controls  (Figure  17B).  The  averaged  freezing  
time  across  the  first  4  tones  in  the  expression  test  was  also  reduced  in  ZL006  
treated  animals  (Figure  17C).  Thus,  similar  to  systemic  disruption  of  
PSD95/nNOS  interaction,  intra-­BLA  treatment  of  ZL006  immediately  following  
fear  conditioning  also  impairs  the  consolidation  of  cue-­induced  conditioned  fear  
memory.  In  3  additional  rats,  the  injection  sites  were  outside  the  BLA  boundaries  
(anterior  to  the  BLA);;  ZL006  injections  at  these  sites  had  no  effects  (data  not  
shown)  and  these  animals  were  removed  from  data  analysis.  
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Figure  17.  Intra-­BLA  disruption  of  PSD95-­nNOS  interaction  by  ZL006  also  
impaired  the  consolidation  of  cue-­induced  conditioned  fear  
  
(A)  Schematic  of  the  behavioral  protocol.  Immediately  after  fear  conditioning,  rats  
were  administrated  with  intra-­BLA  infusion  of  ACSF  (n  =  10)  or  10  µM  ZL006  (n  =  
9)  and  the  retention  of  cue-­induced  fear  memory  was  tested  24  hours  later.  Pre-­
assigned  vehicle  and  ZL006  groups  of  animals  acquired  cue-­induced  fear  
normally  and  equivalently  (Trial:  F2,  34  =  308.8,  P  <  0.0001;;  Treatment:  F1,  17  =  
0.6920,  P  >  0.05;;  Treatment  x  Trial:  F2,  34  =  0.6287,  P  >  0.05)  (B,  Left).  Animals  
with  ZL006  treatment  displayed  significantly  decreased  freezing  responses  in  the  
fear  expression  test  (Treatment:  F1,  17  =  4.974,  P  <  0.05;;  Trial:  F9,  153  =  23.27,  P  <  
0.0001;;  Treatment  x  Trial:  F9,  153  =  0.5252,  P  >  0.05)  (B,  Right).  (C)  Averaged  
freezing  time  across  the  first  4  tones  of  the  expression  test  in  vehicle  and  ZL006  
treated  groups  (unpaired  t  test,  t  =  2.687,  DF  =  17,  P  <  0.05).    *  P  <  0.05  relative  
to  vehicle  group.  
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Inhibiting  PSD95-­nNOS  interaction  directly  in  the  vHP  has  no  effects  on  
cue-­induced  conditioned  fear,  but  leads  to  an  impaired  context-­induced  
conditioned  fear  
In  this  experiment,  a  modified  paradigm  was  utilized  in  order  to  test  both  
cue-­  and  context-­  induced  conditioned  fear.  Animals  were  placed  in  Box  A  to  
receive  fear  conditioning  training.  24  hours  later,  context-­induced  conditioned  
fear  was  tested  in  the  same  box  for  a  total  of  5  minutes  where  animals  were  only  
exposed  to  the  context  without  any  tone  presentation.  Cue-­induced  conditioned  
fear  was  tested  5  minutes  after  contextual  fear  test  in  another  box  (Box  B)  where  
animals  received  multiple  tone  presentations  while  being  exposed  to  a  new  
context  (Figure  18A).  To  investigate  the  effects  of  intra-­vHP  disruption  of  PSD95-­
nNOS  binding  on  both  cue-­  and  context-­  induced  conditioned  fear,  I  implanted  
rats  with  guide  cannulas  into  the  vHP  and  performed  fear  conditioning  seven  
days  after  recovery  from  the  surgery  of  implantation.  Intra-­vHP  infusions  of  
vehicle  or  10  µM  ZL006  (either  250  nl/side  or  500  nl/side)  were  given  
immediately  following  fear  conditioning.  During  conditioning,  all  groups  of  animals  
acquired  fear  normally  and  equivalently  (Figure  18B).  In  the  contextual  fear  test  
that  was  performed  24  hours  after  conditioning,  animals  receiving  a  higher  
volume  (500  nl/side)  of  intra-­vHP  infusion  of  10  µM  ZL006  displayed  significantly  
reduced  freezing  responses  to  the  context  over  time  (multiple  comparisons  post  
hoc  Fisher’s  LSD  test,  P  <  0.05);;  The  total  amount  of  freezing  time  during  this  
test  in  the  500  nl/side  group  was  significantly  less  than  the  other  two  groups  
(Figure  18C).  The  lower  volume  (250  nl/side)  group  failed  to  show  reduced  fear  
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responses  in  this  test.  In  contrast,  in  the  cue-­induced  fear  test,  animals  received  
intra-­vHP  infusion  of  ZL006  (250  nl  or  500  nl  per  side)  displayed  comparable  
freezing  responses  as  animals  treated  with  vehicle  (P  >  0.05)  (Figure  18D  left)  
and  the  averaged  freezing  time  across  the  first  4  tones  in  all  these  groups  are  
comparable  (Figure  18D  right).  Taken  together,  these  results  indicate  that  
PSD95-­nNOS  complex  in  different  brain  regions  mediate  different  aspects  of  
conditioned  fear,  with  amygdalar  PSD95-­nNOS  complex  mediating  the  
consolidation  of  cue-­induced  fear  and  hippocampal  PSD95-­nNOS  complex  
mediating  the  consolidation  of  context-­induced  fear.  
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Figure  18.  Intra-­vHP  disruption  of  PSD95-­nNOS  interaction  by  ZL006  did  
not  affect  cue-­induced  fear  memory,  but  significantly  impaired  context-­
induced  fear  memory  
  
(A)  Schematic  of  the  behavioral  protocol.  Rats  were  given  intra-­vHP  infusion  of  
ACSF  (n  =  5,  250  or  500  nl/side),  ZL006  250  nl/side  (n  =  6)  or  ZL006  500  nl/side  
(n  =  6)  immediately  after  fear  conditioning.  The  retention  of  context-­induced  fear  
memory  was  tested  24  hours  later  in  the  same  box  where  fear  conditioning  was  
performed.  The  cue-­induced  fear  memory  was  tested  5  min  after  the  contextual  
retention  test  in  a  different  box.  (B)  All  of  the  animals  acquired  cue-­induced  fear  
normally  and  equivalently  (Trial:  F2,  28  =  46.55,  P  <  0.0001;;  Treatment:  F2,  14  =  
0.05826,  P  >  0.05;;  Treatment  x  Trial:  F4,  28  =  0.0766,  P  >  0.05).  (C)  In  contextual  
fear  test,  animals  received  500  nl  per  side  of  ZL006  showed  impaired  freezing  
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responses  compared  with  animals  treated  with  vehicle  or  250  per  side  of  ZL006  
(Treatment:  F2,  14  =  3.751,  P  <  0.05,  Trial:  F3,  42  =  3.892,  P  <  0.05;;  Treatment  x  
Trial:  F6,  42  =  0.7694,  P  >  0.05).  The  total  amount  of  freezing  time  during  the  test  in  
the  500  nl  group  was  significantly  less  than  the  other  two  groups.    *  P  <  0.05;;  &  P  
<  0.05  vehicle  Vs  500  nl;;  #  P  <  0.05  250  nl  Vs  500  nl  (D)  In  the  cue-­induced  fear  
test,  animals  with  ZL006  treatments  (250  nl  or  500  nl  per  side)  displayed  
comparable  freezing  responses  as  animals  treated  with  vehicle  (Treatment:  F2,  14  
=  0.5126,  P  >  0.05;;  Trial:  F9,  126  =  16.93,  P  <  0.0001;;  Treatment  x  Trial:  F18,  126  =  
1.039,  P  >  0.05)  (D  left);;  The  averaged  freezing  time  across  the  first  4  tones  in  all  
groups  were  also  comparable  (F2,  14  =  0.044,  P  >  0.05)  (D  right).  
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Cannula  placements  within  the  BLA  and  vHP    
   A  schematic  graph  in  Figure  19  depicts  the  cannula  tips  within  the  BLA  
and  the  vHP.  Cannula  tips  were  observed  throughout  the  BLA  or  vHP  at  various  
rostro-­caudal  levels.  Only  rats  with  cannula  tips  within  the  boundaries  of  the  BLA  
or  the  vHP  were  included  in  the  data  analysis.  In  the  intra-­BLA  infusion  
experiment,  a  total  of  22  rats  were  used,  of  which  three  (one  from  vehicle  group,  
two  from  ZL006  group)  were  with  the  injection  sites  anterior  to  the  BLA  and  were  
removed  from  the  data  analysis.  In  the  intra-­vHP  experiment,  a  total  of  18  rats  
were  used,  of  which  one  vehicle  rat  was  removed  from  the  data  analysis  due  to  
improper  injection  site.  
     
   77  
  
  
Figure  19.  Schematic  image  depicting  the  cannula  placements  within  the  
BLA  and  the  vHP    
  
Left:  The  symbols  represent  the  injection  sites  in  vehicle  (black  circle,  N  =  10)  
and  ZL006  (blue  circle,  N  =  9)  treated  animals  that  were  included  in  the  intra-­BLA  
infusion  experiment.  Right:  The  symbols  represent  the  injection  sites  in  vehicle  
(black  circle,  N  =  5),  ZL006  250  nl/side  (green  circles,  N  =  6)  and  ZL006  500  
nl/side  (orange  circles,  N  =  6)  treated  animals  that  were  included  in  the  intra-­vHP  
infusion  experiment.  Sections  are  based  on  the  atlas  of  Paxinos  and  Watson  
(2005).  Numbers  indicate  the  distance  from  bregma  (in  mm).  
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The  effects  of  disruption  of  PSD95-­nNOS  interaction  on  other  non-­fear  
related  behaviors  
   To  determine  if  the  effects  of  disruption  of  PSD95-­nNOS  interaction  were  
specific  to  fear-­related  behaviors  or  would  be  generalized  to  a  boarder  range  of  
behaviors,  the  following  series  of  behavioral  tests  were  performed  to  examine  the  
effects  of  systemic  ZL006  on  motor  activity,  social  activity,  novel  object  
recognition  memory  and  spatial  memory.  The  effects  of  MK-­801  on  these  
behaviors  were  also  tested  as  a  comparison.  These  tests  were  conducted  
utilizing  ZL006  (10  mg/kg  i.p.)  and  MK-­801  (0.1  mg/kg  i.p),  both  at  the  doses  that  
were  previously  found  effective  in  reducing  fear  memory.  In  the  open  field  (OF)  
test,  the  total  distances  traveled  in  the  open-­field  arena  after  ZL006  injections  
were  comparable  to  the  vehicle  group,  whereas  animals  treated  with  MK-­801  
traveled  further  than  the  other  two  groups  (Figure  20B).  In  the  social  interaction  
(SI)  test,  while  ZL006  treated  animals  displayed  comparable  interaction  activity  
with  the  vehicle  controls,  MK-­801  treated  animals  showed  significantly  less  
interaction  time  (Figure  20C).  In  the  novel  object  recognition  test  (NORT),  
analysis  on  the  discrimination  index  demonstrated  that  ZL006  treatment  had  no  
effects  on  the  discrimination  behavior  when  compared  with  the  vehicle  controls,  
whereas  rats  treated  with  MK-­801  displayed  impaired  discrimination  as  they  were  
unable  to  discriminate  between  the  familiar  and  the  novel  object  (Figure  21B).  Y-­
maze  with  a  two-­trial  test  was  utilized  to  test  the  spatial  memory.  It  was  found  
that  both  vehicle  controls  and  ZL006  treated  animals  displayed  intact  spatial  
recognition  memories:  these  animals  showed  a  higher  frequency  of  visits  
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(Vehicle:  F2,  15  =  4.892,  P  <  0.05;;  ZL006:  F2,  15  =  6.628,  P  <  0.01)  (Figure  22B)  and  
longer  durations  (Vehicle:  F2,  15  =  10.56,  P  <  0.01;;  ZL006:  F2,  15  =  7.965,  P  <  0.01)  
(Figure  22C)  within  the  novel  arm  than  in  the  other  arms.  In  contrast,  the  rats  
treated  with  MK-­801  showed  impaired  spatial  recognition  memories:  they  visited  
the  novel  arm  less  than  the  other  arms  (F2,  15  =  3.896,  P  <  0.05)  (Figure  22B)  and  
spent  same  amount  of  time  in  all  of  the  three  arms  (F2,  15  =  0.3418,  P  >  0.05)  
(Figure  22C).    
  
   In  summary,  these  results  suggested  that  disrupting  PSD95-­nNOS  binding  
by  the  small  molecule  ZL006  does  not  elicit  the  acute  effects  seen  with  NMDA  
receptor  antagonists  MK-­801,  such  as  hyper-­locomotion,  impaired  social  
interaction,  and  disrupted  memories  in  object  recognition  and  spatial  recognition.  
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Figure  20.  The  effects  of  ZL006  and  MK-­801  on  locomotion  and  social  
activity  
  
(A)  Schematic  of  the  behavioral  protocol.  Animals  received  i.p.  injections  of  
vehicle  or  treatments  1  h  prior  to  the  OF  Test.  SI  was  performed  5  min  after  the  
OF  test.  (B)  In  the  OF  test,  MK-­801  treated  animals  displayed  increased  
locomotor  activity  (F2,  25  =  7.562,  P  <  0.01)  whereas  ZL006  treatment  has  no  
effects  on  locomotor  activity  (P  >  0.05).  (C)  In  the  SI  test,  MK-­801  treated  
animals  showed  decreased  social  activity  (F2,  25  =  9.548,  P  <  0.001)  whereas  
ZL006  treatment  has  no  effects  on  social  activity  (P  >  0.05).  n  =  14,  6  and  8  for  
control,  ZL006  and  MK-­801  respectively.      **  P  <  0.01;;  OF,  open  field;;  SI,  social  
interaction  
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Figure  21.  The  effects  of  ZL006  and  MK-­801  on  novel  recognition  task  
  
(A)  Schematic  of  the  behavioral  protocol.  Prior  to  NORT,  animals  were  allowed  to  
explore  the  apparatus  for  5  min  per  day  for  3  consecutive  days.  On  day  4,  
animals  received  i.p.  injections  of  vehicle  or  treatments  immediately  (<  5  min)  
after  the  familiarization  trial  and  the  test  trial  was  conducted  after  a  3  h  ITI.  (B)  
Discrimination  index  for  different  groups  of  animals  during  the  test  trial  
demonstrated  that  MK-­801  treated  rats  showed  deficits  in  the  discrimination  
behavioral  (n  =  11,  9  and  9  for  control,  ZL006  and  MK-­801  respectively;;  F2,  26  =  
5.993,  P  <  0.01).  However,  the  recognition  memory  in  the  ZL006  treated  rats  was  
intact.      **  P  <  0.01;;  ITI,  inter-­trial  interval;;  NORT,  novel  object  recognition  
     
   82  
  
  
Figure  22.  The  effects  of  ZL006  and  MK-­801  on  Y-­maze  task  
  
(A)  Schematic  of  the  behavioral  protocol.  In  the  Y-­maze  test,  animals  received  
i.p.  injections  of  vehicle  or  treatments  immediately  (<  5  min)  after  the  acquisition  
trial  and  the  test  trial  was  conducted  after  a  1  h  ITI.  n  =  6  for  each  group.  (B)  Both  
vehicle  and  ZL006  treated  animals  visited  novel  arm  more  than  the  other  two  
arms  (P  <  0.05);;  however,  animals  with  MK-­801  treatment  visited  novel  arm  less  
that  the  other  arms  (P  <  0.05).  (C)  Both  vehicle  and  ZL006  treated  rats  spent  
more  time  in  the  novel  arm  than  the  other  arms  (P  <  0.01);;  no  arm  difference  was  
found  in  the  rats  treated  with  MK-­801  (P  >  0.05).      *  P  <  0.05,  **  P  <  0.01,  ***  P  <  
0.01;;  ITI,  inter-­trial  interval  
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   The  major  findings  from  this  current  study  are  that  disrupting  PSD95-­
nNOS  interaction  by  ZL006  within  the  amygdala  and  within  the  hippocampus,  
respectively,  impaired  the  consolidation  of  cue-­induced  and  context-­induced  
conditioned  fear.  This  is  consistent  with  a  number  of  previous  studies  with  
pharmacological  inhibition  of  nNOS  and  gene  deletion  of  nNOS  (Itzhak  et  al  
2012,  Kelley  et  al  2009,  Pavesi  et  al  2013,  Schafe  et  al  2005).  Similar  to  ZL006,  
impairment  of  conditioned  fear  was  also  observed  with  NMDA  receptor  
antagonist  MK-­801.  However,  unlike  MK-­801,  ZL006  does  not  appear  to  affect  
locomotion,  social  activity  and  other  short-­term  memory  performances.  
Collectively,  these  results  suggest  that  PSD95-­nNOS  interaction  appears  to  be  a  
selective  downstream  molecular  step  in  the  regulation  of  conditioned  fear  
consolidation  and  that  disruption  of  PSD95-­nNOS  interaction  could  be  a  more  
targeted  approach  to  reduce  fear  without  affecting  other  NMDAR-­dependent  
signaling  pathways.    
  
   The  important  role  of  NMDARs  and  nNOS  activity  in  fear  memory  
formation  have  been  validated  in  a  number  of  studies  where  animals  received  
applications  of  either  NMDARs  antagonists  or  NOS  inhibitors  prior  to  conditioning  
and  displayed  impaired  conditioned  fear  (Campeau  et  al  1992,  Miserendino  et  al  
1990,  Rodrigues  et  al  2001,  Schafe  et  al  2005,  Zhang  et  al  2008).  However,  
these  studies  did  not  exclude  the  possible  explanation  of  the  drug  effects  that  
these  drugs  may  alter  shock-­related  pain  sensitivity  and  thus  affecting  the  
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acquisition  of  fear.  In  the  present  study,  this  issue  was  circumvented  by  applying  
the  treatment  shortly  after  training,  and  found  that  both  MK-­801  and  ZL006  still  
attenuated  fear  memory  when  tested  24  h  after  conditioning.  
  
   Results  from  the  current  study  showed  that  ZL006,  unlike  MK-­801,  
selectively  disrupted  conditioned  fear  memory  without  affecting  many  other  CNS  
functions,  such  as  locomotion  and  social  activity.  It  was  found  that  systemic  
administration  of  MK-­801  at  the  dose  effective  in  reducing  fear  memory  (0.1  
mg/kg)  caused  hyperactivity  in  rats  in  an  OF  test.  Reduced  locomotor  activity  
was  reported  in  animals  treated  with  7-­Ni,  a  non-­selective  inhibitor  of  NOS  
(Harkin  et  al  2003,  Maren  1998).  In  a  SI  test,  animals  received  treatments  of  MK-­
801  displayed  impaired  social  activities,  which  was  in  agreement  with  a  previous  
study  suggesting  a  defective  social  interaction  by  MK-­801  in  a  dose-­dependent  
manner  (Rung  et  al  2005).  7-­Ni  has  been  reported  to  have  anxiolytic  effect  in  the  
SI  test  (Volke  et  al  1997),  our  experiment  failed  to  observe  any  anxiolytic  effect  of  
ZL006  in  the  SI  test.    
  
   Due  to  a  number  of  studies  demonstrating  learning  deficits  caused  by  
NMDAR  antagonists  (Bannerman  et  al  1995,  Butelman  1989,  de  Lima  et  al  2005,  
Shapiro  &  Caramanos  1990)  and  non-­selective  NOS  inhibitors  (Akar  et  al  2009,  
Hölscher  et  al  1996,  Mutlu  et  al  2011,  Zou  et  al  1998)  in  several  hippocampal  
memory  tests,  I  investigated  whether  ZL006  affects  hippocampus-­dependent  
memories  by  utilizing  NORT  and  Y-­maze  test.  In  consistency  with  previous  
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research  (Boultadakis  &  Pitsikas  2010,  Cunha  et  al  2008,  de  Lima  et  al  2005),  it  
was  found  that  post-­training  i.p.  injection  of  MK-­801  disrupted  animals’  
performance  in  both  of  the  tests.  However,  ZL006  application  did  not  cause  
deficits  in  these  tests.  Overall,  these  results  are  consistent  with  the  previous  
findings  that  systemic  ZL006  does  not  affect  locomotor  function  (Lee  et  al  2015,  
Smith  et  al  2016),  spatial  memory  (Zhou  et  al  2010)  or  source  memory  (Smith  et  
al  2016)  in  rodents.    
  
   In  agreement  with  the  effects  of  ZL006  action  on  NORT  and  Y-­maze  test,  
a  previous  study  demonstrated  that  performances  in  NORT  and  Morris  water  
maze  test  remained  intact  after  administering  TRIM,  a  NOS  inhibitor  
preferentially  inhibit  nNOS  over  eNOS  (Mutlu  et  al  2011).  However,  those  
performances  became  disrupted  when  both  nNOS  and  eNOS  were  inhibited  with  
7-­Ni,  a  non-­selective  NOS  inhibitor  (Mutlu  et  al  2011).  Together,  these  findings  
indicate  that  recognition  memory  and  spatial  memory  engage  both  eNOS  and  
nNOS  activities,  and  eNOS  activation  may  be  compensating  for  the  disruption  of  
nNOS  activity.  Therefore,  tests  with  NORT  and  Y-­maze  are  insensitive  to  ZL006  
treatment.  In  support  for  this  view,  an  electrophysiological  study  showed  that  LTP  
in  the  CA1  region  of  the  hippocampus  from  nNOS  knockout  mice  and  eNOS  
knockout  mice  were  intact,  but  LTP  was  significantly  impaired  in  nNOS  and  
eNOS  double  knockout  mice  (Son  et  al  1996).  
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In  the  present  study,  I  showed  that  disruption  of  PSD95-­nNOS  interaction  
by  ZL006  impaired  hippocampus-­dependent  context-­induced  fear  conditioning.  
However,  recognition  memory  and  spatial  memory,  other  two  forms  of  
hippocampus-­dependent  memory  were  not  significantly  affected  by  ZL006  as  
measured  by  NORT  and  Y-­maze  behaviors.  These  findings  suggested  that  fear-­
related  learning  and  non-­fear  related  learning,  although  both  are  believed  to  be  
dependent  on  the  hippocampus,  are  differentially  sensitive  to  inhibition  of  
PSD95-­nNOS  interaction.    
  
Several  factors  might  account  for  the  differential  sensitivities.  Fear  
conditioning  is  a  task  based  on  a  stressful  stimulus  (foot  shock)  and  requires  high  
cognitive  function.  Animals  subjected  to  contextual  fear  conditioning  usually  
display  high  emotionality  and  stress  responses  which  include  the  release  of  
corticosterone  (Kelley  et  al  2009)  and  norepinephrine  (Feenstra  et  al  1999),  two  
primary  stress  hormones.  The  altered  emotional  states  may  interfere  with  
cognitive  function  in  the  stressful  fear  conditioning  test  but  not  in  the  NORT  or  Y-­
maze  tests  which  induce  minimal  stress.  This  view  is  supported  by  a  previous  
study  showing  that  nNOS  knock  out  mice  displayed  impaired  spatial  performance  
in  a  stressful  water  maze,  but  display  no  deficits  in  the  less  stressful  T-­maze  test  
(Weitzdoerfer  et  al  2004).  Although  the  mechanism  through  which  nNOS  
inhibition  affects  cognitive  functions  only  under  stressful  conditions  is  not  clear.  
The  authors  in  this  study  suggested  that  alternations  in  the  serotonergic  system  
might  be  involved  in  the  mechanisms,  considering  the  intensive  interaction  of  
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nNOS  signaling  pathway  with  serotonergic  pathway  (Chanrion  et  al  2007,  
Chiavegatto  et  al  2001,  Chiavegatto  &  Nelson  2003,  Kaehler  et  al  1999).  
  
   In  summary,  the  results  show  that  disrupting  PSD95-­nNOS  interaction  
with  the  small  molecule  ZL006  attenuates  cue-­induced  fear  and  context-­induced  
fear  when  given  locally  into  the  amygdala  and  the  hippocampus,  respectively.  
Unlike  NMDAR  antagonist  MK-­801,  systemic  ZL006  is  devoid  of  effects  on  
locomotor  function,  social  activity,  and  acute  effects  on  non-­fear  related  
memories,  indicating  that  disrupting  PSD95/nNOS  interaction  represents  a  novel  
therapeutic  approach  for  reducing  conditioned  fear  without  eliciting  adverse  
effects.     
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CHAPTER  4    
The  Synaptic  Mechanism  in  the  Amygdala  Associated  with  Conditioned  
Fear  and  The  Effects  of  Disruption  of  PSD95-­nNOS  Interaction  
  
  
   The  results  from  Chapter  3  have  demonstrated  that  disruption  of  PSD95-­
nNOS  interaction  shortly  after  fear  conditioning  with  either  systemic  treatment  of  
ZL006  or  intra-­amygdala  infusion  of  ZL006  could  impair  the  consolidation  of  cue-­
induced  fear  memory.  In  this  chapter,  experiments  were  designed  to  investigate  
the  mechanism  in  the  amygdala  mediating  the  effects  of  disruption  of  PSD95-­
nNOS  interaction  on  cue-­induced  fear.  LTP  is  an  enduring  form  of  synaptic  
plasticity  that  mediates  learning  and  memory  in  mammals  (Maren  1999a).  LTP  in  
the  amygdala  has  been  thought  to  underlie  the  induction  and  expression  of  cue-­
induced  fear  memory  (Rogan  et  al  1997).  To  investigate  the  mechanism  of  
ZL006  action  in  impairing  the  consolidation  of  cue-­induced  fear  memory,  it  was  
examined  whether  local  application  of  ZL006  would  alter  long-­term  synaptic  
plasticity  in  the  BLA  slice  preparations.  To  this  end,  high  frequency  stimulation  
(HFS)  protocol  and  whole-­cell  patch  clamp  technique  were  employed  to  induce  
and  record  LTP  in  the  BLA  projection  neurons;;  and  the  amplitude  of  EPSP  in  the  
ZL006  treated  neurons  were  compared  to  neurons  treated  with  vehicle  or  ZL007,  
an  inactive  isomer  of  ZL006.  
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Disrupting  PSD95-­nNOS  interaction  by  ZL006  prevents  long-­term  
potentiation  of  BLA  neurons    
At  resting  conditions,  perfusion  of  BLA  slices  with  10  μM  ZL006  had  no  
significant  effects  on  evoked  excitatory  post-­synaptic  potentials  (eEPSPs)  or  
input  resistance  during  recordings  of  BLA  neurons.  After  establishing  basal  
responses  to  positive  current  injection,  it  was  observed  that  eEPSPs  of  BLA  
neurons  in  both  vehicle  and  10  μM  ZL007  control  conditions  underwent  a  
sustained  potentiation  upon  HFS  (183.4  ±  7.8  and  185.6  ±  8.4  percent  of  
baseline  at  1  h  for  vehicle  group  and  ZL007  group,  respectively).  However,  
eEPSPs  of  ZL006  treated  BLA  neurons  gradually  returned  to  baseline  levels  
(98.0  ±  3.9  percent  of  baseline  at  1  h)  following  short-­term  potentiation,  and  were  
statistically  different  from  the  eEPSPs  of  control  neurons  at  all  time  points  t  >  16  
min  (Figure  23B  and  C).  The  negative  current  was  injected  once  per  minute  to  
test  whether  changes  to  eEPSP  amplitude  resulted  from  changes  to  membrane  
resistance  and  no  differences  were  detected  between  conditions  or  over  time  
(Figure  23D).  Collectively,  these  findings  indicated  that  disrupting  PSD95/nNOS  
interaction  by  ZL006  impairs  LTP,  a  cellular  signature  of  synaptic  plasticity  in  
BLA  neurons.  
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Figure  23.  Disrupting  PSD95/nNOS  binding  by  ZL006  prevents  HFS  induced  
LTP  of  BLA  neurons  
  
(A)  Schematic  graphs  show  the  experimental  protocol  of  LTP  induction  (B)  
Representative  traces  show  EPSP  responses  before  and  1  h  after  HFS  under  
different  conditions  (C)  LTP  produced  in  the  ZL006  treated  cells  following  HFS  
was  significantly  impaired  compared  with  vehicle  and  ZL007  treated  cells  
(Treatment:  F2,  1243  =  434.0,  p  <  0.0001).  Multiple  comparisons  post  hoc  analysis  
revealed  that  EPSP  responses  in  ZL006  treated  cells  were  different  from  vehicle  
or  ZL007  treated  cells  at  all  time  point  t  >  16  minutes.  ***  P  <  0.001  ZL006  Vs.  
ZL007,  ###  P  <  0.001  ZL006  Vs.  Control  (n  =  10,  6  and  6  for  vehicle,  ZL007  and  
ZL006  respectively).  (D)  All  groups  of  cells  displayed  similar  membrane  
resistance  over  time  (n  =  8,  6  and  5  for  vehicle,  ZL007  and  ZL006  respectively).  
Arrow  indicates  initiation  of  high  frequency  stimulation  (HFS).  (Data  courtesy  of  
Erik  Dustrude).  
  
       
   91  
  
   In  the  electrophysiological  experiments,  the  effects  of  disruption  of  
PSD95-­nNOS  interaction  via  ZL006  on  amygdala  LTP  was  examined  using  a  
high  frequency  stimulation  protocol.  The  findings  showed  that  bath  application  of  
ZL006  effectively  impaired  LTP  in  the  BLA  neurons,  without  causing  effects  on  
baseline  EPSPs  alone.  However,  ZL007,  an  inactive  isomer  of  ZL006  had  no  
such  effects  on  amygdala  LTP.  These  results  suggested  an  involvement  of  
PSD95-­nNOS  interaction  in  the  amygdala  LTP  and  that  blocking  PSD95-­nNOS  
interaction  and  resultant  NO  signaling  leads  to  impaired  LTP  in  the  amygdala.  
This  is  consistent  with  a  previous  study  which  showed  that  bath  application  of  
either  the  NOS  inhibitor  7-­Ni  or  the  NO  scavenger  c-­PTIO  effectively  impaired  
LTP  in  the  BLA  neurons  (Schafe  et  al  2005).  
  
   It  was  found  that  the  impairing  effect  of  ZL006  on  amygdala  LTP  was  not  
shown  until  minutes  after  HFS,  as  the  eEPSPs  of  BLA  neurons  treated  with  
ZL006  underwent  a  short-­term  potentiation  (lasts  for  16  minutes  after  HFS)  
before  gradually  decaying  to  the  baseline  level.  This  observation  indicated  that  
unlike  the  sensitivity  of  the  later  maintenance  phase  of  LTP  to  ZL006  treatment,  
the  initial  induction  phase  of  LTP  was  not  affected  by  ZL006  treatment  at  this  
dose.  In  light  of  this  delayed  block  of  LTP  by  ZL006,  it  would  be  of  interest  to  test  
the  potential  mechanisms  of  the  early  versus  later  stages  of  LTP  induced  by  
HFS,  and  elucidate  the  role  of  PSD95-­nNOS  interactions  in  the  two  stages  of  
fear:  acquisition  versus  consolidation.  Indeed,  a  previous  study  has  shown  that  
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animals  with  intra-­amygdala  infusion  of  the  NOS  inhibitor  7-­Ni  or  the  NO  
scavenger  c-­PTIO  prior  to  training  displayed  no  deficits  in  the  acquisition  of  
conditioned  fear,  but  showed  impaired  consolidation  of  conditioned  fear  (Schafe  
et  al  2005).  
  
   It  has  been  generally  recognized  that  postsynaptic  changes  in  AMPA  
receptor  function  contribute  to  the  expression  of  LTP  (Sweatt  1999).  Considering  
the  compelling  evidences  showing  the  important  role  of  NO  signaling  in  the  
modulation  of  AMPA  receptor  function  (Huang  et  al  2005,  Selvakumar  et  al  2009,  
Selvakumar  et  al  2013,  Serulle  et  al  2007,  Wang  et  al  2005),  it  was  speculated  
that  ZL006  may  impair  amygdala  LTP  through  a  mechanism  altering  surface  
AMPA  receptor  availability  and  function.  Additional  electrophysiological  studies  
conducted  in  our  lab  have  found  that  fear-­conditioning  induced  enhanced  
AMPAR-­mediated  excitatory  post-­synaptic  currents  (EPSCs)  can  be  blocked  by  
ZL006  treatment  (unpublished  data),  indicating  that  ZL006  does  affect  AMPA  
receptor  function.  Further  studies  are  needed  to  investigate  the  detailed  
mechanisms  by  which  ZL006  affect  AMPA  receptor  function.  These  mechanisms  
include:  modulating  AMPA  receptor  trafficking  to  the  synaptic  sites,  regulating  
membrane  expression  level  of  AMPA  receptors  and  altering  AMPA  receptors  
properties  (further  discussed  in  section  5.3.1).  
  
   To  summarize,  the  electrophysiological  studies  using  amygdala  slices  and  
HFS  protocol  showed  that  disruption  of  PSD95-­nNOS  interaction  via  ZL006  
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blocked  LTP  in  the  BLA  neurons.  The  mechanisms  underlying  ZL006  effect  on  
amygdala  LTP  may  be  associated  with  altered  AMPA  receptor  function.  
Additional  experiments  are  needed  to  investigate  the  mechanisms  further.  
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CHAPTER  5    
Summary,  Discussion,  and  Perspectives  
  
  
   The  studies  in  this  dissertation  have  demonstrated  a  critical  role  of  
PSD95-­nNOS  interaction  within  key  limbic  regions  in  the  regulation  of  
conditioned  fear.  First,  I  determined  the  spatial  and  temporal  dynamics  of  
PSD95-­nNOS  interaction  within  the  amygdala,  the  hippocampus,  and  the  mPFC,  
three  key  regions  involved  in  conditioned  fear  (Figure  7).  The  data  showed  that  
PSD95-­nNOS  interaction  within  the  BLA  and  the  vHP  began  to  increase  by  30  
min  following  auditory  fear  conditioning,  peaked  at  1  h,  and  remained  increased  
until  6  h  after  conditioning,  suggesting  involvement  of  amygdalar  and  
hippocampal  PSD95-­nNOS  interaction  in  the  subsequent  consolidation  process  
following  fear  conditioning.  Furthermore,  the  robust  increases  in  PSD95-­nNOS  
interaction  in  both  regions  could  be  prevented  by  pretreatment  of  ZL006,  a  small  
molecule  disruptor  of  PSD95-­nNOS  interaction.  Unlike  the  BLA  and  the  vHP,  
PSD95-­nNOS  interaction  within  the  mPFC  remained  at  the  basal  level  after  fear  
conditioning.  Second,  I  determined  that  systemic  and  intra-­BLA  disruption  of  
PSD95-­nNOS  interaction  by  ZL006  impaired  the  consolidation  of  cue-­induced  
fear  (Figure  15  and  17).  In  contrast,  disruption  of  PSD95-­nNOS  interaction  within  
the  hippocampus  did  not  affect  the  consolidation  of  cue-­induced  fear,  but  
significantly  impair  the  consolidation  of  context-­induced  fear  (Figure  18).  At  the  
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cellular  level,    disruption  of  amygdalar  PSD95-­nNOS  interaction  with  ZL006  was  
found  to  impair  LTP  in  the  BLA  neurons  (Figure  23).  
  
   Similar  to  ZL006,  impairment  in  conditioned  fear  was  also  observed  with  
systemic  application  of  NMDA  receptor  antagonist  MK-­801  (Figure  16),  which  is  
in  agreement  with  previous  studies  (Fendt  2001,  Lee  et  al  2001).  However,  unlike  
the  NMDA  receptor  antagonist,  ZL006  selectively  disrupts  conditioned  fear  
without  affecting  many  other  CNS  functions,  such  as  locomotor  function  (Figure  
20B),  social  activity  (Figure  20C)  and  cognitive  functions  in  NORT  (Figure  21)  
and  Y-­maze  tests  (Figure  22),  indicating  that  disrupting  PSD95-­nNOS  interaction  
may  represent  a  novel  therapeutic  approach  for  reducing  conditioned  fear  without  
eliciting  adverse  effects.  
  
   Collectively,  the  current  discoveries  presented  in  this  dissertation  
demonstrated  that  PSD95-­nNOS  interaction  within  the  fear  network  appears  to  
be  a  critical  molecular  step  in  regulating  synaptic  plasticity  and  the  consolidation  
of  conditioned  fear.  Disruption  of  this  protein-­protein  interaction  attenuates  fear  
consolidation  and  has  no  effects  on  motor  function,  social  activity  and  cognitive  
functions.  Therefore,  PSD95-­nNOS  interaction  holds  promise  as  a  novel  
therapeutic  target  for  fear-­motivated  disorders  with  minimal  side  effects.  These  
studies  have  made  contributions  to  the  fields  of  NMDA-­NO  signaling  and  fear  
memory  research  and  have  opened  up  several  lines  of  research  that  will  be  
discussed  in  section  5.3.  
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In  this  section,  the  role  of  PSD95-­nNOS  interaction  in  cued  and  contextual  
fear  memory  is  further  discussed.  The  translational  impact  of  this  study  is  also  
discussed.  
  
5.2.1  Amygdalar  PSD95-­nNOS  interaction  and  cue-­induced  fear  memory  
   Experiments  in  this  present  study  have  shown  that  the  systemic  disruption  
of  PSD95-­nNOS  interaction  by  ZL006  shortly  after  fear  conditioning  produced  an  
impairing  effect  on  the  long-­term  memory  (LTM)  of  cue-­induced  fear  when  
assessed  the  following  day  (~24  hours  after  fear  conditioning)  (Figure  15);;  and  
the  effect  could  be  recapitulated  by  local  application  of  ZL006  into  the  amygdala  
(Figure  17).  These  results  indicated  that  the  amygdala  might  be  the  locus  
mediating  ZL006  action  on  cue-­induced  fear  responses.  Consistent  with  this  
idea,  a  study  by  Schafe  et  al.  showed  that  intra-­amygdala  infusions  of  either  NOS  
inhibitor  7-­Ni  or  NO  scavenger  c-­PTIO  prior  to  fear  conditioning  also  significantly  
impaired  the  LTM  of  cue-­induced  fear  (Schafe  et  al  2005).  In  addition  to  the  LTM  
assessed  the  following  day,  Schafe  et  al.  also  investigated  short-­term  memory  
(STM)  that  was  examined  1  hour  and  3  hours  after  fear  conditioning.  
Interestingly,  it  was  found  that  STM  was  not  affected  by  pre-­conditioning  
treatment  of  either  7-­Ni  or  c-­PTIO  (Schafe  et  al  2005).  These  results,  together  
with  those  described  in  this  thesis  indicated  that  NO  signaling  in  the  amygdala  is  
required  for  the  long-­term  retention  (or  consolidation)  of  cue-­induced  fear  
memory,  rather  than  the  initial  acquisition  of  conditioned  fear  memory.  
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was  further  supported  by  the  later  studies  from  the  Schafe  group  showing  that  
intra-­amygdala  manipulations  of  several  downstream  molecules  of  NO  signaling,  
namely  sGC,  cGMP,  PKG  and  ERK  also  affect  the  consolidation  of  cued  fear  
memory  (Ota  et  al  2008).  In  support  of  the  role  of  NO  signaling  in  the  
consolidation  of  conditioned  fear,  both  inhibition  of  the  upstream  of  NO  signaling,  
PSD95-­nNOS  interaction,  by  ZL006  and  inhibition  of  the  downstream  
components  of  NO  signaling  by  sGC  inhibitor  and  PKG  inhibitor  impaired  LTP  in  
the  amygdalar  neurons  (Ota  et  al  2008).  
  
   It  could  be  argued  that  disruption  of  NO  signaling  by  ZL006  causes  effects  
on  the  locomotor  function  which  may  confound  with  results  of  fear  conditioning.  
The  results  of  the  current  study  and  those  of  others  (Doucet  et  al  2013,  Tillmann  
et  al  2017)  have  shown  that  i.p.  injection  of  ZL006  at  10  mg/kg,  the  effective  dose  
for  reducing  fear  has  no  acute  effect  on  the  locomotor  activity  1  hour  after  drug  
administration  (Figure  20).  Although  I  did  not  directly  test  the  chronic  effect  of  NO  
signaling  inhibition  by  ZL006  on  the  locomotor  function,  a  previous  study  showed  
that  i.p.  injection  of  NOS  inhibitor  SMTC  (S-­methyl-­L-­thiocitrulline)  did  not  affect  
locomotion  24  hours  after  drug  administration  (Kelley  et  al  2010),  a  time  point  
that  was  used  to  test  the  LTM  of  conditioned  fear.  Also,  results  from  chronic  
treatments  (7  days)  with  ZL006  at  10  mg/kg  in  sham  TBI  model  mice  showed  no  
effects  on  baseline  locomotor  activity  and  fine  motor  functions  (Xiao-­Ming  Xu  et  
al.,  MS  under  review).  These  findings  collectively  suggested  that  disruption  of  NO  
signaling  by  ZL006  has  specific  effects  on  LTM  of  cue-­induced  fear.  
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   The  finding  that  the  systemic  injection  of  ZL006  following  fear  conditioning  
impaired  the  consolidation  of  cued  fear  memory  was  different  from  a  previous  
study  showing  that  immediate  post-­conditioning  administration  of  a  preferential  
nNOS  inhibitor,  SMTC  at  20-­200  mg/kg,  did  not  cause  effects  on  the  
consolidation  of  cued  fear  (Kelley  et  al  2010).  The  author  reasoned  that  the  lack  
of  effects  of  SMTC  may  due  to  its  fast  pharmacokinetics.  As  measured  with  brain  
associated  nitrite  and  nitrate,  two  markers  of  NO  production,  similar  i.p.  doses  of  
SMTC  has  a  very  short  duration  of  action  (<  1hour)  that  may  prevent  it  from  
affecting  the  consolidation  of  conditioned  fear  (Kelley  et  al  2010).  This  is  probably  
the  case  when  considering  the  results  from  the  Co-­IP  experiments  (Figure  7).  
The  Co-­IP  experiments  suggested  a  robust  increase  of  PSD95-­nNOS  interaction  
at  1  hour    and  2  hours  after  conditioning,  and  this  increase  appeared  to  be  
remained  until  6  hours  after  conditioning,  indicating  that  NO  signaling  was  
continuously  activated  during  the  time  period  from  1  hour  to  2  hours  (and  
potentially  up  to  6  hours)  following  conditioning,  and  NO  signaling  within  this  time  
period  was  associated  with  the  molecular  processes  underlying  memory  
consolidation.  Therefore,  drugs  with  a  longer  duration  of  action  that  affect  NO  
signaling  within  this  critical  period  of  time  may  influence  the  consolidation  of  fear  
memory.  It  would  be  of  interest  to  test  if  multiple  doses  of  SMTC  following  fear  
conditioning  could  elongate  the  duration  of  action  and  therefore  affect  the  
consolidation  of  cued  fear  memory.    
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   In  summary,  the  results  suggested  that  PSD95-­nNOS  interaction  plays  a  
critical  role  in  regulating  synaptic  strengthening,  LTP  and  cue-­induced  fear  
memory  consolidation  within  the  amygdala.  Further  studies  are  needed  to  
investigate  the  specific  molecular  mechanisms  underlying  ZL006  action  on  LTP  
and  fear  behaviors.    
  
5.2.2  Hippocampal  PSD95-­nNOS  interaction  and  context-­induced  fear  
memory  
   The  first  study  investigating  the  role  of  NO  signaling  in  the  contextual  fear  
conditioning  reported  that  systemic  administration  of  NOS  inhibitor  7-­Ni  did  not  
have  effects  on  contextual  fear  conditioning  (Maren  1998).  However,  the  results  
may  have  been  influenced  by  the  decreased  locomotor  activity  produced  by  7-­Ni  
(Maren  1998).  A  later  study  employed  several  control  experiments  demonstrated  
that  pharmacological  inhibition  or  enhancement  of  NO  signaling  can  respectively  
impair  or  improve  the  consolidation  of  contextual  fear  and  these  effects  on  
contextual  fear  cannot  be  explained  by  drug  effects  on  locomotor  activity  (Kelley  
et  al  2010).  In  agreement  with  these  findings,  contextual  fear  learning  and  
expression  was  severely  impaired  in  mice  lacking  the  nNOS  gene  (Kelley  et  al  
2009).  Overall,  these  findings  confirmed  an  involvement  of  NO  signaling  in  the  
regulation  of  contextual  fear  memory.  However,  at  present,  few  studies  have  
investigated  the  neural  substrates  mediating  the  effects  of  NO  signaling  inhibition  
on  contextual  fear.    
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   In  the  current  study,  this  question  was  examined  by  focusing  on  the  
ventral  hippocampus  (vHP),  as  a  wealth  of  behavioral  and  anatomical  data  have  
suggested  a  critical  role  of  vHP  in  contextual  fear.  For  example,  ventral  
hippocampal  lesions  impair  the  acquisition  and  expression  of  contextual  fear  
(Maren  1999b,  Trivedi  &  Coover  2004).  In  addition,  intra-­vHP  infusions  of  GABAA  
receptor  agonist  muscimol  (Bast  et  al  2001)  and  NMDA  receptor  antagonist  MK-­
801  (Zhang  et  al  2001)  also  cause  deficits  in  the  contextual  fear.  Anatomically,  
the  ventral  hippocampus  has  intimate  reciprocal  connections  with  the  amygdala  
(Pitkänen  et  al  2000),  a  key  region  where  the  information  of  CS  and  US  
converge,  indicating  an  important  role  of  vHP-­amygdala  interaction  in  contextual  
modulation  of  fear.  In  the  current  study,  by  utilizing  a  Co-­IP  assay,  a  robust  
increase  of  PSD95-­nNOS  interaction  in  the  vHP  was  observed  at  1  hour  and  2  
hours  after  fear  conditioning,  and  this  increase  probably  remained  until  at  least  6  
hours  after  conditioning  (Figure  7).  This  finding  suggested  an  involvement  of  
ventral  hippocampal  PSD95-­nNOS  interaction  in  the  subsequent  consolidation  
process  following  contextual  fear  conditioning.  We  next  showed  that  post-­training  
infusion  of  PSD95-­nNOS  interaction  inhibitor  ZL006  into  the  vHP  significantly  
disrupted  the  conditioned  fear  responses  to  the  context  when  tested  one  day  
later  (Figure  18),  further  supporting  a  role  of  ventral  hippocampal  PSD95-­nNOS  
interaction  in  the  regulation  of  contextual  fear  memory  consolidation.  
  
   NO  signaling  in  the  vHP  has  been  implicated  in  the  modulation  of  anxiety-­
related  behavior.  For  example,  intra-­vHP  inhibition  of  NO  signaling  by  7-­Ni  
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produces  anxiolytic  effects  assessed  by  elevated  T-­maze  test  (Calixto  et  al  
2010).  Hence,  it  could  be  argued  that  modulation  of  NO  signaling  by  ZL006  may  
influence  anxiety-­related  behavior  (e.g.,  anxiolytic  like  behavior),  which  can  
confound  the  measurements  of  fear  responses  (behavioral  freezing).  However,  
data  from  the  current  study  and  those  from  others  suggested  that  this  is  not  the  
case.  I  found  that  intra-­vHP  infusion  of  ZL006  selectively  affected  fear  responses  
to  the  context  but  not  to  the  tone.  If  intra-­vHP  ZL006  produced  anxiolytic  effect,  
then  it  would  be  expected  that  both  contextual  and  cued  fear  memory  would  be  
affected  by  the  ZL006  treatment.  In  addition,  unlike  direct  inhibition  of  the  
enzyme  nNOS,  disruption  of  PSD95-­nNOS  interaction  appears  to  have  no  effect  
on  anxiety/anxiolytics-­related  behavior  assessed  by  multiple  tests,  such  as  social  
interaction  test  (Figure  20),  light-­dark  box  and  elevated  plus  maze  (Doucet  et  al  
2013).  Collectively,  these  data  suggested  that  the  effect  of  intra-­vHP  ZL006  is  
best  interpreted  as  an  effect  on  the  memory  function  of  ventral  hippocampal  
PSD95-­nNOS  interaction.  
  
   One  might  worry  that  the  effect  of  ZL006  treatment  was  due  to  its  
spreading  outside  the  vHP,  such  as  the  dorsal  hippocampus  (dHP).  dHP  has  
also  been  shown  to  be  involved  in  the  modulation  of  contextual  fear  conditioning  
(Holt  &  Maren  1999,  Maren  et  al  1997,  Maren  &  Fanselow  1997,  Matus-­Amat  et  
al  2004,  Matus-­Amat  et  al  2007,  Phillips  &  LeDoux  1992).  Thus,  it  is  possible  that  
the  results  from  the  intra-­vHP  infusion  experiment  were  due  to  ZL006  diffusing  
into  the  dHP.  To  address  this  possibility,  future  studies  can  be  done  using  a  more  
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ventral  infusion  site  in  the  vHP,  which  would  reduce  the  likelihood  of  ZL006  
diffusion  into  the  dHP.  If  the  results  from  our  experiment  were  due  to  ZL006  
diffusion  into  the  dHP,  it  would  be  expected  to  see  no  effect  in  this  future  
experiment;;  However,  if  ventral  hippocampal  ZL006  does  play  a  role  in  the  
regulation  of  contextual  fear,  similar  effects  would  be  observed.  
  
   In  summary,  the  current  study  showed  that  intra-­vHP  infusion  of  ZL006  
significantly  reduced  the  freezing  responses  to  the  contextual  CS;;  However,  the  
freezing  responses  to  the  auditory  CS  remained  unaffected.  This  specificity  has  
also  been  observed  in  an  earlier  study  with  intra-­vHP  infusion  of  NMDA  receptor  
antagonist  MK-­801  (Zhang  et  al  2001).  Together,  these  findings  indicate  that  
NMDA-­NO  mediated  mechanisms  in  the  vHP  are  critical  in  the  memory  formation  
of  contextual  but  not  cued  fear  conditioning.  These  mechanisms  might  be  
required  for  contextual  fear  memory  storage  in  the  vHP.  To  further  address  this  
issue,  electrophysiological  studies  can  be  utilized  to  investigate  the  effects  of  
MK-­801  and  ZL006  on  the  LTP  in  area  CA3-­CA1  of  the  vHP.  These  experiments  
are  currently  being  run  in  our  laboratory.  
  
5.2.3  Non-­specific  effect  profile  of  small-­molecule  inhibitors  of  PSD95-­
nNOS  interaction  
   Despite  the  important  role  of  NMDA  receptors  in  disrupting  fear  memory  
formation,  the  clinical  use  of  NMDA  receptor  antagonists  is  hampered  as  they  
also  produce  adverse  side  effects,  including  cognitive  deficits  and  motor  
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impairments  (Krystal  et  al  1994,  Pal  et  al  2002).  Consistent  with  the  previous  
studies  (Rung  et  al  2005),  I  found  that  i.p.  injection  of  the  NMDA  receptor  
antagonist  MK-­801  at  the  dose  effective  for  reducing  fear  (0.1  mg/kg)  resulted  in  
hyper-­locomotion  and  impaired  social  activity  in  rats  assessed  by  open  field  test  
and  social  interaction  test  respectively  (Figure  20).  In  addition,  in  agreement  with  
previous  research  (Boultadakis  &  Pitsikas  2010,  Cunha  et  al  2008,  de  Lima  et  al  
2005),  the  discrimination  memory  in  NORT  (Figure  21)  and  the  spatial  memory  in  
Y-­maze  test  (Figure  22)  were  also  impaired  in  animals  treated  with  MK-­801.  
However,  I  found  that  ZL006,  unlike  MK-­801,  can  selectively  impair  fear  memory  
without  affecting  locomotor  function  (Figure  20B),  social  activity  (Figure  20C)  and  
the  short-­term  memory  in  NORT  and  Y-­maze  test  (Figure  21  and  Figure  22).  This  
lack  of  acute  motor  and  cognitive  effects  of  ZL006  has  significant  clinical  
implications.  NMDA  receptor  antagonists,  specifically  ketamine,  appears  to  be  an  
effective  treatment  for  reducing  PTSD  symptoms  (Feder  et  al  2014).    However,  a  
significant  limitation  of  drugs  like  ketamine  is  their  acute  effects  on  cognition  and  
mental  state  that  could  last  several  hours  to  days  after  an  initial  administration.  
Based  on  this  current  study,  PSD95-­nNOS  interaction  appears  to  represent  a  
novel  therapeutic  target  that  could  reduce  conditioned  fear  but  without  eliciting  
such  acute  CNS  adverse  effects.  Future  studies  are  needed  to  further  investigate  
the  molecular  mechanisms  underlying  ZL006  action  (further  discussed  in  section  
5.3)  and  support  the  development  of  PSD95-­nNOS  interaction-­based  treatment  
approach  for  fear-­related  disorders,  such  as  PTSD  and  phobias.    
  
   104  
  
The  work  presented  in  this  dissertation  demonstrated  a  critical  role  of  
PSD95-­nNOS  interaction  in  regulating  synaptic  plasticity  and  the  consolidation  of  
conditioned  fear.  However,  there  are  some  aspects  of  the  underlying  mechanism  
that  I  did  not  fully  elucidate  and  were  outside  the  scope  of  my  current  project.  In  
this  section,  I  will  explain  the  limitations  of  this  study  (5.3.1)  and  discuss  the  
future  directions  (5.3.2~5.3.4)  in  further  understanding  the  mechanisms  and  
developing  PSD95-­nNOS  interaction  based  novel  therapeutic  target  for  fear-­
related  disorders.    
  
5.3.1  Limitations  and  Caveats  
The  Co-­IP  experiments  described  in  Chapter  2  demonstrated  a  robust  
increase  in  PSD95-­nNOS  interaction  in  both  BLA  and  vHP  at  1  h  and  2  h  
following  fear  conditioning  (Figure  7),  indicating  increased  nNOS  activity  at  these  
time  points  in  both  regions.  In  support  of  this  view,  a  previous  study  using  in  vivo  
microdialysis  with  Griess  test  found  that  the  NO  production  in  the  amygdala  
began  to  rise  at  1  h  and  maintained  increased  until  3  h  after  fear  conditioning,  as  
measured  by  the  levels  of  nitrite/nitrate  (NO  metabolites)  (Sato  et  al  2006).  
However,  the  levels  of  NO  metabolites  following  fear  conditioning  in  the  BLA  and  
vHP  were  not  directly  tested  in  this  current  study.  Future  experiments  with  Griess  
assay  can  be  done  to  monitor  nitrite/nitrate  levels  in  both  regions  at  different  time  
points  following  fear  conditioning.  Co-­IP  experiment  in  the  current  study  also  
demonstrated  that  ZL006  treatment  is  effective  in  disrupt  PSD95-­nNOS  
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interaction  in  the  BLA  and  vHP  (Figure  11).  However,  whether  ZL006  can  
decrease  nNOS  activity  and/or  NO  production  in  both  regions  was  not  
determined.  Previous  studies  have  verified  the  ability  of  ZL006  to  reduce  NO  
production  in  hippocampal  neurons  (Smith  et  al  2016)  and  cerebellum  slices  
(Tillmann  et  al  2017)  by  the  measurement  of  cGMP  or  nitrite/nitrate  levels.  I  
therefore  reasoned  that  ZL006  treatment  in  this  current  study  should  also  reduce  
cGMP  levels  and/or  nitrite/nitrate  concentrations  in  both  BLA  and  vHP.  Additional  
experiments  using  cGMP  assay  and  Griess  assay  can  be  done  in  tissue  
homogenates  of  BLA  and  vHP  to  confirm  the  NO-­decreasing  effect  of  ZL006.  
This  series  of  experiments  will  enable  a  more  complete  argument  that  ZL006  
action  on  fear  memory  was  mediated  via  NO  signaling-­based  mechanisms.  
  
Behavioral  experiments  in  the  current  study  showed  that  intra-­BLA  and  
intra-­vHP  injection  of  ZL006  can  respectively  impair  the  consolidation  of  cue-­
induced  and  context-­induced  fear  memory  (Figure  17  and  18).  A  limitation  of  
these  behavioral  studies  is  that  I  did  not  determine  if  nNOS,  rather  than  iNOS  or  
eNOS,  was  required  for  the  effects  seen  with  ZL006.  To  define  the  primacy  of  
nNOS  protein  for  the  behavioral  effects  of  ZL006,  the  same  set  of  behavioral  
experiments  can  be  done  in  animals  with  local  anti-­nNOS  shRNA  treatment  in  
the  BLA  or  vHP.  We  anticipate  that  the  fear-­reducing  effect  of  ZL006  treatment  
will  not  be  observed  in  animals  that  have  the  expression  of  the  key  protein  nNOS  
silenced.  
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5.3.2  Molecular  mechanisms  in  the  amygdala  associated  with  cued  fear  
consolidation  and  the  effects  of  disruption  of  PSD95-­nNOS  interaction  
The  results  from  the  present  study  and  those  from  others  (Ota  et  al  2008,  
Paul  et  al  2008,  Schafe  et  al  2005)  clearly  demonstrated  a  critical  role  of  
amygdalar  NO  signaling  in  modulating  the  consolidation  of  auditory  fear  
conditioning.  Consolidation  is  the  process  in  which  temporary  stimulus-­fear  
association  via  CS/US  pairing  is  stabilized  into  a  persistent  memory.  Previous  
research  has  suggested  that  the  consolidation  of  cued  fear  is  characterized  by  
enduring  enhanced  synaptic  efficacy  in  the  BLA  synapses,  which  is  in  part  
attributed  to  enhanced  AMPA  receptor  function  (e.g.  increased  receptor  affinity,  
slowing  receptor  deactivation)  and/or  increased  expression  of  synaptic  AMPARs  
(e.g.  increased  AMPARs  insertion/trafficking  to  the  post-­synaptic  membrane).  
Electrophysiological  studies  with  amygdala  slices  from  my  laboratory  
(unpublished)  found  enhanced  AMPAR-­mediated  EPSCs  (AMPA-­EPSCs)  at  both  
the  early-­  and  the  late-­phase  of  consolidation  (~3.5  hours  and  ~24  hours  
following  auditory  fear  conditioning,  respectively).  Interestingly,  the  enhanced  
AMPA-­EPSCs  at  both  time  points  could  be  blocked  by  pretreatment  of  ZL006,  
indicating  a  role  of  NO  signaling  in  the  regulation  of  AMPARs  properties  and/or  
synaptic  expression  of  AMPARs.  However,  the  precise  molecular  mechanisms  
by  which  NO  signaling  mediates  the  AMPARs  properties  and  synaptic  insertion  
remain  unknown  and  represent  a  fruitful  area  for  further  inquiry.    
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Here,  I  will  discuss  the  potential  mechanisms  based  on  the  previous  
research  and  recent  findings  in  our  laboratory.  Proposed  experiments  that  could  
be  used  to  test  these  mechanisms  are  also  discussed.  A  proposed  model  of  NO-­
signaling  in  the  BLA  neurons  mediating  AMPARs  properties  and  expression  is  
shown  in  Figure  24.  
  
5.3.2.1  NO  signaling  and  AMPARs  in  early  consolidation  
   Previous  research  has  shown  that  activated  PKG  via  NMDAR-­nNOS-­NO-­
sGC  signaling  pathway  binds  the  C-­terminal  domain  of  GluR1,  and  that  in  this  
complex,  PKG  can  phosphorylate  S845  of  GluR1  and  increase  AMPAR  level  in  
the  plasma  membrane  of  hippocampal  neurons  (Serulle  et  al  2007).  In  addition,  
the  increased  surface  AMPARs  can  be  blocked  by  pretreatment  of  nNOS  
inhibitor  and  sGC  inhibitor  (Serulle  et  al  2007).  This  function  of  PKG  provides  a  
mechanism  by  which  NO  signaling  regulates  AMPARs  trafficking  in  the  
hippocampus.  However,  whether  this  mechanism  can  be  generalized  to  the  
amygdala  and  underlies  the  NO  signaling-­mediated  effects  on  fear  consolidation  
in  not  clear.  To  address  this  issue,  synaptosome  extracted  from  the  amygdala  of  
fear-­conditioned  and  non-­conditioned  animals  with  or  without  ZL006  treatment  
can  be  utilized  to  examine  the  levels  of  PKG-­GluR1  interaction  and  GluR1  
phosphorylation.  It  is  expected  to  see  enhanced  PKG-­GluR1  interaction  and  
GluR1  phosphorylation  in  the  amgydalar  synaptosome  from  fear-­conditioned  
animals  when  compared  with  those  from  non-­conditioned  animals,  and  the  
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increased  expression  of  PKG-­GluR1  complex  and  phosphorylated  GluR1  can  be  
blocked  in  animals  treated  with  ZL006.  
  
   In  addition  to  the  PKG-­dependent  mechanism,  NO  signaling  can  also  
influence  AMPARs  trafficking  via  a  post-­translational  mechanism  called  S-­
nitrosylation.  It  has  been  reported  that  NO  production  upon  NMDARs  stimulation  
elicits  S-­nitrosylation  of  stargazin  and  NSF  (N-­ethylmaleimide  sensitive  factor),  
two  AMPA  receptor  regulatory  proteins.  While  nitrosylated  stargazin  causes  an  
increased  surface  expression  of  AMPARs  by  enhancing  stargazin  binding  with  
GluR1  (Selvakumar  et  al  2009),  nitrosylated  NSF  facilitates  the  surface  insertion  
of  AMPARs  by  enhancing  NSF  binding  with  GluR2  (Huang  et  al  2005).  Additional  
experiments  with  biotin-­switch  assay  will  allow  us  to  examine  if  fear  conditioning  
induces  S-­nitrosylation  of  stargazin  and  NSF  and  if  pretreatment  of  ZL006  could  
block  the  increase  of  nitrosylated  stargazin  and  NSF.  
  
   While  affecting  the  membrane  expression  of  AMPARs,  NO  has  also  been  
implicated  in  the  modulation  of  AMPARs  properties.  Receptor  binding  studies  
with  brain  sections  from  different  regions  reported  that  NO  appears  to  be  able  to  
increase  the  affinity  of  AMPARs,  thus  increasing  the  synaptic  responses  (Dev  &  
Morris  1994).  The  underlying  mechanisms  could  be  cGMP-­dependent  or  cGMP-­
independent  (Dev  &  Morris  1994).  Additional  experiments  are  required  to  test  if  
NO  can  increase  AMPARs  affinity  in  the  amygdala  slices  and  if  the  increased  
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affinity  of  AMPA  binding  site  can  be  decreased  by  disruption  of  PSD95-­nNOS  
interaction  by  ZL006.  
  
5.3.2.2  NO  signaling  and  AMPARs  in  late  consolidation  
   Transcriptional  profiling  studies  in  my  laboratory  (unpublished)  have  
revealed  a  set  of  differentially  expressed  genes  (DEGs)  in  the  amygdala  24  
hours  following  auditory  fear  conditioning.  Some  of  the  DEGs,  such  as  igf2  
(insulin-­like  growth  factor  2)  and  itgb6  (integrin  beta  6)  can  be  rescued  by  ZL006  
treatment.  Recent  studies  have  shown  that  both  IGF-­II  and  integrins  can  regulate  
surface  expression  of  AMPARs  via  endocytosis  (Alberini  &  Chen  2012,  Chen  et  
al  2011,  Cingolani  et  al  2008,  Pozo  et  al  2012).  Thus,  IGF-­II-­dependent  and/or  
integrin-­dependent  endocytosis  of  AMPARs  may  represent  one  of  the  
mechanisms  underlying  the  increased  AMPA-­EPSCs  and  the  effects  of  ZL006  
that  were  observed  at  the  late-­stage  of  consolidation.  Confirmatory  studies,  such  
as  intra-­amygdala  inhibition/activation  of  gene  expression  or  protein  function,  will  
be  needed  to  definitively  conclude  the  role  of  these  genes  in  the  regulation  of  
AMPARs  expression  and  the  consolidation  of  fear  memory.  The  effects  of  
disruption  of  PSD95-­nNOS  interaction  on  the  expression  of  IGF-­II  and  integrins  
can  be  further  confirmed  with  PCR  and  western  blotting  experiments.  
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Figure  24.  A  proposed  model  of  NO-­signaling  in  the  BLA  neurons  
mediating  AMPARs  properties  and  expression  which  underlies  the  
consolidation  of  fear  
  
(A)  Before  fear  conditioning,  nNOS  enzyme  displays  minimum  activity  due  to  a  
lack  of  interaction  with  the  scaffold  protein  PSD95;;  therefore,  NO  signaling  is  
largely  inhibited.  (B)  Upon  fear  conditioning,  nNOS  translocates  from  the  cytosol  
to  membrane  via  PSD95-­nNOS  interaction,  which  is  critical  for  the  efficient  
activation  of  nNOS  by  the  Ca2+  influx  through  the  NMDARs.  Upon  the  activation  
of  nNOS,  NO  is  synthesized  and  acts  on  multiple  targets  that  are  potentially  
involved  in  the  regulation  of  AMPARs  properties  and  expression.  During  the  early  
phase  of  consolidation  (~  3.5  h  following  fear  conditioning),  increased  NO  
promotes  membrane  expression  of  AMPARs  either  via  activation  of  NO-­cGMP-­
PKG  pathway  or  through  modifying  the  regulatory  proteins  of  AMPARs  by  S-­
nitrosylation.  Specifically,  activated  PKG  forms  a  complex  with  GluR1  and  
directly  phosphorylated  GluR1,  which  facilitating  synaptic  insertion  of  AMPARs;;  
NO-­induced  nitrosylated  stargazin  and  NSF  (N-­ethylmaleimide  sensitive  factor)  
can  both  enhance  their  binding  with  AMPARs  and  thus  promoting  membrane  
expression  of  AMPARs.  In  addition,  NO  appears  to  be  able  to  increase  the  
affinity  of  AMPARs  through  an  unclear  mechanism.  During  late  consolidation  (~  
24  h  after  fear  conditioning),  NO  associated  signaling  pathway  downregulated  
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the  gene  expression  of  igf2  (insulin-­like  growth  factor  2)  and  itgb6  (integrin  beta  
6)  via  unknown  mechanisms.  IGF-­II-­  and  integrin  β3-­dependent  endocytosis  of  
AMPARs  are  therefore  reduced  and  membrane  expression  of  AMPARs  is  
correspondently  increased.  In  animals  treated  with  ZL006,  the  interaction  
between  PSD95  and  nNOS  is  significantly  disrupted,  leaving  nNOS  activation  at  
a  minimal  level.  Therefore,  NO  signaling  and  the  resultant  various  synaptic  
outcomes  are  impaired/prevented.    
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5.3.3  PSD95-­nNOS  interaction  in  different  stages  of  fear  memory  
   Although  the  current  study  and  studies  from  others  have  clearly  shown  an  
important  role  of  NO  signaling  in  fear  memory  consolidation,  it  remains  unclear  if  
NO  signaling  has  a  consistent  role  in  other  aspects  of  fear  memory,  namely,  
reconsolidation  and  extinction.  Specifically,  whether  inhibition  of  NO  signaling  by  
disrupting  PSD95-­nNOS  interaction  consistently  impair  fear  memory  across  
conditioning,  reactivation  and  extinction  remains  unknown.  Future  studies  
addressing  these  issues  will  provide  additional  insights  into  the  field  of  NMDA-­
nNOS-­NO  signaling  and  fear  memory  research.  
  
5.3.3.1  NO  signaling  and  reconsolidation  of  fear  memory  
   Although  fear  memories  are  consolidated  following  conditioning,  they  can  
be  labile  (destabilized)  after  its  retrieval  through  a  process  that  has  been  termed  
reconsolidation.  Memory  retrieval  or  reactivation  is  usually  done  by  a  single  
presentation  of  CS  that  was  used  to  signal  shock  during  acquisition.  Once  
reactivated,  memories  enter  into  a  labile  state  and  require  reconsolidation  
processes  in  order  to  be  retained  (Alberini  2005,  Johansen  et  al  2011,  Tronson  &  
Taylor  2007).    
  
   Ample  evidence  suggests  that  reconsolidation  and  consolidation  of  fear  
memories  may  share  some  key  features  in  terms  of  the  intracellular  cascade  of  
events  triggered  by  NMDARs  activation  (Alberini  2005,  Johansen  et  al  2011,  
Tronson  &  Taylor  2007).  Indeed,  NO  signaling,  as  a  downstream  of  NMDARs  
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activation,  has  been  implicated  in  the  reconsolidation  of  associative  memories  
using  various  conditioning  paradigms.  For  example,  post-­retrieval  administration  
of  either  NMDARs  antagonist  MK-­801  or  NOS  inhibitor  7-­Ni  impaired  the  memory  
of  cocaine-­induced  conditioned  place  preference  (CPP)  in  mice  (Itzhak  2008);;  
additionally,  administration  of  NO  donor  molsidomine  following  retrieval  of  place  
preference  enhanced  reconsolidation  and  improved  CPP  expression  in  nNOS  
knockout  mice  (Itzhak  &  Anderson  2007).  Similarly,  by  using  inhibitory  avoidance  
task,  inhibition  of  NO  signaling  has  also  been  shown  to  impair  the  reconsolidation  
of  the  original  learning  (Baratti  et  al  2008).    
  
   Despite  the  critical  role  of  NO  signaling  in  memory  reconsolidation  in  CPP  
and  inhibitory  avoidance  tasks,  few  studies  have  investigated  the  role  of  NO  
signaling  in  the  reconsolidation  of  fear  memory  using  fear  conditioning  
paradigms.  At  present,  only  one  study  directly  addressed  this  question  by  
infusing  7-­Ni  into  the  amygdala  of  fear  conditioned  rats  (Schafe  et  al  2005).  
However,  in  this  study,  the  authors  failed  to  observe  any  effects  of  intra-­
amygdala  7-­Ni  on  the  reconsolidation  of  auditory  fear  conditioning.  Several  
factors  may  account  for  the  negative  results.  First,  the  effects  of  NO  signaling  
inhibition  on  memory  reconsolidation  may  be  dependent  on  the  timing  of  drug  
administration.  In  CPP  and  inhibitory  avoidance  tasks,  drugs  were  given  
immediately  after  memory  retrieval  (reactivation),  in  contrast,  in  the  auditory  fear  
conditioning  task,  drugs  were  administrated  30  minutes  prior  to  memory  retrieval.  
Second,  it  is  possible  that  other  brain  regions,  such  as  hippocampus  and  mPFC  
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may  be  the  neural  locus  mediating  the  effects  of  NO  signaling  in  the  fear  memory  
reconsolidation.  Clearly,  additional  experiments  are  required  to  further  determine  
the  role  of  NO  signaling  in  the  regulation  of  memory  reconsolidation  of  fear  
conditioning.      
  
5.3.3.2  NO  signaling  and  extinction  of  fear  memory  
   Fear  extinction  is  a  form  of  inhibitory  learning  after  repeated  presentation  
of  the  CS,  without  the  US,  which  results  in  a  gradual  reduction  of  previously  
acquired  conditioned  fear  responses  (Myers  &  Davis  2007).  There  is  increasing  
interest  in  the  research  elucidating  the  neural  circuits  and  molecular  mechanisms  
supporting  fear  extinction  due  to  its  clinical  relevance  in  fear-­related  disorder,  
such  as  PTSD.  Previous  work  has  identified  a  facilitatory  role  of  BDNF-­TrkB  
signaling  in  fear  extinction  (Andero  &  Ressler  2012).  A  recent  study  revealed  that  
PSD95-­nNOS  interaction  may  be  a  novel  fear  extinction  modulator  that  acts  
through  BDNF-­TrkB  signaling  (Cai  et  al  2018).  The  authors  showed  that  intra-­
hippocampal  disruption  of  PSD95-­nNOS  interaction  by  repeated  infusion  of  small  
molecule  ZL006  or  peptide  Tat-­nNOS1-­133  following  fear  recall  can  significantly  
facilitate  the  extinction  of  contextual  fear  memory  (Cai  et  al  2018).  
Mechanistically,  disruption  of  PSD95-­nNOS  association  in  CA3  of  the  
hippocampus  upregulated  BDNF  expression  and  the  coupling  of  TrkB  with  
PSD95  in  this  area;;  and  the  extinction-­enhancing  effects  of  disruption  of  PSD95-­
nNOS  interaction  could  be  abolished  by  BDNF  scavenger  and  TrkB  receptor  
antagonist  (Cai  et  al  2018).  Since  fear  extinction  is  a  complex  phenomenon  
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which  primarily  involves  not  only  the  hippocampus  but  also  the  amygdala  and  the  
mPFC  (Bredy  et  al  2007,  Chhatwal  et  al  2006,  Peters  et  al  2010,  Rosas-­Vidal  et  
al  2014),  it  is  tempting  to  examine  if  the  up-­regulatory  role  of  disruption  of  
PSD95-­nNOS  interaction  in  BDNF  signaling  can  be  generalized  to  the  other  two  
brain  regions.  Also,  it  is  of  interest  to  investigate  if  disruption  of  PSD95-­nNOS  
interaction  facilitates  the  extinction  of  cue-­induced  fear  memory,  which  is  more  
dependent  on  the  amygdala.  
  
5.3.4  NO  signaling  in  conditioned  fear:  Relevance  to  PTSD  
   Normal  fear  learning  and  memory  is  essential  to  animals’  survival  as  it  
allows  animals  to  predict  and  avoid  physical  dangers.  However,  dysregulated  
fear  learning  and  memory  following  traumatic  events  can  lead  to  symptoms  of  
syndromes,  such  as  post-­traumatic  stress  disorder  (PTSD).  Numerous  clinical  
studies  of  PTSD  demonstrated  that  repetitive  recall  of  traumatic  memories,  
avoidance  symptoms,  and  chronic  hyperarousal  are  the  defining  features  of  
PTSD  (Sherin  &  Nemeroff  2011).  PTSD  is  frequently  accompanied  by  other  
comorbid  psychiatric  illness  along  with  high  rates  of  functional  disability  
(Galatzer-­‐‑Levy  et  al  2013).  While  PTSD  is  recognized  as  a  significant  health  
challenge,  there  is  no  highly  effective  treatments  for  it  (Berg  et  al  2007).  The  
current  first-­line  medication  for  treating  PTSD  symptoms  is  serotonin  reuptake  
inhibitors  (SRIs,  such  as  fluoxetine,  sertraline,  and  venlafaxine),  which  produce  
only  partial  effectiveness  (Berg  et  al  2007).  Additionally,  a  substantial  proportion  
of  patients  are  resistant  to  this  treatment  (Stein  et  al  2006).    
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   PTSD  is  considered  as  a  fear  pathology  in  which  the  memories  of  learned  
fear  are  likely  to  sustain,  generalized,  and  resistant  to  extinction  (Elzinga  &  
Bremner  2002).  Therefore,  understanding  the  neural  basis  underlying  fear  
memory  itself  is  critical  for  identifying  the  etiology  of  PTSD  and  for  developing  
better  drugs.  Pavlovian  fear  conditioning  is  a  leading  animal  model  for  studying  
fear  learning  and  memory  (Johansen  et  al  2011).  By  using  fear  conditioning,  
studies  have  revealed  a  distributed  network  of  brain  regions  that  are  involved  in  
fear  learning  and  extinction.  Three  brain  regions  that  have  received  the  most  
intensive  research  are  amygdala,  hippocampus,  and  medial  prefrontal  cortex.  
These  three  different  brain  structures  regulate,  in  concert,  the  various  aspects  of  
fear  memory  (see  Chapter  1).  The  roles  of  these  brain  regions  in  fear  memory  
were  validated  in  human  fear  conditioning  studies  using  functional  magnetic  
resonance  imaging  (fMRI).  It  has  been  shown  that  the  activity  of  amygdala  was  
increased  during  the  acquisition  of  both  cue-­  and  context-­induced  fear  
conditioning  (Alvarez  et  al  2008,  Delgado  et  al  2006,  LaBar  et  al  1998).  
Hippocampus  is  significantly  activated  during  contextual  fear  conditioning  
(Alvarez  et  al  2008).  Activation  of  mPFC  was  observed  during  fear  extinction  
(Milad  et  al  2007,  Phelps  et  al  2004).  Furthermore,  these  brain  regions  have  
been  shown  to  be  dysregulated  in  patients  with  PTSD.  Several  functional  
neuroimaging  studies  demonstrated  that  PTSD  patients  displayed  greater  activity  
in  the  amygdala  in  response  to  trauma-­related  stimuli  (e.g.  combat  sounds,  
emotional  words  and  faces)  when  compared  with  control  subjects  (Etkin  &  Wager  
2007,  Liberzon  et  al  1999).  Functional  imaging  studies  in  the  hippocampus  have  
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yielded  mixed  findings.  Some  studies  reported  increased  activation  in  the  
hippocampus  in  PTSD  patients  (Thomaes  et  al  2011,  Werner  et  al  2009);;  Other  
studies  found  a  failure  of  hippocampal  activation  in  patients  with  PTSD  (Bremner  
et  al  2003).  Dorsal  anterior  cingulate  (dACC)  and  ventral  mPFC  (vmPFC)  are  
thought  to  be  the  putative  human  homologues  of  the  PL  and  IL  in  rodents,  
respectively  (Milad  &  Quirk  2012).  Studies  have  shown  increased  dACC  activity  
during  fear  conditioning  (Rougemont-­‐‑Bücking  et  al  2011)  and  decreased  dACC  
activity  during  extinction  (Bremner  et  al  2005)  in  PTSD  patients  relative  to  
controls.  Deficits  in  the  recall  of  extinction  memory  in  subjects  with  PTSD  were  
found  to  be  correlated  with  lower  activity  in  vmPFC  (Milad  et  al  2009).  These  
findings  from  human  studies,  especially  those  studies  in  PTSD  patients,  
underscore  the  translational  validity  of  rodent  models  of  fear  conditioning.  
  
   By  utilizing  fear  conditioning  model  in  rodents,  numerous  studies  have  
been  done  to  investigate  the  molecular  and  cellular  mechanisms  underlying  fear  
learning  and  memory.  Studies  described  in  this  thesis  and  those  from  others  
collectively  suggested  a  critical  role  of  PSD95-­nNOS  interaction  in  different  
stages  of  fear  memory,  namely  consolidation,  reconsolidation  and  extinction,  
supporting  PSD95-­nNOS  interaction  as  a  promising  target  for  reducing  fear  
memories  in  animals  and  eventually  PTSD  patients.  Importantly,  disruption  of  
PSD95-­nNOS  interaction  with  small  molecules  elicits  minimal  adverse  effects  
while  reducing  fear  responses  (Figure  20,  21  and  22).    
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Despite  the  mounting  evidence  regarding  the  beneficial  effects  of  
disruption  of  PSD95-­nNOS  interaction  on  reducing  fear,  to  my  knowledge,  
previous  studies  were  only  undertaken  in  normal  animals  exposed  to  fear  
conditioning  alone,  which  is  insufficient  to  produce  PTSD  phenotype  (Pitman  et  al  
1993).  To  elucidate  the  role  of  PSD95-­nNOS  interaction  in  the  pathophysiology  
of  PTSD  and  to  further  support  the  development  of  PSD95-­nNOS  interaction-­
based  avenues  for  PTSD  treatment,  it  is  essential  to  conduct  investigations  using  
valid  animal  models  of  PTSD.  Although  inducing  PTSD-­like  symptoms  in  animals  
is  challenging,  there  are  several  animal  models  that  have  been  proven  to  
resemble  clinical  situation  with  better  face  validity  (how  well  the  model  captures  
the  symptomatology  of  diseases)  and  construct  validity  (how  well  the  model  
reflects  the  underlying  theory)  than  fear  conditioning  model  (Daskalakis  et  al  
2013).  One  of  these  models  is  predator  exposure/predator  scent  exposure  
(PredEX).  In  this  model,  exposed  animals  usually  develop  sustained  behavioral  
manifestation  of  anxiety,  which  mimics  persistent  anxiety  phenotype  seen  with  
PTSD  patients  (Adamec  et  al  1993,  Zoladz  et  al  2008).  Interestingly,  a  recent  
study  in  humans  demonstrated  a  critical  role  of  a  functional  nNOS  gene  variation  
in  the  regulation  of  anxiety  process  (Kuhn  et  al  2016).  nNOS  gene  with  a  
variation  in  the  exon  1f  (NOS1  ex1f-­VNTR,  short  alleles)  has  been  shown  to  be  
associated  with  increased  expression  of  nNOS  mRNA  in  human  amygdala  
tissues  (Weber  et  al  2015).  Subjects  with  this  variation  displayed  enhanced  
anxiety  traits  (Kuhn  et  al  2016).  It  is  tempting  to  investigate  whether  inhibition  of  
nNOS  by  disrupting  PSD95-­nNOS  interaction  with  ZL006  could  alleviate  anxiety-­
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like  behaviors  in  the  PredEX  model  of  PTSD.  Other  PTSD  models  include  
exposure  to  single  prolonged  stress  (SPS)  and  exposure  to  foot  shock  with  
additional  stressors,  in  which  exposed  animals  would  display  increased  acoustic  
startle  response,  a  feature  symptom  of  PTSD  (Pitman  et  al  2012).  Future  studies  
investigating  the  role  of  PSD95-­nNOS  interaction  with  the  use  of  animal  models  
of  PTSD  will  provide  powerful  insight  on  the  mechanisms  underlying  abnormal  
fear  responses  in  PTSD  and  thus  further  facilitating  the  development  of  PSD95-­
nNOS  interaction  based  treatment  for  PTSD  symptoms,  such  as  re-­experiencing  
traumatic  events.  
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CHAPTER  6    





   Adult  male  Sprague-­Dawley  rats  (250-­300g,  Harlan,  IN,  USA)  were  
utilized  for  the  behavioral  and  biochemical  experiments.  Rats  were  allowed  to  
acclimate  to  housing  for  at  least  3  days  following  delivery;;  and  they  were  housed  
singly  on  a  regular  12-­hour  light/dark  cycle  (lights  on  at  0700  hours)  in  a  
temperature-­controlled  room  (22˚C),  with  free  access  to  food  and  water.  Each  rat  
was  handled  daily  for  a  minimum  of  3  days  before  any  behavioral  experiment.  
Animal  care  procedures  were  conducted  under  the  NIH  Guidelines  for  the  Care  
and  Use  of  Laboratory  Animals,  8th  Edition  and  approved  by  the  IUPUI  
Institutional  Animal  Care  and  Use  Committee.    
  
6.1.2  Drugs  and  chemicals  
   To  perform  i.p.  injections  of  drugs,  ZL007  and  ZL006  were  dissolved  in  a  
vehicle  of  10%  DMSO  (Sigma  Aldrich,  St.  Louis,  MO,  USA),  with  the  remaining  
90%  consisting  of  100%  ethanol  (Fisher  Scientific,  Pittsburgh,  PA,  USA),  
emulphor  (Alkamuls  EL-­620,  Solvay,  Brussels,  Belgium)  and  sterilized  saline  at  a  
ratio  of  1:1:8,  respectively.  ZL007  was  synthesized  in  the  laboratory  of  Dr.  
Ganesh  Thakur  at  the  Northeastern  University  Center  for  Drug  Discovery  
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(Boston,  MA,  USA).  ZL006  was  purchased  from  Sigma.  MK-­801  was  dissolved  in  
sterilized  saline  and  was  also  purchased  from  Sigma.  The  volume  for  an  i.p.  
injection  was  1mg/kg  and  control  animals  were  injected  with  an  equal  volume  of  
vehicle.  To  perform  local  infusions,  ZL006  was  diluted  from  ZL006  stock  solution  
(dissolved  in  100%  DMSO)  at  1:1000  in  ACSF  (artificial  cerebrospinal  fluid)  to  
yield  a  final  concentration  of  10  µM.  ACSF  containing  in  mM:  130  NaCl,  3.5  KCl,  





6.2.1  Behavioral  tests  
6.2.1.1  Fear  conditioning  and  fear  expression  tests  
   Rats  were  habituated  to  the  conditioning  box  measuring  L  25.5  ×  W  25.5  ×  
H  39.5  cm  for  10  minutes  the  day  before  conditioning.  The  conditioning  box  (Box  
A)  was  situated  in  a  larger  sound-­attenuated  chamber,  which  was  illuminated  
with  a  white  15-­Lux  light.  The  floor  of  Box  A  was  constructed  of  parallel  stainless-­
steel  bars  and  connected  to  a  scrambled  shock  generator  (Stoelting  Co.,  Wood  
Dale,  IL,  USA).  In  the  rear  wall  of  the  chamber,  a  speaker  was  mounted  and  
operating  to  provide  white  noise  during  all  experimental  sessions.  Before  
conducting  fear  conditioning  for  each  animal,  both  the  chamber  and  the  
conditioning  box  were  thoroughly  cleaned  with  70%  ethanol  (Fisher  Scientific)  to  
remove  olfactory  cues.  During  fear  conditioning,  rats  were  trained  with  3  
   122  
tone/shock  pairings,  with  each  pairing  consisting  of  a  20  s,  4  kHz,  80  dB  tone  that  
co-­terminated  with  a  0.5  s,  0.8  mA  footshock.  The  inter-­trial  interval  (ITI)  was  120  
s.  Each  rat  was  allowed  to  explore  the  conditioning  box  and  the  chamber  for  100  
s  before  fear  conditioning  began  and  remained  in  the  conditioning  box  for  60  s  
after  the  last  tone/shock  trial.  Animals  in  the  ‘Tone  only’  group  were  placed  in  the  
conditioning  box  and  exposed  to  3  tones  only  (20  s,  4kHz,  80  dB)  without  
receiving  footshocks.  Shortly  after  fear  conditioning  (<  5  min),  animals  were  
treated  with  drugs  or  vehicle.  Cue-­induced  conditioned  fear  memory  was  tested  
in  the  same  conditioning  box  (Box  A)  with  a  presentation  of  10  tones  (4  kHz,  80  
dB,  20  s,  ITI  60  s)  24  hours  after  fear  conditioning.  Total  time  of  freezing  during  
the  tone  presentations  were  recorded  and  scored  manually  by  blinded  raters.  
Data  was  expressed  as  a  percentage  of  the  total  tone  duration.    
  
In  the  experiment  with  intra-­vHP  infusions  where  both  context-­induced  and  
cue-­induced  fear  were  tested,  animals  were  first  placed  into  the  conditioning  box  
(Box  A)  for  contextual  fear  test  and  then  into  Box  B  for  cued  fear  test.  For  
context-­induced  fear  test,  rats  were  exposed  to  the  context  of  the  box  without  
tone  or  shock  for  a  total  of  5  minutes.  Total  time  freezing  during  the  last  4  
minutes  were  recorded  and  scored  for  each  rat.  The  cue-­induced  fear  test  was  
the  same  as  described  above,  excepted  that  it  was  tested  in  Box  B,  a  novel  box.  
The  context  of  Box  B  is  different  from  Box  A  in  that  the  floor  of  the  Box  B  was  
constructed  of  a  smooth  black  plastic  board  and  the  four  walls  of  the  box  were  
decorated  with  black/white  checked  paper  sheets.  When  tested  in  Box  B,  the  
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olfactory  cues  between  animals  were  cleared  by  using  1%  acetic  acid  (Fisher  
Scientific).  Freezing  was  defined  as  the  absence  of  all  movement  except  for  
normal  breathing.  
  
6.2.1.2  Open  field  test  
   The  open  field  apparatus  consisted  of  a  Plexiglas  open-­topped  chamber  
measuring  L  91.5  ×  W  91.5  ×  H  30.5  cm,  a  ceiling-­mounted  CCD  camera  and  a  
25  W  red  light  bulb  placed  2  meters  above  the  center  of  the  chamber.  Rats  were  
gently  placed  in  the  center  of  the  chamber  1  hour  following  treatments  of  vehicle  
or  drugs  and  allowed  to  freely  explore  the  chamber  5  min  while  being  tracked  by  
an  automated  tracking  system  (ANY-­MAZE,  Stoelting  Co.,  Wood  Dale,  IL,  USA).  
Total  distance  traveled  was  used  to  measure  locomotor  activity  and  results  were  
normalized  to  vehicle  controls.  
     
6.2.1.3    Social  interaction  test  
   Social  interaction  test  was  performed  5  min  after  open  field  test  in  the  
same  apparatus.  The  protocol  used  for  the  social  interaction  test  has  been  
described  previously  (Sanders  &  Shekhar  1995a,  Sanders  &  Shekhar  1995b).  
Briefly,  the  ‘experimental’  rat  and  the  ‘partner’  rat  were  simultaneously  placed  
into  the  chamber  and  were  allowed  to  move  for  a  total  of  5  min  freely.  The  age,  
sex  and  weight  of  the  ‘partner’  rats  were  matched  to  the  ‘experimental’  rats.  
Social  interaction  time  (in  seconds)  for  each  pair  of  rats  was  measured  as  time  
spent  by  the  ‘experimental’  rat  engaging  in  non-­aggressive  physical  investigation  
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of  the  ‘partner’  rat;;  This  is  defined  by  the  ‘experimental’  rat  sniffing,  climbing  over  
and  crawling  under  the  ‘partner’  rat,  mutual  grooming,  genital  investigation  or  
following  and  walking  around  the  partner.  All  tests  were  video  recorded  from  
above  and  then  manually  scored  by  blinded  raters  using  ODlog  for  Mac  OS  X  
version  2.6.1.  
     
6.2.1.4  Novel  object  recognition  test  
   NORT  was  performed  as  previously  described  (Pitsikas  et  al  2006)  with  
minor  modifications.  Prior  to  testing,  animals  were  placed  into  an  open  field  box  
(L  100  ×  W  100  ×  H  20  cm)  and  allowed  to  freely  explore  the  box  for  5  min  per  
day  for  3  consecutive  days  with  no  objects  present.  The  experiment  is  consisted  
of  two  2  min  trials:  familiarization  trial  and  test  trial.  During  the  familiarization  trial,  
rats  were  placed  into  the  box  containing  two  identical  objects  (plastic  cylinders  6  
cm  in  diameter  and  12  cm  tall  in  white  and  red)  in  two  opposite  corners.  The  rats  
were  released  against  the  center  of  the  opposite  wall  with  its  back  to  the  objects.  
According  to  previous  reports,  this  was  done  to  prevent  coercion  to  explore  the  
objects  (Reger  et  al  2009).  The  rats  were  considered  to  be  exploring  when  they  
were  facing,  sniffing  or  biting  the  object  with  nose  and/or  forepaws.  Shortly  
following  familiarization,  rats  were  treated  with  vehicle  or  drugs  systemically,  and  
were  returned  to  their  home  cages.  Rats  were  allowed  to  stay  in  their  home  
cages  for  a  period  of  3  hours  (ITI  =  3  h)  before  they  were  placed  back  into  the  
box  for  the  test  trials.  During  this  trial,  a  novel  object  (plastic  building  block  in  
yellow  or  green,  L  7  ×  W  3.5  ×  H  9  cm)  replaced  one  of  the  familiar  objects  used  
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in  the  familiarization  trial.  The  box  and  the  objects  were  thoroughly  cleaned  with  
70%  of  ethanol  after  each  trial.  The  time  spent  in  exploring  each  object  during  
both  trials  were  recorded  manually  by  using  a  stopwatch.  Discrimination  index  
(DI)  used  to  measure  the  object  recognition  memory  was  calculated  as  the  
difference  in  exploration  time  for  the  novel  (TN)  versus  familiar  objects  (TF),  then  
dividing  this  value  by  the  total  time  spent  exploring  the  two  objects  in  the  test  
trial:     (Cavoy  &  Delacour  1993).    
     
6.2.1.5  Y-­maze  test  
   Y-­maze  task  was  performed  as  previously  described  (Conrad  et  al  1996)  
with  minor  modifications.  The  apparatus  employed  for  the  Y-­maze  test  was  
constructed  of  acrylic  plexiglass  with  ‘Y’  shaped  arms;;  each  of  the  three  arms  
measured  L  34  ×  W  8  ×  H  14.5  cm.  Visual  cues  (paper  cuts  in  different  colors  
and  shapes)  were  placed  on  the  walls  of  the  maze.  The  maze  was  located  in  a  
room  with  a  light  of  350  Lux  brightness.  Several  distal  cues  (tables,  chairs,  
computers,  and  multiple  different  small  objects)  were  around  the  Y-­maze  and  
were  kept  constant  during  the  entire  behavioral  testing  period.  The  floors  and  
walls  of  the  maze  were  cleaned  thoroughly  with  70%  ethanol  between  trials  to  
remove  olfactory  cues.  The  three  arms  were  randomly  designated  as  start  arm,  
in  which  the  animals  started  to  explore  (always  open),  novel  arm,  which  was  
blocked  during  the  1st  trial,  but  open  during  the  2nd  trial,  and  other  arm  (always  
open).  There  are  two  trials  in  the  Y-­maze  test:  acquisition  trial  and  test  trial.  
During  the  10-­min  acquisition  trial,  the  rat  was  allowed  to  freely  explore  the  start  
DI = TN −TF /TN +TF
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arm  and  the  other  arm  only,  with  no  access  to  the  novel  arm.  Shortly  after  the  
familiarization  trial,  animals  were  treated  with  vehicle  or  drugs  and  placed  back  to  
their  home  cages.  The  test  trail  was  performed  after  1  h  waiting  period  (ITI  =  1  h)  
in  the  home  cages.  During  this  trial,  the  novel  arm  was  opened  and  the  animals  
were  allowed  to  freely  explore  all  three  arms  for  5  min.  All  trial  were  recorded  by  
a  ceiling-­mounted  CCD  camera.  Video  recordings  were  later  analyzed  by  a  
blinded  rater  to  determine  the  number  of  entries  and  the  time  spent  in  each  arm  
for  each  rat.    
     
6.2.2  Co-­immunoprecipitation  analysis  
   Following  fear  conditioning,  rats  were  sacrificed  at  different  time  points  by  
decapitation  under  isoflurane  and  the  brains  were  immediately  removed  and  
frozen  in  iso-­pentane  (Thermo  Fisher  Scientific)  on  dry  ice.  Brain  samples  were  
stored  at  -­80˚C  until  processed.  Punches  containing  the  mPFC  or  BLA  or  vHP  
were  obtained  using  a  1  mm  diameter  Harris  micro-­punch  (Electron  Microscopy  
Sciences,  Hatfield,  PA,  USA)  from  300  μm  thick  sections  taken  on  a  freezing  
microtome  (see  Figure  14  for  locations  of  micropunches).  Punches  were  
immediately  transferred  into  100  ul  (for  mPFC  and  BLA  punches)  or  150  ul  (for  
vHP  punches)  of  ice-­cold  lysis  buffer  (25  mM  Tris,  150  mM  NaCl,  1  mM  EDTA,  
5%  glycerol,  1%  NP-­40,  PH  7.4)  supplemented  with  Halt  protease  inhibitor  
cocktail  and  Halt  phosphatase  inhibitor  cocktail  (Thermo  Fisher  Scientific,  
Rockford,  IL,  USA)  and  then  lysed  on  ice  for  15  min  by  dounce  homogenization.  
Samples  were  then  centrifuged  at  13,000g/4  ˚C  for  15  min.  The  supernatants  
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were  pre-­incubated  with  control  agarose  resin  (25  ul,  Thermo  Fisher  Scientific)  
for  1  hour  at  4  ˚C  and  then  centrifuged  to  remove  proteins  that  bind  
nonspecifically  to  the  resin.  The  supernatants  were  then  incubated  overnight  (>  
16  hours)  at  4  ˚C  with  nNOS  antibody  at  2  ug  per  100  ug  total  protein.  Protein  
A/G  Agarose  (Thermo  Fisher  Scientific)  was  added  to  the  antibody/lysate  sample  
the  next  day  and  incubated  for  1  hour  at  4  ˚C.  Immune  complexes  were  
precipitated  by  centrifugation  and  washed  5  times  with  lysis  buffer.  The  bound  
proteins  were  then  eluted  by  heating  at  95  ˚C  in  loading  buffer  for  10  min.  After  
cooling  down,  the  protein  samples  were  then  used  for  western  blot.  Samples  
were  loaded  to  acrylamide  denaturing  gels  (10%)  and  transferred  to  
nitrocellulose  membranes  (Amersham,  Pittsburgh,  PA,  USA).  Membranes  were  
then  blocked  for  an  hour  with  5%  milk  in  TBST  buffer  (50  mM  Tris-­Cl,  pH  7.6;;  150  
mM  NaCl;;  0.1%  Tween  20)  prior  to  overnight  incubation  with  primary  nNOS  and  
PSD95  antibodies.  On  the  next  day,  the  membranes  were  incubated  with  
appropriate  secondary  antibodies.  Protein  bands  were  visualized  by  adding  
chemoluminescent  buffer  (Millipore,  Billerica,  MA,  USA)  to  the  blots.  Films  were  
scanned  and  densitometry  of  protein  band  was  performed  using  ImageJ  1.48  
software  (NIH).  Antibodies  used  in  Co-­IP  and  the  following  western  blotting  are  
listed  in  Table  1.  
  
6.2.3  Western  blot  analysis  
The  expression  levels  of  PSD95  and  nNOS  were  determined  by    
immunoblotting  analysis.  Punches  were  obtained  and  lysed  as  described  above.  
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Protein  concentrations  were  determined  by  BCA  assay  (Pierce  BCA  protein  
assay  kit,  Thermo  Fisher  Scientific).  Protein  samples  were  treated  with  Laemmli  
2X  loading  buffer  (Bio-­Rad,  Hercules,  CA,  USA)  and  heated  at  95  ˚C  for  5  
minutes.  Equal  amount  of  proteins  were  electrophoresed  and  transferred  to  
nitrocellulose  membranes.  Membranes  were  blocked  with  Odyssey  blocking  
buffer  (LI-­COR,  Lincoln,  NE,  USA)  and  then  incubated  with  mouse  nNOS  
antibody  at  1:1000,  (Santa  Cruz),  mouse  PSD95  antibody  at  1:1000  (Invitrogen)  
and  mouse  β-­actin  antibody  at  1:10000  (Santa  Cruz).  Subsequently,  membranes  
were  incubated  with  IRDye  800CW  secondary  antibody  from  LI-­COR.  Protein  
band  signals  were  detected  by  using  Odyssey  CLx  Imaging  System  (LI-­COR)  
and  quantified  by  Image  studio  Lite  software  (LI-­COR).  The  total  protein  levels  
were  normalized  to  β-­actin  protein  levels.  Antibodies  used  in  western  blotting  are  
listed  in  Table  1.  
     
   129  
Table  1.  Antibodies  used  in  Co-­IP  and  Western  blotting  
  





Catalog  #  and  
Manufacturer  
Dilution  
nNOS  (A-­11)   Mouse   sc-­5302;;  Santa  Cruz  
Biotechnology,  Dallas,  TX  
2  µg  per  100  µg  
protein  for  pull  down  
nNOS  (A-­11)   Mouse   Sc-­5302;;  Santa  Cruz  




Mouse   MA1-­046;;  Invitrogen,  
Rockford,  IL  
1:  2000  
β-­actin  (C4)   Mouse   Sc-­47778;;  Santa  Cruz  






Manufacturer   Dilution  
anti-­mouse  IgG  
(HRP)  
Goat   Sc-­2005;;  Santa  Cruz  
Biotechnology,  Dallas,  TX  
1:  2000  for  nNOS;;  1:  
5000  for  PSD95;;  1:  
10000  for  β-­actin  





Manufacturer   Dilution  
β-­actin  (C4)   Mouse   Sc-­47778;;  Santa  Cruz  




Mouse   MA1-­046;;  Invitrogen,  
Rockford,  IL  
1:  1000  
nNOS  (A-­11)   Mouse   Sc-­5302;;  Santa  Cruz  






Manufacturer   Dilution  
anti-­mouse  lgG  
(IRDye  800CW)  
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6.2.4  Surgery  
   Prior  to  surgery,  rats  were  anesthetized  in  a  closed  plastic  box  connected  
to  an  Isoflurane  system  (MGX  Research  Machine,  Vetamac,  Rossville,  IN,  USA).  
Following  anesthesia  in  the  box,  the  animals  were  secured  on  a  stereotaxic  
instrument  (Kopf  Instruments,  Tujunga,  CA,  USA).  Anesthesia  was  maintained  
through  a  nose  cone,  which  allowed  for  a  flow  of  isoflurane  at  constant  rate  (2–
3%  by  volume)  throughout  the  surgery.  After  making  an  incision  in  the  scalp  and  
cleaning  the  skull,  two  stainless-­steel  guide  cannulas  (26  gauge,  Plastics  One,  
Roanoke,  VA,  USA)  were  implanted  bilaterally  into  the  BLA  (anterior,  -­2.3  mm;;  
lateral,  ±4.9  mm;;  and  ventral,  -­7.4  mm)  or  into  the  ventral  hippocampus  (vHP)  
(anterior,  -­5.1  mm;;  lateral,  ±5.0  mm;;  and  ventral,  -­5.2  mm)  with  the  guidance  of  
the  brain  atlas  of  Paxinos  and  Watson  (Fifth  edition).  The  guide  cannulas  were  
secured  into  place  using  three  2.4mm  screws  anchored  into  the  skull  along  with  
cranioplastic  cement.  To  prevent  occlusions,dummy  cannulas  (Plastics  One)  with  
lengths  matching  the  guide  cannulas  were  placed  inside  the  guide  cannulas.  All  
rats  were  treated  with  pain  medication  (buprenorphine,  Indiana  University  School  
of  Medicine  Laboratory  Animal  Resources)  following  surgery  and  were  allowed  to  
recover  in  their  home  cages  for  7  days  before  any  behavioral  test.  During  the  
recovery  period,  rats  were  gently  handled  every  day  for  a  minimum  of  2  min.  
  
6.2.5  Intracranial  Injections  
To  execute  local  infusions  into  BLA  or  vHP,  the  dummy  cannulas  were  
quickly  removed  from  the  guide  cannulas  and  were  replaced  by  injection  
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cannulas  which  are  extended  1.0  mm  beyond  the  guide  cannulas  (Plastics  One).  
The  injection  cannulas  were  connected  via  polyethylene  tubing  to  10  µl  
microsyringes  (Hamilton,  Reno,  NV,  USA).  Injections  were  performed  using  a  
Harvard  PHD  2000  (Harvard  Apparatus,  Inc.,  South  Natick,  MA,  USA)  syringe  
pump  at  a  rate  of  0.1  µl/min.  After  drug  infusion,  injection  cannulas  remained  in  
the  guide  cannulas  for  1  min  to  allow  diffusion  of  the  drug  from  the  tip.  After  
behavioral  tests,  rats  were  euthanized  by  an  overdose  of  isoflurane  and  perfused  
with  4%  Paraformaldehyde  (PFA)  (Fisher  Scientific).  Neutral  red  staining  and  
light  microscopy  were  used  to  verify  the  locations  of  the  cannula  tips  within  the  
BLA  and  the  vHP.    
  
6.2.6  Slice  Electrophysiology  
   Electrophysiological  recordings  were  conducted  as  previously  described  
(Rainnie  1999).  Rats  (150-­200  g)  were  sacrificed  under  isoflurane  by  
decapitation.  Brains  were  then  rapidly  removed  and  placed  in  ice-­cold  
oxygenated  artificial  cerebrospinal  fluid  (ACSF,  solution  in  mM:  130  NaCl,  3.5  
KCl,  1.1  KH2PO4,  2.5  CaCl2,  1.3  MgCl2,  30  NaHCO3,  10  glucose,  315  mOsm,  7.4  
pH).  Coronal  slices  (350  µM)  containing  the  BLA  (BLA,  ~  -­2.3  mm  from  bregma)  
were  prepared.  To  improve  cell  viability,  slices  were  first  incubated  in  30  °C  
ACSF  for  30  min  and  then  in  room  temperature  ACSF  until  recording.  
Oxygenated  ACSF  was  warmed  to  30  °C  and  perfused  at  a  rate  of  2-­3  ml/min  
during  recording  on  the  platform  of  a  Nikon  E600FN  Eclipse  microscope  (Nikon  
Instruments,  Melville,  NY,  USA).  Borosilicate  glass  electrodes  (WPI,  Sarasota,  
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FL,  USA)  (resistances  3-­6  MΩ)  were  filled  with  potassium  gluconate  based  
recording  solution  containing  in  mM:  130  K-­Gluconate,  3  KCl,  3  MgCl2,  2  K-­ATP,  
0.2  Na-­GTP,  10  HEPES,  5  phosphocreatine,  0.05  picrotoxin  (Sigma)  and  whole-­
cell  patch  clamp  recordings  in  current  clamp  mode  were  obtained  by  standard  
techniques  using  Multiclamp700B  amplifier  and  Digidata1440  digitizer  (Molecular  
Devices,  Sunnyvale,  CA,  USA).  Pyramidal  neurons  in  the  BLA  were  identified  
according  to  their  characteristic  size  and  shape  and  further  validated  by  basic  
electrophysiological  property  of  input  resistance  with  ~35  MΩ  (McDonald  et  al  
2005).  GABA-­B  receptor  antagonist  CGP52432  (Tocris,  Minneapolis,  MN,  USA)  
at  1µM  and  ZL006/ZL007  compounds  at  10  µM  were  added  directly  to  the  ACSF  
solution.  Cell  holding  potential  was  maintained  at  -­70  mV  and  Master8  pulse  
stimulator  (A.M.P.I,  Jerusalem,  Israel)  was  utilized  to  provide  stimulation  as  
previously  described  (Li  et  al  2011).  eEPSPs  were  generated  by  electrical  
stimulation  with  a  concentric,  platinum/iridium,  bipolar  electrode  (FHC,  Bowdoin,  
ME,  USA)  placed  ~1  mm  from  the  recorded  neurons,  within  the  BLA  and  directly  
medial  to  the  external  capsule.  A  10-­min  baseline  period  was  recorded  at  the  
beginning  of  each  experiment  to  verify  consistent  cell  properties  of  resistance  
and  evoked  response  amplitude.  For  conditions  where  ZL006  or  ZL007  were  
tested,  an  extended  baseline  period  (20  min)  was  recorded  to  determine  if  the  
drug  treatments  had  any  effect  on  amplitude  of  eEPSPs.  The  injecting  current  for  
evoked  responses  was  adjusted  for  each  neuron  to  produce  roughly  5  mV  
depolarization.  HFS  was  applied  to  neurons  that  demonstrated  a  consistent  
baseline  to  induce  potentiation  of  eEPSPs  as  previously  described  (Molosh  et  al  
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2014).  When  bursts  of  100  pulses  at  100  Hz  was  delivered  once  every  20  sec  
(20  bursts  total),  it  was  able  to  produce  short-­term  and  long-­term  potentiation.  
Cells  that  did  not  display  short-­term  potentiation  were  removed  from  analysis.  
  
  
   The  effects  of  treatment  and  time  across  the  trials  in  the  fear-­related  
behavioral  experiments  were  compared  using  two-­way  repeated  ANOVA  with  
post  hoc  Fisher’s  LSD  test.  Differences  between  treatments  and  overtime  in  the  
slice  electrophysiology  experiment  were  analyzed  using  two-­way  ANOVA  
followed  by  post  hoc  Fisher’s  LSD  tests.  In  other  experiments  where  more  than  
two  groups  are  compared,  statistical  differences  were  calculated  by  one-­way  
ANOVA  followed  by  post  hoc  Fisher’s  LSD  tests.  When  compare  means  between  
two  groups,  unpaired  two-­tailed  t-­test  was  utilized.  The  Greenhouse-­Geisser  
correction  was  applied  when  the  assumption  of  sphericity  was  violated.  Data  
were  expressed  as  Mean  ±  SEM.  The  sample  size  was  determined  based  on  
power  calculations  from  previous  reports  and/or  pilot  studies  in  my  laboratory.  
GraphPad  Prism  6  software  (GraphPad  Software,  La  Jolla,  CA,  USA)  was  
utilized  for  data  analysis,  and  a  P  value  <  0.05  was  taken  to  indicate  significant  
differences.  
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Certificates  
2019         Good  Clinical  Practice  (GCP),  CITI  Program  
2019         Good  Laboratory  Practice  (GLP),  CITI  Program  
2017   Certificate  of  Completion  in  Making  Medicines:  The  Process  
of  Drug  Development  Course,  Eli  Lilly  
